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ABSTRACT OF THE DISSERTATION  
 
 
Effects of Omega-3s and Vitamin E Prophylactic Diets and the Implications of Lipid 
Transport in Spinal Cord Injury 
by 
Kathia Cordero-Cabán 
Doctor of Philosophy, Graduate Program in Physiology 
Loma Linda University, June 2018 
Dr. Marino De León, Chairperson 
 
Traumatic injury to the central nervous system (CNS) presents a devastating 
problem to our society. Although current interventions are promising, no effective 
treatments are available. The neural membrane fatty acid composition is markedly altered 
during the first few days after spinal cord injury (SCI). SCI results in autonomic 
dysfunction, paralysis, spasticity, and significant chronic neuropathic pain. The trauma 
leads to significantly increased levels of free radical and oxidative stress that contribute 
to obstructing tissue healing and recovery. A growing body of evidence shows that 
administration of hydrophobic molecules such as Vitamin E and long-chain omega-3 
polyunsaturated fatty acids (ω3PUFAs) are capable of attenuating secondary damage, 
while promoting functional recovery after SCI. The precise molecular mechanisms 
coupling ω3PUFAs and Vitamin E to pro-restorative targets, is not well understood. 
Increasing attention is now being paid to understand the cellular targets of these 
hydrophobic molecules and how they are being transported after CNS trauma. The 
present study investigates the impact pre-treatment with ω3PUFAs and Vitamin E (alpha-
tocopherol) in key functional outcomes observed during the acute phase of SCI. 
Additionally, we explored potential mechanisms through which these hydrophobic 
 xxii 
molecules were exerting its beneficial effects such as the survival of motor neurons and 
oligodendrocytes and the transport of ω3PUFAs and Vitamin E. Due to the 
hydrophobicity of ω3PUFAs and Vitamin E, membrane transport may be required to 
facilitate their mobilization and meet the increased metabolic demand at the injury site. 
The fatty acid translocase/membrane cluster of differentiation 36 (FAT/CD36) is a B 
class scavenger receptor, which has been implicated in the uptake and signaling of 
hydrophobic molecules, including ω3PUFAs and Vitamin E. Female adult Sprague-
Dawley rats were received tail injections with ω3PUFAs (i.e. DHA) or were fed either 
with a normal diet or a regiment supplemented with ω3PUFAs and Vitamin E for eight 
weeks. Following the treatment animals were exposed to a contusion SCI or Sham. All 
animals were examined using standard functional behavior analysis. We report that pre-
treatment with DHA injections improved locomotion, bladder recovery, and survival of 
both neurons and oligodendrocytes. Dietary ω3PUFAs pre-treatment yielded the same 
results as DHA injections and in addition it decreased neuropathic pain as measured 
through thermal hyperalgesia and allodynia.  Dietary Vitamin E improved locomotion, 
improved H-reflex depression (indirect measure for spasticity), accelerated bladder 
recovery, and significantly increased the numbers of oligodendrocytes, but did not seem 
to preserve neurons in the ventral horn of injured rats. Further, dietary Vitamin E also 
increased the levels of supraspinal serotonin immunoreactivity. FAT/CD36 mRNA levels 
were increased at 7 days post-injury and its protein levels remained constant despite 
neuronal and oligodendrocyte loss. We observed the highest IR in motor neurons of the 
ventral gray matter and mature oligodendrocytes expressing the adenomatous polyposis 
coli protein (APC). Quantitative analysis of FAT/CD36 expression showed only Vitamin 
 xxiii 
E upregulated this protein in neurons after SCI. Our findings support the complementary 
use of ω3PUFAs and Vitamin E to ameliorate motor, sensory, and autonomic 
dysfunctions observed following SCI. Lastly, given the beneficial roles of ω3PUFAs and 
Vitamin E in ameliorating functional recovery, FAT/CD36 may be a contributor to basic 
protection mechanisms in the injured spinal cord. Future pharmacological studies will 
confirm the role of FAT/CD36 in cell survival after SCI. 
 
 
 
 1 
CHAPTER ONE 
INTRODUCTION 
 
Traumatic spinal cord injury (SCI) is an incapacitating disorder which affects 
millions of people and results in motor, sensory, and bladder dysfunction. Traumatic SCI 
is a main cause of disability among young adults. Epidemiologic studies show SCI affects 
more than 12,000 people per year in the US. Not included in these counts, are the 
incidences of non-traumatic SCI caused by congenital, developmental, inflammatory, and 
degenerative disorders [1]. Patients undergoing surgery of the spinal cord [2-4], athletes 
[5], and military personnel[6] are particularly susceptible and at higher risk for incurring 
SCI. 
Initial mechanical injury to the spinal cord initiates multiple cascades of 
secondary events responsible for neurological dysfunction and associated comorbidities. 
These events are pronounced within the first few days and up to a week following injury, 
and include metabolic alterations [7-15], oxidative stress, inflammation[16-26], 
demyelination/axonal damage [26-31], apoptosis [32-35], neurogenic shock, vascular 
insults, excitotoxicity, and calcium-mediated injury [18, 36-37].  
Our studies investigate preventive approaches that confer resistance to damage in 
the spinal cord and promote physiological responses that improve recovery following 
injury. In many cases SCI cannot be prevented, but we aim to ameliorate the secondary 
damage responsible for neurological dysfunction in affected patients. There are very few 
studies focusing on SCI susceptibility and, therefore, an urgent need to provide clinically 
translational methods to prevent dysfunction. Studies performed in the last decade show 
 2 
that detrimental outcomes in SCI are not dependent on the presence of set factors, but 
rather the balance between restorative and destructive molecular signals. [38]. As 
mentioned before, the secondary events responsible for neurological dysfunction in SCI 
occur within the first few days and up to a week after injury. For this reason, our studies 
focused on investigating the neuroprotective effects of prophylaxis with docosahexaenoic 
acid (DHA; 22:6 n-3) and Vitamin E during this acute injury phase.   
SCI causes prominent dysregulation of lipid homeostasis, specifically in 
polyunsaturated fatty acids (PUFAs). Following injury, there is a preferential breakdown 
of arachidonic acid (AA, O6PUFA) from cell membrane components and marked 
peroxidation of  docosahexaenoic acid (DHA, O3PUFA [8, 10, 41-45]. As a result, there 
is a deficiency in O3PUFAs as O6PUFAs are metabolized, thus changing the homeostatic 
ratio of O3PUFAs/ O6PUFAs in the spinal cord. PUFAs are thought to be involved in 
nerve cell responses to injury. DHA has been correlated with improved functional 
recovery [46, 51-56] while AA has been implicated in the secondary events leading to 
neurological dysfunction [46-50]. We attribute these correlations, in part, to the pro-
inflammatory and anti-inflammatory properties of AA and DHA, respectively. DHA is 
anti-inflammatory [57-59], neuroprotective [60-62], and able to upregulate survival 
proteins such as Akt and CREB, which are in involved in pathways leading to myelin 
stabilization and neuroprotection [67-70]. Evidence to the advantages of DHA has been 
shown in various models of neurological dysfunction [71-74] that include SCI [46, 51-
53]. Furthermore, studies have shown that treatment with DHA improves neurological 
dysfunction by targeting multiple cascades involved in the pathophysiology of SCI [57-
66].  
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In addition to DHA, our studies investigated the prophylactic effects of Vitamin 
E. Dietary Vitamin E supplementation improves locomotor recovery and [75-78] 
ameliorates nerve conduction deficits following SCI [75, 76]. Although it has been 
proposed that Vitamin E protects neural tissue by decreasing lipid peroxidation of 
products such as thiobarbituric acid reactive substances (TBARS) [75] and 
malondialdehyde [79], there is still a need to understand the mechanisms underlying its 
protective effects. Our aim is to provide evidence that prophylactic dietary intervention 
with O3PUFAs and Vitamin E will improve resiliency and functional recovery following 
SCI. We are specifically interested in prophylactic interventions because of their potential 
impact in populations at high risk for neurological injury (i.e., surgery, 
neurodegenerative/congenital disorders, athletes, and military personnel). Also, our 
findings will help in identifying key biomarkers contributing to the susceptibility of the 
spinal cord to secondary injury and dysfunction (locomotor dysfunction, neuropathic 
pain, bladder dysfunction, and spasticity).  
It is well documented that the spinal cord circuitry contributes to the control of 
movement [80, 81]. For example, stretch reflexes are single-phased motor responses to 
sensory input that are produced by the spinal cord. After SCI, there is disruption and, 
eventually, a deficiency in the mechanistic components that inhibit lower extremity H-
reflexes –– the electrical analogues of stretch reflexes. Inhibition of these reflexes during 
the gait cycle is important for normal walking, and disruption of these during SCI 
explains why paralysis or abnormal gait occurs. There is dysfunctional reflex inhibition 
following injury which dysregulates the motor output necessary for normal gait[82-86].  
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The spinal cord is also able to generate more complex rhythmic behaviors on its 
own (without supraspinal or proprioceptive signals from the central nervous system) 
through spinal central pattern generators (CPGs). CPGs are an organizational system in 
charge of producing basic motor patterns. Higher centers activate the appropriate sets of 
spinal CPGs to modify them. Thus, spinal CPGs have the intrinsic capacity to produce 
movement without proprioceptive or supraspinal input [81, 87-90]. The control of motion 
does need supraspinal influence for the initiation and termination of locomotion, but, due 
to the significant automaticity and well-integrated nature of its sensorimotor responses, 
the specific millisecond to millisecond control of the musculature performing locomotor 
functions is accomplished by the spinal circuitry [91]. Lastly, the spinal cord processes 
and integrates complex sensory information which serves to generate motor responses for 
a particular group of sensory input [92, 93].  
When the spinal cord is lesioned, the amount of fibers spared in the 
ventrolateral/dorsolateral funiculi (where the corticospinal, rubrospinal, and  
reticulospinal tracts are located) positively correlate with increased locomotor scores in 
open field and grid tests [94]. Additional studies also show that the severity of 
dysfunction after SCI is closely linked to the amount of white matter spared in the 
lesioned area [95-100]. These findings demonstrate the importance of the spinal cord for 
proper locomotion. Moreover, following weeks of body weight support exercises, the 
spinal cord can potentiate motor patterns in the lower limb muscles. Lumbosacral 
coordination of lower limb motor pools can occur when enough proprioceptive 
information related with weight support stepping is relayed through the lumbosacral 
spinal cord to the neural control circuitry. Complete injuries to the spinal cord are unable 
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to activate the motor pools necessary for weight support stepping due to an inability to 
activate enough motor units. This may be due to either insufficient proprioceptive input 
or muscle atrophy [101-105]. Certainly, the spinal cord, its organization, and associated 
structures are crucial for locomotion.  An additional focus of our study is to determine the 
prophylactic effect of O3PUFAs and Vitamin E on locomotor recovery in different SCI 
models. 
In addition to locomotor and sensory dysfunction, SCI predisposes patients to 
chronic neuropathic pain, a condition which adversely impacts their quality of life [106]. 
The existing therapies aimed at treating chronic neuropathic pain are not efficient 
enough, have considerable side effects, and have low tolerance. We propose that 
prophylactic therapies such as O3PUFAs (i.e. DHA) can ameliorate the development of 
chronic neuropathic pain by increasing the resiliency of the spinal cord prior to injury. 
PUFAs have been shown to mediate pain processing. For example, rats on diets with high 
omega-3 to omega-6 PUFA ratios have increased thresholds for thermal and neuropathic 
pain [107]. Also, O3PUFAs and their metabolites decrease thermal and chemical 
stimulation in animal models [108-110]. Interestingly enough, there are studies where 
pain behaviors related to nerve injuries are influenced by diet when the injury occurs 
[111-115]. These studies lead us to hypothesize that a prophylactic diet with O3PUFAs 
can play a significant role in abrogating/ameliorating chronic neuropathic pain after SCI. 
We specifically assessed if O3PUFAs are effective in decreasing thermal pain stimuli 
after SCI and the modulators responsible for their potential effects. A group of bioactive 
lipids, N-Acylated ethanolamines (NAEs) and endocannabinoids (eCBs) have been 
associated to pain[116-118], regulate anti-inflammatory processes, and act on 
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cannabinoid receptors as endogenous agonists [119-122]. Due to the association of NAEs 
and eCBs to pain, inflammation, and cannabinoid receptors, we studied if O3PUFAs are 
involved in their modulation after SCI. Our goal was to find the metabolomic profiles 
that would increase chronic pain and the one profile that would ameliorate it.  
SCI causes areflexia and muscle weakness leading to paralysis and chronic pain, 
both of which are negatively affected by the development of spasticity[123-126] as  the 
nerve cell network recovers. Spasticity results from increased excitatory and decreased 
inhibitory signals in the neuronal circuitry as the injured nervous tissue tries to 
compensate for descending and motor-sensory input loss [123, 127, 128]. It is 
characterized by increased resistance to passive stretch, reduced joint range of motion, 
and voluntary muscle activity such as spasms, hyperreflexia, clonus, co-contraction [124, 
129, 130]. Involuntary muscle spasms (i.e., prolonged contractions) and tone in extensor 
muscles can facilitate walking, standing, and transfers [131-133], but excessive spasticity 
will hinder functional recovery. We wanted to investigate whether Vitamin E and 
O3PUFAS could improve the excessive spasticity seen after SCI. Our rationale for 
Vitamin E usage is derived from studies showing that Vitamin E supplementation 
improved the recovery of spinal evoked potentials after injury [75, 76]. Vitamin E is a 
powerful antioxidant and O3PUFAs are highly anti-inflammatory which makes both 
hydrophobic molecules particularly helpful in the context of SCI. Decreased ROS and 
inflammation may decrease the damage done to the neuronal network after SCI, which 
contributes to the development of spasticity. O3PUFAs have been shown to be 
neuroprotective in the context of SCI and its effects may extend to the amelioration of 
spasticity. 
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In addition to paralysis and chronic pain, SCI patients also experience life-
threatening secondary complications associated with autonomic bladder dysfunction 
[134, 135]. Unfortunately, there is no safe or effective treatment to treat bladder 
dysfunction. Although electrical modulation of spinal command centers involved in 
controlling micturition behaviors is a selective and potentially safe treatment option, there 
is an urgent medical need for studies identifying safe pharmacological interventions. 
Bladder dysfunction initially presents as areflexia and then develops into bladder 
hyperreflexia [136, 137], dysfunctional relaxation of the bladder neck, abnormal 
contraction of the external urethral sphincter [138], and detrusor-sphincter dyssynergia 
(DSD) [136] after the acute stage. The pathophysiological change from areflexia to 
hyperreflexia and abnormal relaxation/contraction of bladder neck and sphincters is 
attributed to (i) the loss of supraspinal descending regulation of lumbosacral autonomic 
neurons, (ii) the emergence of reorganized spinal micturition reflex pathways after injury, 
(iii) and the activation of mechano-insensitive unmyelinated C-fibers that usually do not 
respond to bladder distention to mechano-sensitive fibers in addition to the normally 
mechano-sensitive A-delta fiber afferents [139, 140].  
Current interventions to ameliorate bladder dysfunction after SCI include 
cholinergic muscarinic receptor antagonists [141-147], chemical blockade of C-fiber 
afferent neurotransmission with capsaicin or resiniferatoxin[148-154] and alpha1-AR 
receptor antagonists[155-161]. Additional interventions include suppression of motor-
neuron or interneuron excitation in the spinal cord by glycine, GABA agonists, and 
baclofen which is currently being used to treat dysfunctional contraction of the external 
urethral sphincter[162-168]. Botulin toxin, a presynaptic neuromuscular blocker, is now 
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FDA-approved to treat bladder hyperreflexia and DSD by inducing reversible muscle 
weakness [169-174]. Notably, antioxidant therapy is a promising therapy to improve 
bladder function following SCI. For example, treatment with quercetin improved bladder 
contractility, while decreasing reactive oxygen species, plasma cytokines, and caspase 3, 
and prevented depletion of free radical scavengers after SCI in rats [175].  Another study 
showed decreased urinary tract infections when SCI patients were treated with anti-
oxidant cranberry extract supplements for at least 6 months [176]. Due to its ample anti-
oxidant properties, it seemed reasonable to investigate if Vitamin E prophylaxis can 
improve bladder function. Additionally, we investigated if O3PUFAs improved bladder 
function due to their anti-inflammatory properties and neuroprotective effects in various 
models of SCI. 
In addition to functional recovery our project focused on potential mechanisms 
through which O3PUFAs and Vitamin E are protective in the context of spinal cord 
injury. Not only were we interested in knowing if O3PUFAs and Vitamin E are major 
modulators of repair mechanisms following SCI, the molecular mediators and targeted 
cell types coupling these hydrophobic molecules to functional recovery after SCI were 
studied. 
The first molecular mediator we were interested in is the fatty acid translocase 
membrane cluster of differentiation 36 (FAT/CD36). FAT/CD36 is a B class scavenger 
receptor and lipid transporter highly expressed in models of neurological and 
cardiovascular injury and implicated in the uptake and signaling of fatty acids and 
Vitamin E [177-180]. FAT/CD36 have been shown to be beneficial or detrimental after 
injury [181-186]. One of the long-term goals of our laboratory is to delineate the 
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contribution of lipid transport proteins such as FAT/CD36 to differential outcomes 
following neurotrauma. The objectives of this application were to characterize the 
spatiotemporal expression and functional roles of CD36 after SCI and find out if 
prophylactic diets enriched with O3PUFAs and Vitamin E modulate the expression of 
this protein in specific cell types important for functional recovery (i.e. mature 
oligodendrocytes and motor neurons). (references in my proposal). As previously 
mentioned cell death, neuroinflammatory processes, and deregulated lipid metabolism are 
markedly increased during the first week of injury in rats. These events lead to 
detrimental alterations in spinal cord tracts and results in neuronal dysfunction.   
Functional neuronal cells and oligodendrocytes in the spine are essential for 
locomotion and proper conduction. For this reason, we investigated whether, in addition 
to improving functional recovery, a prophylactic diet enriched with O3PUFAs and 
Vitamin E decreased neuronal and oligodendrocytic cell death within the spinal cord. 
Previous work has found that intravenous administration of O3PUFAs right before injury 
(30 minutes before) increases neuronal and oligodendrocyte survival [52]. There is less 
published work about the effects of dietary Vitamin E prophylaxis compared to 
O3PUFAs prophylaxis in the context of SCI. Vitamin E is powerful antioxidant that may 
decrease neuronal and oligodendrocyte death in the context of SCI. Oligodendrocytes are 
extremely susceptible to reactive oxygen species (ROS) [187, 188] and Vitamin E has 
been shown to decrease the accumulation of intracellular ROS in rat brain 
oligodendrocytes and pre-OLs in vitro [189-192]. Increased oligodendrocyte survival in 
Vitamin E fed rats may result in better conduction by way of increased myelination. 
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Increased myelination ,then, would lead to enhanced preservation of the neuronal tracts 
responsible for locomotion and conduction [31, 193-198]. 
In summary, this study investigated the impact of O3PUFAs and Vitamin E 
(alpha-tocopherol) dietary prophylaxis in key functional outcomes observed during the 
acute phase of SCI. Additionally, we also investigated potential mechanisms through 
which these hydrophobic molecules were exerting their beneficial effects, i.e. survival of 
motor neurons survival of oligodendrocytes, and the role of FAT/CD36 in the 
pathophysiology of SCI. Our findings support the complementary use of O3PUFAs and 
Vitamin E to improve motor, sensory, and autonomic dysfunctions observed following 
SCI. Given the beneficial roles of O3PUFAs and Vitamin E in assisting functional 
recovery, its transport, potentially by FAT/CD36, may be a contributor to basic 
protection mechanisms in the injured spinal cord. 
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Abstract 
Currently, few interventions have been shown to successfully limit the expansion 
of secondary damage pathways that are initiated during the acute phase of spinal cord 
injury (SCI). Docosahexaenoic acid (DHA, C22:6 n-3) is neuroprotective when 
administrated following SCI, but its potential as a pretreatment modality has not been 
addressed. This study used a novel DHA pretreatment experimental paradigm that targets 
acute cellular and molecular events during the first week after SCI in rats. We found that 
DHA pretreatment reduced functional deficits during the acute phase of injury, as shown 
by significant improvements in BBB locomotor scores and the detection of transcranial 
magnetic motor evoked potentials (tcMMEPs) responses when compared to vehicle-
pretreated animals. Histopathological analyses of DHA-pretreated rats showed increased 
white matter tissue preservation and more axons immunoreactive for phosphate-
dependent neurofilament heavy domains. We found a significant increase in the survival 
of NG2+, APC+, and NeuN+ cells in the ventrolateral funiculus (VLF), dorsal 
corticospinal tract, and ventral horns and dorsal horns, respectively.  Interestingly, these 
DHA protective effects were observed despite the lack of inhibition of high expression of 
inflammatory markers for monocytes/macrophages and astrocytes, ED1/OX42 and 
GFAP. Further, DHA pretreatment induced levels of Akt and cyclic AMP responsive 
element binding protein (CREB) mRNA and protein. This study shows for the first time 
that DHA-pretreatment ameliorates functional deficits, increases tissue sparing, and 
precursor cell survival. DHA induction of pro-survival/anti-apoptotic pathways may be 
independent of its anti-inflammatory properties. 
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Introduction 
Traumatic spinal cord injury (SCI) is a devastating disorder affecting several 
million people worldwide. Interestingly, the prevalence of non-traumatic SCI as 
consequence of congenital, developmental, inflammatory, and degenerative disorders 
suggest that the number of SCI patients would more than quadruple if non-traumatic 
causes were included [1]. The spinal cord is also at significant risk of injury in numerous 
surgical interventions [2, 3], sports [4], and military conflicts [5]. Although SCI may 
prove difficult to prevent in most instances, there is a need to further investigate effective 
preventive strategies to ameliorate the physiological outcomes in the event of damage. 
This could have important clinical implications in situations where injury is an 
unavoidable risk.  
Injury to the spinal cord results in immediate mechanical primary damage, which 
is followed by secondary injury mediated by a complex cascade of molecular events [6]. 
These immediate and acute secondary mechanisms include neurogenic shock, vascular 
insults, excitotoxicity, calcium-mediated injury, inflammation, cell death, and additional 
cellular and molecular disturbances [7]. Based on evidence that proposes that the major 
occurrence of apoptosis, white matter degeneration, and inflammatory responses occur 
during the first week after SCI [8-11], we focused this study on investigating the 
neuroprotective efficacy of a prophylactic docosahexaenoic acid (DHA; 22:6n-3) 
treatment during the acute injury phase. DHA is a promising intervention to prevent 
neurodegeneration because it can simultaneously target several pathways that contribute 
to acute SCI pathophysiology. For instance, DHA and its derivatives show anti-
inflammatory [12-14] and neuroprotective attributes [15-17]. Moreover, DHA activates 
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both Akt and CREB, which have been associated with neuroprotection and myelin 
stability in vitro and in vivo [18-21]. These beneficial effects have been reported in a 
number of neurological studies [22-25], including SCI [26-29]. However, there is a lack 
of consensus regarding the primary neuroprotective mechanisms of DHA and whether the 
protection is primarily due to direct activation of pro-survival pathways or to modulation 
of inflammation. 
Initial experiments from our lab showed that two low dose tail injections of DHA 
administered one week apart in advance of SCI significantly improved important 
functional outcomes without inhibiting microglial activation at one week after SCI. Based 
on these findings, we focused this study on the characterization of these protective 
prophylactic effects to provide strong support for the idea that DHA pretreatment may 
target various secondary injury processes associated with acute neurological impairments 
after SCI. This study further supports our initial observations and demonstrates, for the 
first time, that DHA is neuroprotective, increases functional white matter tissue 
preservation, and ameliorates locomotor and conduction deficits in the presence of an 
inflammatory environment when administered in a prophylactic manner in a rodent 
model of SCI. Our results suggest that this neuroprotection may be attributable, at least 
partially, to the activation of Akt and CREB signaling pathways and support the use of 
DHA pretreatment to successfully target the secondary injury response associated with 
acute SCI.  
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Materials and Methods 
Experimental procedures were performed in compliance with Loma Linda 
University and University of Puerto Rico School of Medicine regulations and 
institutional guidelines consistent with the NIH Guide for the Care and Use of Laboratory 
Animals.  
 
Animals 
 Young adult (200-250 grams) female Sprague-Dawley rats were used based on 
their behavioral and anatomical traits; females are normally less aggressive and less 
prone to urinary tract infections than their male counterparts. Animals were obtained 
from Hilltop Lab (Scottsdale, PA) and Charles River Laboratories (Portage, MI). Animals 
were housed with a light/dark cycle of 12/12 h, and fed ad libitum. Following preliminary 
experiments to investigate dose- and time-dependent responses, four groups of animals 
received a tail vein injection of either vehicle or docosahexaenoic acid (DHA; Compound 
ID: 445580; Source: Sigma-Aldrich; IUPAC: 4Z, 7Z, 10Z, 13Z, 16Z, 19Z-docosa-4, 
7,10,13,16,19-hexaenoic acid; MW: 328.488280 g/mol; MF: C22H32O2) at a dose of 250 
nmol/kg (~82 μg/kg) in a volume of 5 mL/kg before undergoing contusive spinal cord 
injury (SCI) or spinal cord laminectomy only (sham). The DHA stock was dissolved at 1 
M in ethanol, diluted with sterile saline, adjusted to pH 7.4, and used immediately after 
preparation. This bolus administration has been shown to lead to a concentration of ~3.8 
μM of DHA in the blood (50 nmoles DHA/13 mL blood) and is neuroprotective while 
promoting recovery in rodents at 7 days and 6 weeks when administered 30 min after 
contusive SCI [27-29]. We performed preliminary experiments to evaluate the effects of 
 31 
multiple DHA doses, routes of administration, and time of intervention. We found that 
neither a single DHA injection administered one week before nor one hour after SCI was 
sufficient to ameliorate the locomotor functional impairments when compared to vehicle 
controls (data not shown). As a consequence, the results reported herein include animal 
groups that were pretreated one week and one hour before undergoing trauma to the 
spinal cord (See Figure 1). Animals did not receive further DHA administration after 
injury. The number of animals per group was 4-6 in the sham and preliminary study 
groups and 11-12 rats in the SCI groups discussed in this manuscript.  
 
Surgical Procedures 
 To perform the injury to the spinal cord, animals were deeply anesthetized with a 
mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg). It is noteworthy that ketamine 
has been shown to induce metabolic changes and increased lipid turnover [30]. However, 
this finding seems to be significant only at higher doses than the one used in this study. 
The spinal cord was injured at thoracic level 10 (T10) using the NYU/MASCIS impactor 
device; a reliable and consistent model, which exhibits a progressive secondary injury 
expansion, including apoptotic cell death and activation of inflammatory pathways [31, 
32]. Briefly, the skin and muscles overlying the spinal column were incised and a 
laminectomy performed at T10, leaving the dura intact. The T8 and T12 spinal processes 
were clamped to the Impactor and contusion injuries were produced by releasing a 10-g 
rod from 12.5-mm onto the exposed T10 cord. Analysis of impact parameters was used to 
identify potential outliers. Behavioral analyses were also used to corroborate differences 
in injury severity within groups. Two were excluded from the study based on these 
 32 
criteria. Sham animals received only a laminectomy to expose the spinal cord. After 
surgery, muscle layers were sutured and skin layers closed with wound clips.  
 
Post-injury Care 
 Each animal received 5 mL of sterile saline injected subcutaneously. Cefazolin 
(Bristol Myers Squibb, New York, NY; 25 mg/kg, s.q.) and Buprenex® (buprenorphine; 
Reckett and Colman Pharmaceuticals, Inc. Richmond, VA; 0.05 mg/kg, s.c.) were given 
to all rats for 5 and 3 consecutive days, respectively. The bladders of injured rats were 
expressed using the Crede’s maneuver (abdominopelvic compression) three times a day 
until voiding reflex was restored. All animals survived for 7 days after surgery and 
behavioral testing was performed during this acute phase. Severe urinary tract infections, 
autophagy, mortality and morbidity are some of the major problems in post operative care 
of spinal cord injured animals. Three out of fifty-two animals were excluded from the 
data analysis because of the aforementioned reasons.   
 
Analysis of Locomotion Function 
 Rats’ spontaneous open-field locomotion was evaluated using the 22-point (0-21) 
BBB scale (Basso-Beattie-Bresnahan; [33, 34]. Briefly, animals were acclimatized to the 
open field environment during several sessions before testing. Subsequently, two double-
blinded and trained observers assessed the locomotive function, joint movement, paw 
placement and rotation, coordination, and tail and trunk position and stability for four 
minutes. In this scale, a completely paralyzed rat scores 0, a rat with increasing joint 
movements but without weight support scores between 1 and 8, a rat with abnormal 
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locomotion but with weight supported steps (plantar or dorsal) and graded coordination 
patterns scores between 9 and 20, and a normal (and sham) rat scores 21.  
 Because our data was focused on the behavioral effects of DHA during the acute 
injury phase, locomotor scores were transformed to help assure that the data were 
amendable to parametric analyses and to increase statistical power [35]. This 
transformation produces a continuous distribution by pooling together scores from 2-4 
and thus avoids potentially suspect measures of performance in the lower end of the 
scale.  Additional statistical power was also achieved by obtaining a measure of 
locomotor performance during earlier injury stages at 1, 3, and 5 days post injury (dpi). 
This provides a behavioral index of the injury extent that is correlated with long-term 
recovery (approximate values of r > 0.40, 0.60, 0.70, respectively p < 0.05, [36].  
 
Electrophysiological Assessment of Recovery 
 Analyses of axonal conductance were performed using transcranial motor evoked 
potential (tcMMEPs) studies using electrophysiological methods described previously 
[32, 37, 38]. Animals were sedated with a cocktail containing ketamine (i.m. 40 mg/kg; 
Fort Dodge Animal Health, Fort Dodge, IA) and acepromazine (i.m. 2.5 mg/kg; Vetus 
Animal Health, Rockville Center, NY). Once restrained, the magnetic transducer was 
placed over the skull and a short magnetic pulse (70 μsec; clockwise direction) was 
delivered using a Maxim 2002 stimulator (Magstim Company Limited, Spring Gardens, 
Whitland, United Kingdom) attached to a 50-mm-diameter hand-held magnetic 
transducer. Magnetically evoked EMG responses were recorded using monopolar needle 
electrodes placed on both gastrocnemius muscles. Data was amplified using Magstim 
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Neurosign 100 (Magstim Company Limited, Spring Gardens, United Kingdom). 
Afterward, the signal was converted and analyzed using the Digidata 1322A (Molecular 
Devices Corporation, Whipple Road Union City, CA) and Axoscope 8.2/Axograph X 
software, respectively (Molecular Devices Corporation). Only responses with amplitude 
measurements above 130 μV, and latencies shorter than 25 msec appearing at 70%, 85%, 
and maximum stimulation intensity were considered. Following our behavioral and 
electrophysiological assessment, animals were processed for mRNA and histological 
analyses to evaluate acute outcome measures.  
 
Tissue Preparation 
To prepare the tissue for histopathological analyses, we followed previously 
published procedures [32, 39]. Animals were submitted to fast and humane euthanasia 
with Fatal-Plus™ (Vortech; Dearborn, MI) and perfused transcardially with phosphate 
buffered saline (PBS), followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate 
buffer. During rostro-caudal tissue harvest, the area of visible bruising of the cord from 
rod impact at T10-11 was marked. The spinal cords were removed and post-fixed for 3 
hours in 4% PFA, cryoprotected in 30% sucrose for 12-16 hours at 4°C, embedded in 
Tissue-Tek® O.C.T.™ compound (Sakura, Torrance, CA), and immediately frozen on 
dry ice. A series of transverse 20-μm coronal cryodissections were cut on a Richart-Jung 
Cryocut 1800 cryostat (Leica, Deerfield, IL) kept at -20°C. Every 5th section was 
collected and placed on consecutive microscope slides (Superfrost Plus; Fisher Scientific, 
Pittsburgh, PA). Thus, each slide contained sections 1 mm apart. The slides were stored 
at  -20°C until use. 
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Myelin Staining and Quantification of White Matter Spared 
 To study the integrity of myelin and cell survival after the DHA intervention, 
histological analysis was performed on coded Luxol fast blue/cresyl violet stained 
coronal sections, as described before (Figueroa et al., 2006). The stained sections were 
visualized with an Olympus BX50 microscope and digitized with a SPOT color cooled 
CCD camera (Diagnostic Instruments, Sterling Heights, MI). Double-blinded 
morphometric analyses were performed using ImageJ software (US National Institutes of 
Health, Bethesda, MD; http://rsbweb.nih.gov/ij/index.html) to determine the extent of 
Luxol fast blue staining. 
 
Immunofluorescence 
Immunofluorescence double labeling has been described previously [32]. Spinal 
cord coronal sections were dried at room temperature for 10-15 min, washed with PBS, 
and post-fixed with 4% PFA for 10 minutes. The sections were washed, blocked and 
incubated in either mouse anti-Neun monoclonal antibody (Clone A60; 1:250; Millipore, 
Billerica, MA), mouse anti-APC-7 monoclonal antibody (Clone CC-1; 1:500; 
Calbiochem, San Diego, CA), mouse anti-NG2 chondroitin sulfate proteoglycan 
monoclonal antibody (1:250; Millipore), and mouse anti-neurofilament, heavy tail 
domain monoclonal antibody (Clone RMO-24; 1:100; Millipore) to examine the 
immunoreactivity (IR) and cell numbers of neurons, mature oligodendrocytes, 
oligodendrocyte precursor cells, and phosphate-dependent NF-H domains in axons, 
respectively. Alternatively, sections were incubated in mouse anti-GFAP (1:200; 
Millipore), mouse anti-CD11b (OX42; 1:100; AbD Serotec, Raleigh, NC), and mouse 
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anti-CD68 (ED1; 1:100; AbD Serotec) to examine the infiltration, proliferation, and 
recruitment of reactive astrocytes, monocytes/macrophages and microglial cells, 
respectively. For double-labeling immunohistochemistry, sections were concomitantly 
incubated with either anti-NeuN, anti-APC-7, and anti-NG2 antibodies and either rabbit 
anti-pAkt or rabbit anti-pCREB (1:100, 1:50, respectively; Cell Signaling, Danvers, MA). 
The antibody solutions were applied to the sections overnight at 4°C. On the following 
day, the sections were incubated with Alexa Fluor® 488 or 594-conjugated donkey anti–
mouse or anti-rabbit antibodies (1:250; Invitrogen, Carlsbad, CA). Primary antibody 
omission controls, antibody preabsorption with immunizing peptide, and normal mouse 
and donkey serum controls were used to further confirm the specificity of the IR. Slides 
were examined with an Olympus Optical Fluoview FV1000 confocal microscope. The 
images were prepared for publication with Photoshop CS4 software (Adobe Systems, San 
Jose, CA).   
 
TdT FraEL Labeling (TUNEL) and Quantification of Cell Death 
 To investigate the oligoprotective role of DHA after SCI, NG2+ cells were 
visualized and quantified after being exposed to the terminal deoxynucleotidyl transferase 
(TdT) FragEL DNA fragmentation detection kit as previously described [32]. Briefly, for 
double-label immunofluorescence, TUNEL, and NG2+ cell analyses, sections were 
respectively labeled using Fluorescein-FragEL (Oncogene Research Products, Boston, 
MA) and a primary antibody against mouse anti-NG2 chondroitin sulfate proteoglycan 
(1:250; Millipore, Billerica, MA) that was subsequently labeled with Alexa Fluor® 594-
conjugated donkey anti–mouse antibody (1:250; Invitrogen, Carlsbad, CA). Sections 
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were then coverslipped with Hoechst 33342 mounting media and observed under an 
Olympus FluoView™ FV1000 confocal microscope (Olympus America, Inc., Center 
Valley, PA). Photomicrographs were captured and analyzed for colocalization by blinded 
investigators using NIH ImageJ software. 
 
Stereological Methods and Histological Analysis 
Our unbiased stereological methods were based on the following steps: 1) 
estimation of the injury area before quantification. Spinal cords epicenters were marked 
during tissue harvest and sections were collected in successive slides thus providing a 
clearer estimation of the spinal cord regions. In addition, investigators used Luxol fast 
blue-cresyl violet staining and qualitative morphometric analyses to determine the region 
of interest before proceeding with quantification. The lesion epicenter was defined as the 
spinal cord sections containing the least amount of spared white matter. 2) 
Randomization of location and orientation within the ventrolateral funiculus (VLF), 
corticospinal tract (CST), and ventral gray matter (VGM) using appropriate sampling 
techniques. 3) Counting of cells, pixel profiles, and areas by a defined test area within an 
unbiased counting frame. 4) Normalization of time required for image acquisition to 
prevent photobleaching. 5) Digitalization and image quantification was carried out by 
blinded observers in at least four animals per group. For staining analyses, a minimum of 
four images per area per animal was used from the epicenter and 6 areas immediately 
adjacent to the lesion site. Image analyses of similar areas were averaged and the total 
sample number used for statistical analysis equaled the number of animals used. 6) Cells 
identified as positive IR were manually quantified for cells counts. Automated particle 
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analyses were used after threshold correction to detect the levels of phosphorylated Akt 
and CREB in spinal cord sections. 7) To assess the extent of white matter content, 
automated particle detection was performed using ImageJ. Briefly, images were 
converted to a binary outline image and adjusted to a similar intensity threshold. The 
number of particles in an unbiased VLF rectangular selection was quantified using the 
particle analysis tab on ImageJ. 8) Nucleic acid fragmentation in NG2+ cells was 
quantified using NIH ImageJ, adapted from previous methods [32]. The total FragEL 
fluorescence and the number of NG2+ cells that co-localized with Fluorescein-FragEL 
staining were quantified using the colocalization finder plug-in on NIH ImageJ software.    
 
RNA Extraction and Real-Time PCR 
 Animals were submitted to humane euthanasia with Fatal-Plus™ (Vortech; 
Dearborn, MI) and perfused transcardially with ice-cold 0.01 M phosphate buffered 
saline (PBS) solution, pH 7.4 (Sigma-Aldrich, St. Louis, MO) as previously described 
[32]. Spinal cord segments containing the laminectomy/injury area (5 mm) were collected 
at 7 days post operation (dpo). Total RNA was extracted using Trizol reagent (Invitrogen 
Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions and the 
RNA concentration was determined on a NanoDrop spectrophotometer (Thermo 
Scientific, Waltham, MA). One microgram (μg) of total RNA from each sample was used 
for the first strand cDNA synthesis. The first-strand cDNA synthesis was primed using 
oligo (dT) based on the SuperScript II First-Strand synthesis kit (Invitrogen, Carlsbad, 
CA). The synthesized cDNA was used as template for relative quantification of target 
transcription in spinal cord tissue by real-time PCR. The cDNA was amplified by PCR 
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using a pair of primers specific for protein kinase B (Akt, Akt1 primers were used in this 
study; FWD: 5’-TAC CAT GAA CGA CGT AGC CA-3’ and REV: 5’-AGG TGC CAT 
CAT TCT TGA GG-3’) and the cyclic AMP responsive element binding protein (CREB; 
FWD: 5’- CAT GGA CTC TGG AGC AGA CA-3’ and REV: 5’-GGG CTA ATG TGG 
CAA TCT GT 3’). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; FWD: 5’- 
TGC CAC GAA GAC TGT GG-3’ and REV: 5’- TTC AGC TCT GGG ATG ACC TT-
3’) and β-actin (FWD: 5’- GGG AAA TCG TGC GTG ACA TT-3’ and REV: 5’-GCG 
GCA GTG GCC ATC TC-3’) served as internal controls for data normalization. Real-
time PCR amplification and analysis were carried out on a CFX96 Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA). SYBR green I (P/N 4309155; 
Applied Biosystems, Foster City, CA) was used as a fluorescent reporter dye for the 
presence of double stranded DNA. After optimization of PCR conditions, 25 μl reactions 
containing cDNA, SYBR Green PCR Master Mix, and forward/reverse primers were 
prepared in triplicates. Each PCR run was repeated twice. Cycles consisted of 10 seconds 
at 95°C for denaturation and 30 seconds at 60°C for annealing/extension. A negative 
(mock) control reaction without reverse transcription was also performed to verify for 
genomic DNA contamination in our samples. The specificity of real-time PCR products 
was confirmed by melting curve analysis. A single melting curve peak was used to 
determine specificity for each gene target. Since the PCR efficiencies of our target and 
control genes were similar, the relative levels of target mRNAs were calculated using the 
comparative Ct (crossing threshold) values as previously described [32, 40, 41].  
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Statistical Analysis 
 Data are presented as mean  SEM. Two-way ANOVA followed by Bonferroni 
post hoc comparisons was used to determine the effect of our intervention and time on 
open field locomotion scores. Fisher’s exact test was used to determine the effects of our 
DHA pretreatment on the tcMMEP conduction latencies, followed by a relative risk 
estimate of the data. All other data were assessed by t-test. Statistical analyses were 
performed using Prism 5 Software (GraphPad Software Inc., San Diego, CA). Outliers 
were identified using the Grubbs’ method, also known as ESD (extreme studentized 
deviate). Alternatively, values falling more than 2 SD from the mean were excluded from 
all statistical analyses. Only two animals were excluded from the study after using these 
exclusion methods. Statistical differences were considered significant at P < 0.05. 
 
Results 
Effects of DHA Pretreatment on Hindlimb Recovery During the Acute Phase of Injury 
 After a five-day training and behavioral habituation period, female Sprague-Dawley 
rats were given two DHA injections; one at one week and an additional challenge dose at 
one hour before contusive spinal cord injury (SCI). Our rationale for the pretreatment 
schedule is based on longstanding pharmacokinetic analysis showing that intravenous 
administration of DHA results in fast incorporation [42] and accumulates in neurons and 
glia up to 7 days after injections [43]. In addition, interventions for inflammatory 
conditions, such as the use of methotrexate for rheumatoid arthritis, are administered 
weekly and in low doses [44]. Animals were allowed to survive for a full week after 
injury while behavioral data was collected at 1, 3, 5, and 7 days post-injury (dpi). At the 
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end of the study, spinal cords were harvested and tissues were used for 
inmmunohistochemical studies, RNA and protein analyses (Fig 1A summarizes the study 
timeline). 
 The Basso, Beattie, and Bresnahan (BBB) locomotor grading scale was used to 
assess the effects of DHA pre-administration in the locomotive behavior of injured rats. 
Analysis of BBB scores during the acute injury phase demonstrate significant 
improvements in locomotor behavior in DHA-pretreated rats (Fig. 1B; untransformed 
data means ± SEM: 21 ± 0, 1.5 ± 0.8, 4.5 ± 0.9, 7.1 ± 0.7, at baseline, 1, 3, 5, and 7 dpi, 
respectively; n = 10) when compared to animals treated with vehicle injections at 1, 3, 5, 
and 7 dpi (untransformed data means ± SEM: 21 ± 0, 0 ± 0, 0.4 ± 0.2, 2.3 ± 0.6, 3.5 ± 0.7 
at baseline, 1, 3, 5, and 7 dpi, respectively; n = 9) [F(3,100) = 373.19, MSE = 2289, **P 
< 0.01 at 1, 3 and 5 dpi, ***P < 0.0001 at 7 dpi]. 
  To validate our acute behavioral results, we used a simple post hoc transformation 
that improves the metric properties of the lower portion of the BBB scale [35]. 
Transformation (pooling) of BBB scores 2–4 removes the discontinuity in the grading 
scale to obtain an ordered scale and improves statistical power. Two-way ANOVA 
analysis followed by Bonferroni post hoc test after employing this approach 
demonstrated very significant differences in locomotor behavior between treatment 
groups. Our data transformation and analysis revealed improved BBB scores in the DHA-
pretreated group (Fig. 1C; transformed data means ± SEM: 12 ± 0, 1.1 ± 0.6, 2.1 ± 0.5, 
3.8 ± 0.8, 5.8 ± 0.7 at baseline, 1, 3, 5, and 7 dpi, respectively; n = 10) when compared to 
controls (transformed data means ± SEM: 12 ± 0, 0 ± 0, 0.3 ± 0.2, 1.9 ± 0.5, 2.4 ± 0.4 at 
baseline, 1, 3, 5, and 7 dpi, respectively; n = 9) [F(3,100) = 176.5, MSE = 687.6, **P < 
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0.01 at 3 and 5 dpi, ***P < 0.0001 at 7 dpi].  
 A video recording of each subject’s performance in the open field was obtained at 
1, 3, 5, and 7 dpi. Still images from representative vehicle subjects show limited 
movement, dragging of hindlegs (Fig. 1D), and slight movement of hindlimb joints (Fig. 
1E) at 7 dpi. Remarkably, DHA-pretreated animals began to show signs of intermediate 
locomotor recovery indicated by their ability to produce extensive movements of their 
joints with dorsal stepping patterns (Fig. 1F). Further, end-point BBB score analysis 
revealed a group of DHA-pretreated animals with scores at or above 8, as evidenced by 
weight supported locomotive behavior (Fig. 1G).  
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Figure 1. Acute beneficial effects of DHA pretreatment on the hindlimb neurological 
function of rats after a moderate injury, assessed by the BBB Locomotor Rating Scale. (A) 
Timeline showing the DHA injection schedule and the timepoints of behavioral assays, 
surgical procedures, and tissue sample collection. (B-G) Effect of DHA-pretreatment on 
locomotor function. Time (in days) following pretreatment and spinal cord compression 
(injury) or laminectomy (sham) is shown on the horizontal axis and untransformed (B) and 
transformed (C) Basso, Beattie, and Bresnahan (BBB) locomotor rating score is shown on 
the vertical axis. Animals pretreated with DHA had higher BBB scores at day 3, 5, and 7 
when compared to controls. Open-field locomotion still images from vehicle- (D, E) and 
DHA-pretreated animals (F, G) at 7 dpi. Mean DHA-pretreatment scores revealed that most 
animals exhibited extensive movements of three joints. DHA-pretreated animals also 
showed plantar and dorsal weight supported steps at 7 dpi (8-10 untransformed BBB 
scores). Error bars indicate SEM; vehicle vs. DHA **P < 0.01, ***P < 0.001; sham DHA, 
n = 4; sham vehicle, n = 6; injury vehicle, n = 9; injury DHA, n = 10  animals. 
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DHA Pretreatment Significantly Improves Axonal Conduction at 7 Days Post-
Contusive Spinal Cord Injury 
 Transcranial magnetic motor evoked potential (tcMMEPs) in vivo 
electrophysiology was used to evaluate the integrity of thoracic ventrolateral spinal 
myelinated tracts, which are involved in rodent locomotion [37, 45]. Electrophysiological 
responses were recorded before lesion (baseline) and at 7 days post injury (dpi). Figure 1 
shows representative tcMMEP traces for baseline (Fig. 2A) and treatment groups (Fig. 
2B, C). Animals receiving vehicle injections displayed no tcMMEP responses at 7 dpi 
(Fig. 2B). Remarkably, 67% of the DHA-pretreated animals showed latencies below 25 
msec and amplitudes above 130 V after transcranial magnetic stimulation at 7 dpi (Fig. 
2C). Data from baseline and treated animals is summarized in Fig. 2D-E. Contingency 
table and statistical analyses revealed a P value of 0.0303 using Fisher’s exact test (n = 
12). Strength of association analysis demonstrated an odds ratio of 23.40 CI (0.8925 to 
613.5) with a sensitivity of 1.000 CI (0.5407 to 1.000) and a specificity of 0.6667 CI 
(0.2228 to 0.9567).   
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Figure 2. DHA administration before SCI reduces some of the conduction blockade 
associated with SCI at 7 dpi. Transcranial magnetic motor evoked potential (tcMMEP) 
responses recorded bilaterally from gastrocnemius muscles at 7 dpi. (A) Baseline; (B) 
Vehicle; and (C) DHA-pretreated animal at 7 dpi. (D) Sixty-seven percent (67%) of the 
pretreated animals showed improved nerve conduction and were considered responsive. 
All vehicle treated animals were non-responsive at 7 dpi. (E) Summary of tcMMEP 
conduction latencies (ms) averages on responsive animals. Contingency table and 
statistical analyses revealed a P value of 0.0303 using Fisher’s exact test, n = 12.   
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DHA Pretreatment Increased the Density of the Ventrolateral Funiculi (VLF) Spared 
White Matter at One Week Post-Injury 
 To evaluate the histopathology of functionally significant ventrolateral white 
matter tracts and to validate our behavioral and electrophysiological findings, we 
performed Luxol fast blue (LFB) staining in spinal cord sections of DHA-pretreated and 
control animals. Figure 3A shows representative gray-scaled LFB stained transverse 
sections encompassing seven distinct areas at 1mm intervals that extend 3 mm rostrally 
and caudally from the lesion epicenter. The lesion epicenter (0 mm) was defined as the 
section exhibiting the largest white matter damage at 7 dpi. Closer examination showed 
contusion-induced white matter degeneration as evidenced by reduced LFB staining (Fig. 
3B-C). The staining density of randomized ventral white matter areas was quantified 
using automated particle counter analysis on binary photomicrographs from different 
VLF regions (Fig. 3B’-C’). Quantitative histological analyses revealed increased myelin 
staining in the epicenter of DHA-pretreated rats when compared to vehicle treated 
animals at 7 dpi (Fig. 3D; Student’s t-test, n at least 4 animals, *P < 0.05). 
Immunohistochemistry with anti-neurofilament H, NF-H, was used to assess axonal 
integrity after our DHA intervention. Qualitative analysis of immunostained sections 
revealed more NF-H immunoreactivity in the ventrolateral white matter of DHA-
pretreated animals when compared to our control group (Fig. 3E-F). Control experiments 
were carried out to determine antibody specificity (Fig. 3G and 3H). Arrows denote NF-
H positive axons in white matter. 
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Figure 3. DHA-pretreatment increase white matter sparing of functionally significant areas 
of the spinal cord at 7 dpi. (A, B) Luxol fast blue (LFB)-stained spinal cord sections from 
vehicle- (A) and DHA-pretreated rats (B) were taken from the lesion epicenter and adjacent 
areas of  at 7 dpi. (B, C) LFB-stained sections were morphometrically analyzed after 
tresholding binary images using ImageJ software (B’, C’). (D) Results from quantification 
of particle counts on bilateral analysis of VLF regions (rectangles in B and C) in seven 
spinal cord areas (ranging from +3 to -3 mm from lesion epicenter (0 mm). Analysis of 
LFB staining in VLF regions revealed that DHA pretreatment significantly increases white 
matter spared in the lesion epicenter when compared to vehicle-treated animals at 7 dpi. 
Student’s t-test analysis was carried out to determine the statistical significance differences 
between treatments. (E, F) Laser scanning confocal microscope photomicrographs 
revealed that DHA-pretreatment increased neurofilament (NF-H) immunoreactivity in 
ventrolateral white matter regions at 7 dpi. (G) Dorsal roots were used as positive controls 
for NF-H immunoreaction. (H) Primary antibody omission controls were used to further 
confirm the specificity of the immunohistochemical labeling. Error bars represent means ± 
SEM. *P < 0.05; n = 4-8 animals per area (at least 5 photomicrographs/animal/spinal cord 
area). Scale bars: B-C, 100 m; E-F, 50 m; G-H; 50 m.  
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DHA Pretreatment Decreases Apoptotic Cell-death in Functionally Relevant White 
Matter Areas and Oligodendrocyte Precursor Cells After SCI 
 To investigate whether DHA-pretreatment reduces the activation of apoptotic 
pathways after SCI, we assessed apoptotic cell death in the white matter using fluorescent 
TUNEL. We observed a marked reduction in the number of TUNEL-positive cells in the 
WM as compared to those found in vehicle controls at 7 dpi (Fig. 4A; **P = 0.0043; n = 
8 per group). Representative photomicrographs of white matter spinal cord regions 
stained with Fluorescein-FragEL and counterstained with DAPI (B-E). Images 
demonstrate increased DNA fragmentation in vehicle-treated animals (B, C) when 
compared to DHA-pretreated animals (D, E).  
 To investigate whether DHA decreases the susceptibility of oligodendrocyte 
precursor cell (OPC) to undergo apoptosis after SCI, we quantified the DNA 
fragmentation in NG2+ cells using immunohistochemical analysis. Examination of 
immunoreactivity in the VLF revealed that the number of NG2+ cells undergoing DNA 
fragmentation was significantly reduced in our DHA-pretreated group at 7 dpi (Fig. 4A; 
*P = 0.0320; n = 4 per group). In these analyses, apoptotic cells (Fluorescein-FragEL+) 
were examined and scored as positive only if they colocalized with NG2+ and DAPI 
immunoreactivity (Fig. 4F-G).  
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Figure 4.  Prophylactic intervention with DHA reduces the number of white matter cells 
undergoing apoptosis after SCI. (A) Results from ImageJ-assisted co-localization analysis 
showed a significant reduction in the number of total DAPI/FragEL+ and FragEL+/NG2+ 
cells in the WWM regions. Representative photomicrographs from white matter analyses 
show increased DNA fragmentation in control groups (B, C) when compared to DHA-
pretreated animals at 7 dpi (D, E). Images from representative triple-labeled (DAPI, NG2, 
FragEL) sections show that vehicle groups had increased DNA fragmentation marker in 
NG2+ cells (F) when compared to DHA-pretreated animals (G). Student’s t-test analysis 
was carried out to determine the statistically significant differences between treatments. 
Error bars represent means ± SEM. **P = 0.0043, n = 8 in total WM analysis; *P = 0.0320, 
n = 4 in NG2+ cell analysis. Scale bar: B-E, 50 m; F, G, 10 m. DAPI, blue; anti-NG2, 
red; FragEL, green; arrows = colocalization. 
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DHA Pretreatment Increases NeuN+, APC+, and NG2+ Cell Numbers 
 To determine the quantity of neurons, oligodendrocytes, oligodendrocyte lineage 
cells, and inflammatory cells in areas involved in the observed locomotor and 
electrophysiological responses, immunohistochemical analyses were performed at the 
critical apoptotic stage of 7 dpi. Detection of neuronal and oligodendrocyte phenotypes 
was assessed by anti-NeuN and anti-adenomatosis polyposis coli (APC) antibodies, 
respectively. Alternatively, the anti-NG2 antibody was used to determine the number of 
potential oligodendrocyte precursor cells (OPCs). Cell counts were made in relevant 
areas involved in rodent locomotion such as ventral gray matter (VGM), ventrolateral 
funiculus (VLF), and dorsal corticospinal tract (dCST; Fig. 5A). Our results revealed a 
significant increase in the number of NeuN+ cells in the ventral gray matter of DHA-
pretreated animals (* P < 0.05; vehicle, n = 10; DHA, n = 9). In addition, the relative 
number of oligodendrocytes and OPCs was doubled in the DHA-pretreated groups at 7 
dpi (both * P < 0.05; vehicle, n = 6 rats; DHA, n = 7 rats). Representative images from 
sections labeled with anti-Neu N (Fig. 5C-D), anti-APC (Fig. 5E-F), and anti-NG2 (Fig. 
G-H) show increased numbers of neurons, oligodendrocytes, and oligodendrocyte 
precursor cells in the DHA-pretreated group at 7 dpi.  
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Figure 5. Pretreatment with DHA preserves neurons, oligodendrocytes, and 
oligodendrocyte precursor cells at one week after SCI. (A) Expression of cellular markers 
were quantified in the ventral gray matter (VGM), ventrolateral funiculi, and dorsal 
corticospinal tract (dCST). These regions were identified by superimposing a series of 
photomicrographs to a T10-T11 spinal cord diagram from the Watson, Paxinos, Kayalioglu 
spinal cord atlas. (B) Manual quantification of cell numbers and normalization to vehicle 
controls revealed increased numbers of NeuN+, APC+, and NG2+ cells in the VGM, dCST, 
and VLF, respectively. Confocal images from sections immunoreacted against NeuN (C, 
D), APC (E, F), and NG2 (G, H) demonstrate increased immunoreaction to each marker in 
the DHA-pretreated animals when compared to controls. Student’s t-test analysis was 
carried out to determine the statistical significance differences between treatments. Error 
bars represent means ± SEM. (NeuN, * P < 0.05, vehicle, n = 10, DHA, n = 9; both APC 
and NG2 * P < 0.05, vehicle, n = 6, DHA, n = 7. Scale bars: A-F, 50 m; G-H, 25 m. 
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Prophylactic Injection with DHA Did Not Result in Significant Anti-inflammatory 
Effects at 1-week Following Compression Injury 
 Although the beneficial effects of inflammation in SCI remain controversial, it 
has been increasingly recognized that the recruitment and activation of inflammatory 
cells during the first week after trauma may play a critical role in modulating functional 
recovery after SCI [46]. To determine whether DHA pretreatment reduces the expression 
of these inflammatory markers in physiologically relevant areas, we quantified the 
number of immunoreactive particles using immunohistochemical analysis. Surprisingly, 
DHA pretreated animals showed no significant differences in the immunoreactivity to 
ED1 (monocytes/macrophages/microglia; Fig. 6A-E) and GFAP (astrocytes; Fig. 6F-J) 
when compared to vehicle controls (P > 0.05; n = at least 4 animals). To validate our 
ED1 results and determine whether our DHA prophylactic intervention reduced the 
activation of microglia, OX42 antibody was employed to examine the expression of 
CD11b/c in microglia in the spinal cord. No significant differences were observed 
between the studied groups (data not shown).  
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Figure 6. Pretreatment with DHA did not affect inflammatory markers after SCI. 
Photomicrographs from ED1 labeled monocytes/macrophages in animals injected with 
vehicle (A, B) or DHA (C, D). (E) Quantitative analysis showed no significant changes in 
the number of ED1 immunoreactive particles between treatment groups in any of the 
regions of interest (ROI) studied at 1 week post-injury. Representative images from GFAP 
labeling of astrocytes in animals injected with vehicle (F, G) or DHA (H, I). (J) Quantitative 
analysis at 1 week revealed no significant changes in the optical density of GFAP-
immunoreactive particles between treatment groups. Error bars represent means ± SEM. n 
= at least 4 animals. VLWM, ventrolateral white matter; VGM, ventral gray matter; dCST, 
dorsal corticospinal tract.  Scale bar: A-D and F-I, 200 m.   
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DHA-pretreatment Induces the Up-regulation and Activation of Akt and CREB 
After Contusive SCI 
 Akt and CREB have been associated with DHA protective effects on survival and 
myelin stability in vitro and in vivo [18-21]. We examined whether DHA-pretreatment 
increases the mRNA and protein phosphorylation levels of Akt and CREB after acute 
SCI. Real-time PCR analysis revealed that DHA pretreatment increased Akt and CREB 
levels 1.61- and 2.03-fold, respectively, at 7 dpi when compared to the vehicle controls 
(Fig. 7A; both *P < 0.05; n = 4 animals/group). Quantitative determination of Akt and 
CREB protein phosphorylation was performed by measuring the relative 
immunoreactivity to anti-pAkt and anti-pCREB antibodies. Gray-scale calibration of 0-
255, representing white-to-black, permitted measurements of optical density values in 
immunoreactive sections. Quantitative analysis of pAkt and pCREB immunoreactivity in 
our DHA-pretreated group demonstrated a 1.59- and 1.70-fold increase, respectively, 
when compared to controls (Fig. 7B; both *P < 0.05; vehicle, n = 4 animals; DHA, n = 5 
animals). Interestingly, DHA-pretreatment did not change the levels of pAkt and pCREB 
in the uninjured spinal cord (data not shown). Gray matter photomicrographs show pAkt 
(Fig. 7C-D) and pCREB (Fig. 7F-G) immunoreactivity in neuron like cells (arrows). 
These cells had an intensely positive pAkt and pCREB signal in nuclear and perinuclear 
regions (Fig. 7D and G). Antibody preabsorption with blocking peptides shows reduced 
immunoreactivity; thus confirming the specificity of each antibody (Fig. 7E and H).  
 We also examined whether DHA-pretreatment resulted in increased pAkt and 
pCREB levels in the different cellular phenotypes that were neuroprotected at 7 dpi. Gray 
matter double-labeling immunohistochemistry revealed increased neuron cell numbers 
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and immunoreactivity for pAkt (Fig. 8A-L) and pCREB (Fig. 9A-L). White matter 
photomicrographs also demonstrated increased cell numbers with concomitant expression 
of pAkt and pCREB in NG2+ (Fig. 8M-R; Fig. 9M-R, respectively) and APC+ cells (Fig. 
8S-X; Fig. 9S-X, respectively).  
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Figure 7. Intravenous administration of DHA before of SCI results in increased mRNA 
and phosphorylated protein levels of Akt and CREB at 7 days post-injury. (A) Quantitative 
analyses of real-time PCR crossing thresholds showed a significant increase in the mRNA 
levels of Akt and CREB in the DHA-pretreated group when compared to control animals. 
(B) Quantification of immunoreactive particle counts in ventral gray and white matter 
using ImageJ revealed increased levels of pAkt and pCREB in the DHA-pretreated group 
at 7 dpi. (C-H) Photomicrographs of immunostained section confirmed the specificity of 
pAkt and pCREB reactions. This immunoreaction was abolished after preincubating pAkt 
and pCREB antibodies with their respective blocking peptides (E, H). Antibody specificity 
was also demonstrated by immunoblot (C, E, F, H, insets). Student’s t-test analysis was 
carried out to determine the statistical significance between treatments. Error bars represent 
means ± SEM. mRNA studies *P < 0.05; n = 4 per group; IMH studies *P < 0.05; n = 4, 
vehicle, n = 5, DHA. Arrows, immunoreactive cells in ventral gray matter. Arrowheads, 
no immunoreactive cells. Scale bars: D and G, 50 m; C, E, F, and H, 50 m. 
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Figure 8. Double labeling and merge photomicrographs of NeuN, APC, and NG2 cells 
immureactive for pAkt in transverse sections at the ventral and dorsal gray matter, 
ventrolateral funiculus, and dorsal corticospinal tract of the T10-T11 spinal cord segment. 
pAkt expression and neuron cell numbers were higher in ventral gray motor neurons of 
DHA-pretreated (A-C) when compared to vehicle sections (D-F). pAkt was more 
abundantly expressed in dorsal gray motor neurons of DHA-pretreated animals (G-I) when 
compared to controls (J-L).  Ventrolateral white matter photomicrographs show more pAkt 
and NG2+ cells in DHA-pretreated animals (M-O) when compared to vehicle controls (P-
R). Images from representative dorsal columns/dorsal corticospinal tract in DHA-
pretreated (S-U) and control groups (V-X). Scale bars: A-F, 50 m; G-L, 50 m; M-R, 50 
m; S-X, 50 m.  
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Figure 9. Double labeling and merge photomicrographs of NeuN, APC, and NG2 cells 
immureactive for pCREB in transverse sections at the ventral and dorsal gray matter, 
ventrolateral funiculus, and dorsal corticospinal tract of the T10-T11 spinal cord segment. 
Photomicrographs show increased pCREB expression and neuron cell numbers in ventral 
(A-F) and dorsal (G-L) gray motor neurons of DHA-pretreated (A-C, G-I) when compared 
to vehicle sections (D-F, J-L). pCREB was robustly colocalized with NG2 
immunoreactivity in the ventrolateral white matter of DHA-pretreated animals (M-O) 
when compared to controls (P-R). Images from dorsal corticospinal tract revealed more 
pCREB in APC+ cells of DHA-pretreated groups (S-U) when compared to controls (V-X). 
Scale bars: A-F, 50 m; G-L, 50 m; M-R, 50 m; S-X, 50 m.  
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Discussion 
The results presented herein clearly demonstrate that docosahexaenoic acid 
(DHA), when injected in a prophylactic manner, resulted in amelioration of locomotor 
and conduction deficits observed during the acute phase of SCI.  These acute beneficial 
effects were evidenced by (i) improved BBB scores, (ii) the emergence of motor evoked 
potentials, (iii) white matter tissue preservation, (iv) increased numbers of neurons, 
oligodendrocytes, and precursor cells, (v) activation of pro-survival and anti-apoptotic 
responses without reduction in inflammatory markers, and (vi) increased gene expression 
and activation of Akt and CREB. Altogether, these data suggest that DHA-mediated 
neuroprotection can occur even under significant inflammatory conditions and supports 
the prophylactic use of DHA in situations of anticipated high risk of damage to the spinal 
cord. 
There are numerous clinical and occupational scenarios that are known to exhibit 
a significant risk for SCI. Example of these conditions include cerebral palsy, spina 
bifida, amyotrophic lateral sclerosis, vitamin B12 deficiency, herpes simplex viral 
infection, multiple sclerosis, atherosclerosis, iatrogenic ischemia, syringomyelia, 
spondylolysis, disc herniations, radiation toxicity, tumors, contact sports, and warfare [1, 
4, 5]. Although the primary pathophysiology of non-traumatic SCI is disease-specific, the 
clinical signs, symptoms, and general therapeutic principles are similar to traumatic SCI. 
The clinical safety and neuroprotective properties of DHA make it an ideal prophylactic 
treatment in these situations because its ability to simultaneously inhibit multiple 
pathways involved in cell death and dysfunction such as apoptosis [47], excitotoxicity 
[48], ROS generation [49] and inflammation [50]. Interestingly, contrary to dietary DHA, 
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a single low dose DHA injection results in acute blood-brain-barrier penetration and 
incorporation in the brain [51] and is rapidly metabolized and accumulated in neurons 
and glial cells even at 7 days after the injection [43]. This is consistent with recent studies 
revealing that DHA injections are neuroprotective at 7 dpi when administered after injury 
to the spinal cord [27] whereas dietary supplementation with DHA did not confer 
neuroprotection [28]. It is reasonable that injection pretreatment with DHA could lead to 
a significant inhibition of very early damaging events and promote recovery after SCI. 
A striking finding of this study is that DHA pretreatment led to a significant 
reduction in locomotor deficits associated with contusive SCI, as evidenced by the 
improvements in BBB locomotor scores at different time points during the acute phase of 
SCI. Remarkably, DHA-pretreated animals exhibited extensive movements in all three 
joints and weight supported steps at 7 days post-injury (dpi). Our findings are supported 
by studies showing that pretreatment with polyunsaturated fatty acids (PUFAs) provide 
tolerance against ischemic-induced neurodegeneration [52], reduce disabilities after 
traumatic brain injury in rats [53], confer neuroprotection from brain hypoxia-ischemia 
[54], and increase resistance to PTZ-induced seizures [55].  
Another important finding of our study is the emergence of transcranial magnetic 
motor evoked potential (tcMMEPs) electrophysiological responses at 7 dpi. The 
appearance of these responses provide a reproducible and objective assessment of axonal 
conduction of descending motor pathways in both the normal and injured spinal cord [32, 
56, 57]. Moreover, this measurement is useful to evaluate the conduction capacity and 
integrity of descending myelinating pathways located in the medial ventrolateral 
funiculus (VLF) [37, 38]. Our results are the first demonstration of in vivo 
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electrophysiological improvements after acute bolus administration of DHA before SCI. 
This may represent preservation of myelinated fibers and return of function in spared 
reticulospinal fibers, which run mainly in the VLF and carry important motor 
information. Our anatomical and histological data support this idea by showing increased 
ventrolateral white matter tissue sparing and axonal integrity in DHA-pretreated animals 
when compared to vehicle controls at 7 dpi.    
  Both neurons and oligodendrocytes are extremely vulnerable to cell death 
following SCI [58]. Several lines of evidence demonstrate that during the first few days 
after injury, acute apoptotic and autophagic waves contribute to tissue damage and loss of 
function after SCI in animals [9, 10, 59-62], and humans [63]. Here, we demonstrated 
that bolus DHA injection given before SCI significantly increased neuronal and 
oligodendrocyte cell survival at 7 dpi. In support of this finding, DHA has been shown to 
be neuro- and oligoprotective when administered and supplemented after SCI [26-29]. 
Previous in vitro work from our laboratory is also in agreement with these 
neuroprotective actions after showing that preventive administration of DHA in advance 
of lipotoxic injury protects NGFD-PC12 cells from apoptotic cell death (Almaguel et al., 
2009).  
 Proliferation of progenitor cells expressing NG2 proteoglycans may play a role in 
replenishing oligodendrocytes and may determine neurological outcomes after acute SCI 
[64-66]. It was recently proposed that these precursor cells might also have a broader 
relevance for gray matter physiology based on the observation that some of these cells 
can mature into cortical projection neurons [67]. Therefore, strategies targeting precursor 
cells with beneficial pro-survival agents may represent a viable mechanism for neuronal 
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and oligodendrocyte replacement, spinal cord homeostasis, and functional recovery. Our 
results show, for the first time, not only that DHA pretreatment leads to increased 
numbers of NG2+ cells, but also that DHA prevents apoptotic cell death in these cells 
after SCI. Apoptotic reduction may be partially responsible for the white matter sparing 
and improved functional behavior observed in our study [68, 69]. Future studies are 
needed to clarify the effects of DHA in precursor cell survival, proliferation, and 
differentiation after SCI.  
  Although DHA plays an important role in neuroprotection and functional 
recovery, we lack information regarding its underlying mechanisms after SCI. Previous 
reports suggest that therapeutical treatment with DHA after SCI may exert its 
neuroprotective effects, at least partially, through negative modulation of cycloxigenase-2 
protein expression and by means of reducing peroxidation and oxidation products [28]. 
This same group demonstrated that DHA administration after SCI results in improved 
recovery associated with a significant reduction of inflammatory markers, such as ED1 
[27, 28]. Contrary to this finding, this study showed no significant differences in the 
immunoreactivity levels of various inflammatory makers, including GFAP (astrocytes), 
CD68 (macrophages), and CD11b (microglia). This discrepancy suggests that DHA 
pretreatment may have different targets during the first few minutes after injury. DHA is 
rapidly and selectively incorporated into the central nervous system (CNS) when injected 
in rats [51] and it is also acutely released from cell membranes after SCI [70]. Thus, it is 
plausible that acute accretion of DHA in advance of SCI might promote neuroprotection 
by triggering the docosanoid pathway and DHA-derived messengers, including 
docosatrienes, resolvins, and neuroprotectins, such a neuroprotectin D1 (Bazan, 2006). 
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Also, while DHA multiple double bonds are excellent targets for lipid peroxidation and 
could potentiate neurotoxicity, DHA may also function as a free-radical scavenger to 
reduce the neuronal and glial susceptibility to oxidative stress after trauma. We cannot 
discard the possibility that DHA could reduce the effects of primary injury by modulating 
the biophysical properties of membranes and axons [71]. Future work is needed to study 
the acute targets of DHA when administered before injury to the spinal cord. 
  Dietary DHA increases the levels of activated Akt and CREB in rats [19]. These 
signaling pathways play a major role in DHA-mediated neuronal survival [72], provide 
resistance to CNS insults [73-75], and increase endogenous protection in the retina [76]. 
Our findings showing that Akt and CREB expression was up-regulated in DHA 
pretreated rats are in agreement with the involvement of these molecules in estrogen-
mediated neuroprotection after SCI [77]. Current work in our lab is aimed at investigating 
whether Akt/CREB activation is required to exert DHA neuroprotective effects in a 
prophylactic manner (Descoberth et al., Unpublished observations).  
 In summary, our findings are the first to demonstrate that acute pretreatment with 
DHA renders neural tissue more resistant to SCI-induced secondary damage possibly by 
limiting the expansion of the apoptotic pathways (See summary in Table 1). This report 
substantiates the relevance of DHA as a preventive neuroprotective agent, which may 
confer a clear advantage in situations of anticipated neuronal damage, and deserves 
further consideration as an innovative approach to prevent neurodegeneration and injury 
expansion after SCI. Further studies testing the durability of these neuroprotective effects 
over longer post-SCI survival times are being tested. 
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Table 1. Summary. 
 
DHA pretreatment in advance of contusive SCI results in relevant physiological, 
anatomical, histological, and molecular changes. Our electrophysiological, 
immunohistochemical, and molecular biology assays indicate that two bolus injections 
of DHA given 1 week and 60 min before SCI reduces locomotor impairments and 
conduction latencies, increased neuroprotection, and results in increased mRNA and 
phosphorylated protein levels of the pro-survival proteins Akt and CREB.  
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Abstract 
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) confer multiple health benefits 
and decrease the risk of neurological disorders. However, studies are needed to identify 
promising cellular targets and to assess their prophylactic value against 
neurodegeneration. The present study (1) examined the efficacy of a preventive diet 
enriched with ω-3 PUFAs to reduce dysfunction in a well-established spinal cord injury 
(SCI) animal model and (2) used a novel metabolomic analysis to identify potential 
mechanisms and neurolipidomic targets. Rats were fed with either control chow or chow 
enriched with ω-3 PUFAs (750 mg/kg/day) for 8 weeks before being subjected to a sham 
or a contusion SCI operation. We report new evidence showing that rats subjected to SCI 
after being pretreated with a diet enriched with ω-3 PUFAs exhibit significantly better 
functional outcomes. Pretreated animals exhibited lower sensory deficits, autonomic 
bladder recovery and early improvements in locomotion that persisted for at least 8 
weeks after trauma. We found that SCI triggers a robust alteration in the cord PUFA 
neurolipidome, which was characterized by a marked DHA deficiency. This DHA 
deficiency was associated with dysfunction and corrected with the ω-3 PUFA-enriched 
diet. Multivariate data analyses revealed that the spinal cord of animals consuming the ω-
3 PUFA-enriched diet had a fundamentally distinct neurolipidome, particularly increasing 
the levels of essential and long chain ω-3 fatty acids and lysolipids at the expense of ω-6 
fatty acids and its metabolites. Altogether, dietary ω-3 PUFAs prophylaxis confers 
resiliency to SCI mediated, at least in part, by generating a neuroprotective and 
restorative neurolipidome.  
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Introduction 
Spinal cord injury (SCI) leads to debilitating and long-lasting motor, sensory, and 
bladder dysfunction. Primary mechanical injury to the spinal cord initiates a complex 
cascade of secondary damaging events, including prominent metabolic alterations, axonal 
damage, inflammation, cell death, and demyelination.[1] Although current therapeutic 
strategies aimed at alleviating the secondary injury are promising,[2, 3] studies 
identifying and addressing potential determinants of vulnerability to neurological 
dysfunction in experimental models of injury are very limited. Accumulating evidence 
suggests that the susceptibility to damage that follows SCI depends on the intrinsic 
balance between neurorestorative and neurodestructive signals.[4] 
Injury to the spinal cord results in a robust deregulation of membrane 
polyunsaturated fatty acid (PUFA) homeostasis; leading to membrane derangements and 
preferential release of arachidonic acid (AA; 20:4, ω-6 PUFA) and peroxidation of 
docosahexaenoic acid (DHA; 22:6, ω-3 PUFA).[5-11] These derangements can lead to ω-
6 fatty acid metabolism and marked ω-3 PUFA deficiencies, altering PUFA nutritional 
requirements. Further, the essential role of these lipids in physiology and cell signaling is 
believed to be important in the neural responses to injury and could predispose nerve 
cells to dysfunction. For instance, AA and its potent pro-inflammatory mediators are 
implicated in secondary damage cascades and dysfunction after SCI.[12-16] In contrast, 
ω-3 PUFAs, such as DHA, are anti-inflammatory, confer neuroprotection, and play 
significant roles in facilitating functional recovery in various SCI animal models.[12, 17-
22]  
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One important hypothesis arising from our work and from other published 
epidemiological evidence is that dietary ω-3 PUFAs can confer resiliency and facilitate 
recovery, even when administered before SCI. We recently reported that acute parenteral 
administration of DHA before injury leads to early improvements in conduction and 
locomotor function following SCI.[22] This finding is consistent with studies showing 
the efficacy of ω-3 PUFAs as a post-treatment modality to ameliorate secondary damage 
and dysfunction.[12, 17-24] However, there is still a significant gap in our knowledge 
concerning the therapeutic effects of prophylactic ω-3 PUFAs against neurotrama.  
Here, we assessed whether SCI significantly alters ω-3 PUFA requirements in the 
cord, and whether pretreatment with dietary ω-3 PUFAs, without further 
supplementation, is sufficient to reduce dysfunction following SCI. Addressing this 
question is particularly important for populations where neurological injury is an 
unavoidable high risk (i.e., neurodegenerative conditions, contact sports, and military 
conflicts) and can have major implications for the identification of biomarkers of neural 
vulnerability to dysfunction. 
 
Materials and Methods 
Animals 
 Experimental procedures were performed in compliance with the Loma Linda 
University School of Medicine regulations and institutional guidelines consistent with the 
NIH Guide for the Care and Use of Laboratory Animals. A total of fifty-four female 
Sprague-Dawley rats weighing 182-212 g were received from Charles River Laboratories 
(Portage, MI). Animals were housed in individual cages with food and water ad libitum 
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and exposed to alternate light and dark periods of 12 h.  
 
Study Design 
The animals were allowed to acclimatize for one week after arriving to the animal 
facility and were randomly divided into two main groups: (Group A) animals received 
the control diet (n = 27) and (Group B) animals received the ω-3 PUFA-enriched diet (n 
= 27) (Fig. 1A). After 8 weeks on these diets, the rats were further divided into four 
groups based on their dietary and surgical interventions: Group 1 was the control diet, 
sham operated group (n = 8); Group 2 was the control diet, spinal cord injured group (n = 
19); Group 3 was the ω-3 PUFA-enriched diet, sham operated group (n = 8); and Group 4 
was the ω-3 PUFA-enriched diet, spinal cord injured group (n = 19). The respective 
dietary interventions were continued after surgery. Autonomic bladder, sensory and 
motor functions were assessed after surgery. The best attempts were made to perform 
behavioral tests in a blinded manner. Spinal cord tissue was collected for analyses at 8 
weeks post-operation (wpo).  
 
Diet Composition 
 Custom isocaloric AING-93-based diet formulations were designed with 
modifications to the fat composition (Bio-Serv, Frenchtown, NJ). The level of dietary fat 
was approximately 6% of dry weight supplied as either soybean oil (control chow) or 
menhaden fish oil (ω-3 PUFA-enriched chow). Both of the diets were stored refrigerated. 
Lab analyses using gas chromatography coupled with mass spectrometry demonstrated 
that the level of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in the 
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menhaden fish oil was 12.82-gm and 6.91-gm, respectively, per 100 gm of diet. The level 
of cholesterol was 0.582-gm/100 gm. This amount was added to control diets to make the 
levels consistent to that of the fish oil diet. The selection of soybean oil as control fat in 
our diets was based on the following observations: (1) soybean oil is the principal source 
of ω-3 fatty acids in the U.S., and (2) mammals have a limited capacity to convert DHA 
from linolenic acid (LA: 18:3, ω-3). 
 
Spinal Cord Injury Surgical and Post-Operative Procedures  
After 8 weeks of receiving either dietary intervention, the animals were deeply 
anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg). The spinal 
cord was injured at thoracic level 10 (T10) using the well-characterized NYU 
Impactor.[25] Briefly, the skin and muscles overlying the spinal column were incised. A 
laminectomy was performed at T9-T10, leaving the dura intact and the T8 and T12 spinal 
processes were clamped to the Impactor. A 10-g rod was released from 12.5-mm onto the 
exposed spinal cord to induce mild to moderate trauma. Analysis of the biomechanical 
impact parameters revealed no significant differences between control and treated groups 
(control diet group: 1.799  0.051-mm, 0.478  0.005 m/s, and 0.382  0.007 m/s vs. ω-3 
PUFA-enriched diet group: 1.748  0.058-mm, 0.478  0.008 m/s, and 0.385  0.013 m/s 
values for compression, impact velocity, and compression rate, respectively; average  
SEM). The sham animals received only a laminectomy to expose the spinal cord. During 
surgery, the body temperature of the animals was maintained at 37°C using a 
thermostatically controlled heating pad with a rectal thermometer (Physitemp TCAT-
2LV; Physitemp, Clifton, NJ). After surgery, the muscle layers were sutured and the skin 
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layers were closed with wound clips. The bladders of injured rats were expressed using 
the Crede’s maneuver three times a day until voiding reflexes were restored. Cefazolin 
(Bristol Myers Squibb, New York, NY; 25 mg/kg, s.q.) and Buprenex® (buprenorphine; 
Reckett and Colman Pharmaceuticals, Inc. Richmond, VA; 0.05 mg/kg, s.c.) were given 
to all rats for 5 and 3 consecutive days, respectively. Two animals died because of 
surgical complications during this study. All other animals were allowed to survive for 8 
wpo. 
 
Autonomic Function Testing 
Autonomic Bladder Control Recovery 
For all injured animals, the residual volume of urine expressed each morning was 
measured during the first 11 days post-injury (dpi; period during which full recovery of 
bladder function occurs after mild to moderate contusive injury in the rat). We also 
recorded the day on which autonomic bladder control was restored (e.g., when the 
maximal volume of urine collected in one session is consistently below 500 µL).  
 
Motor Function Testing 
Behavioral Evaluation of Spontaneous Locomotion.  
Rats’ spontaneous open-field locomotion was evaluated using the 22-point (0-21) 
Basso-Beattie-Bresnahan scale.[26, 27] Briefly, animals were acclimatized to the open 
field environment during 5 daily sessions one week before SCI. After the SCI, the open 
field locomotion test was videotaped weekly. Subsequently, two observers assessed the 
locomotive function, joint movement, paw placement and rotation, coordination, and tail 
 79 
and trunk position and stability. For each hindpaw, the averaged consensus score was 
used for analyses. In this scale, a completely paralyzed rat scores 0, a rat with increasing 
joint movements but without weight support scores between 1 and 8 (recovery stage 1), a 
rat with abnormal locomotion but with weight supported steps scores between 9-13 
(recovery stage 2), graded coordination patterns, paw position, and trunk stability scores 
between 14 and 20 (recovery stage 3), and a normal (and sham) rat scores 21.   
Locomotor scores were transformed using a simple post hoc method that reduces 
error variance and improves the metric properties of the BBB, effect size, and power.[22, 
28] This transformation produces a continuous distribution by pooling together BBB 
scores from 2–4 and 14-21 and thus avoids potentially suspect measures of performance 
from unlikely observations in the lower/higher end of the scale. 
 
Sensory Function Testing 
Habituation 
Animals were habituated to sensory behavioral tests during 5 daily sessions held 
one week prior to baseline recordings. 
 
Electronic von Frey Test 
Sensory function was assessed by measuring the withdrawal threshold of the 
hindpaws in response to a mechanical stimulus using an electronic von Frey 
aesthesiometer (model 2391C; IITC Life Science, Woodland Hills, CA, USA). Each 
animal was placed in a Plexiglas chamber positioned on an elevated metallic grid floor, 
which provided access to the plantar surface of the hind paw. Animals were allowed to 
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acclimate to the environment for 30 min before testing. A rigid blunt tip attached to the 
meter was applied to the plantar surface from under the floor. The withdrawal threshold 
was defined as the average force (g) required for paw removal in five trials separated by a 
1-min interval. The maximum and minimum threshold values were excluded from each 
paw after each testing session. The data was normalized to the percent change from 
baseline and sham animals. The normalized % change from baseline represents 
[(withdrawal threshold injury @ baseline – withdrawal threshold injury @ time point X) / withdrawal 
threshold injury @ baseline] X 100 – [(withdrawal threshold shams  @ baseline – withdrawal 
threshold shams @ time point X) / withdrawal threshold shams @ baseline] X 100.  
 
Metabolomic Analyses 
Metabolon’s Sample Preparation and Metabolic Profiling 
The unbiased metabolic profiling platform employed for this analysis combined 
three independent platforms:  ultrahigh performance liquid chromatography/tandem mass 
spectrometry (UHPLC/MS/MS2) optimized for basic species, UHPLC/MS/MS2 
optimized for acidic species, and gas chromatography/mass spectrometry (GC/MS). The 
spinal cord samples were processed essentially as described previously.[29, 30] For each 
sample, 100μL was used for analyses. Using an automated liquid handler (Hamilton 
LabStar, Salt Lake City, UT), protein was precipitated from the plasma with methanol 
that contained four standards to report on extraction efficiency. The resulting supernatant 
was split into equal aliquots for analysis on the three platforms. Aliquots, dried under 
nitrogen and vacuum-desiccated, were subsequently either reconstituted in 50μL 0.1% 
formic acid in water (acidic conditions) or in 50μL 6.5mM ammonium bicarbonate in 
 81 
water, pH 8 (basic conditions) for the two UHPLC/MS/MS2 analyses or derivatized to a 
final volume of 50μL for GC/MS analysis using equal parts bistrimethyl-silyl-
trifluoroacetamide and solvent mixture acetonitrile:dichloromethane:cyclohexane (5:4:1) 
with 5% triethylamine at 60°C for one hour. In addition, three types of controls were 
analyzed in concert with the experimental samples: aliquots of a well-characterized 
human plasma pool served as technical replicates throughout the data set, extracted water 
samples served as process blanks, and a cocktail of standards spiked into every analyzed 
sample allowed instrument performance monitoring. The experimental samples and 
controls were randomized across the platform run days. 
For UHLC/MS/MS2 analysis, aliquots were separated using a Waters Acquity 
UPLC (Waters, Millford, MA) and analyzed using an LTQ mass spectrometer (Thermo 
Fisher Scientific, Inc., Waltham, MA), which consisted of an electrospray ionization 
(ESI) source and linear ion-trap (LIT) mass analyzer.  The MS instrument scanned 99-
1000 m/z and alternated between MS and MS2 scans using dynamic exclusion with 
approximately 6 scans per second. Derivatized samples for GC/MS were separated on a 
5% phenyldimethyl silicone column with helium as the carrier gas and a temperature 
ramp from 60°C to 340°C and then analyzed on a Thermo-Finnigan Trace DSQ MS 
(Thermo Fisher Scientific, Inc.) operated at unit mass resolving power with electron 
impact ionization and a 50-750 atomic mass unit scan range. 
Metabolites were identified by automated comparison of the ion features in the 
experimental samples compared to a reference library of chemical standard entries that 
included retention time, molecular weight (m/z), preferred adducts, and in-source 
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fragments as well as associated MS spectra. The metabolites were curated by visual 
inspection for quality control using software developed at Metabolon.[31]  
 
RNA Isolation and Reverse Transcription 
Animals were submitted to humane euthanasia with Fatal-Plus, and perfused 
transcardially with ice-cold 0.01 M PBS solution, pH 7.4 (Sigma-Aldrich). Spinal cord 
segments containing the injury areas adjacent to the injury site (5 mm each) were 
collected at 8 weeks post-operation (wpo). Total RNA was extracted using the Trizol 
reagent (Invitrogen) according to the manufacturer’s instructions and the RNA 
concentration was determined on a NanoDrop spectrophotometer (Thermo Scientific). 
cDNA was prepared with 800 ng of RNA by reverse transcription using SuperScript II 
and random primers (Invitrogen). 
Real time PCR. PCR amplification and analyses were carried out on a CFX96 
Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). The cDNA 
was amplified by PCR using pairs of primers specific for protein kinase B (Akt1; FWD: 
5’-TAC CAT GAA CGA CGT AGC CA-3’ and REV: 5’-AGG TGC CAT CAT TCT 
TGA GG-3’), and the cyclic AMP responsive element binding protein (CREB; FWD: 5’-
CAT GGA CTC TGG AGC AGA CA-3’ and REV: 5’-GGG CTA ATG TGG CAA TCT 
GT 3’). Each well contained 25 µL as the final PCR reaction volume containing cDNA, 
primers and the SYBR green PCR master mix (Applied Biosystems, Foster City, CA). 
All samples were run in triplicates. Thermal cycling conditions were as follow: 10 sec at 
95°C for denaturation, and 30 sec at 60°C for annealing/extension. Relative mRNA 
quantities were compared between groups using the crossing threshold values. 
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; FWD: 5’-TGC CAC GAA GAC 
TGT GG-3’ and REV: 5’-TTC AGC TCT GGG ATG ACC TT-3’) was used as the 
internal control gene, and amplification specificity was checked using melting curve 
analyses. Mock reactions were performed as negative controls.  
 
Immunodetection 
Western Blot 
Eight weeks after the operations, the spinal cord segments were processed for 
Western blot analysis as described previously.[32] Briefly, 5 mm spinal cord segments 
were dissected and immediately frozen. The tissue containing injured epicenter-to-caudal 
regions was then homogenized manually with a Dounce tissue grinder in 200 µL of 1% 
SDS in Tris–EDTA buffer with proteinase inhibitors (10 µg/mL aprotinin, 1 µg/mL 
leupeptin, and 1 mM PMSF) and then sonicated. After centrifugation at 14,000 rpm, the 
supernatant was assayed for protein concentration using the method of Lowry[33] and 
bovine serum albumin as a standard. Thirty micrograms of protein were diluted in 
Laemmli’s buffer, loaded and run in 4-12% SDS-polyacrylamide gels, and transferred to 
nitrocellulose membranes. Membranes were blocked using Odyssey blocking buffer (LI-
COR Biosciences, Lincoln, NE). The relative amounts of Akt and CREB proteins were 
detected using rabbit anti-Akt and anti-CREB antibodies (1:1000 each; Cell Signaling, 
Danvers, MA). After a 2 h incubation in primary antibodies, the membranes were washed 
three times for 10 min in Tris-buffered saline with 0.1% Tween-20 and incubated in 
donkey anti-rabbit IgG conjugated with IRDye® 800CW for 1 h (1:15,000; LI-COR 
Biosciences). Membranes were washed as above and the images were captured using an 
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Odyssey infrared imaging system (LI-COR Biosciences). Protein relative expression was 
standardized to -actin levels, which were detected using mouse anti--actin antibodies 
(1:2000; Abcam, Cambridge, MA) and goat anti-mouse IRDye® 680RD secondary 
antibodies (1:20000, LI-COR Biosciences). Quantitative analyses were carried out using 
ImageJ 1.45I software (http://rsb.info.nih.gov/ij/ index.html).  
 
Statistical Analysis 
Statistical analyses were performed using SPSS 20.0 (IBM: SPSS, Armonk, New 
York), Prism 5 software v5d (GraphPad Software Inc., San Diego, CA), MetaboAnalyst 
(www.metaboanalyst.ca), and the “R” program (http://cran.r-project.org/). Two-Way 
Analysis of Variance (ANOVA) followed by Bonferroni post-hoc comparisons were used 
to determine the effect of our dietary/surgical intervention and time on rat’s pellet 
consumption, weights, residual urine volume, open-field locomotion scores, and sensory 
threshold changes. ANCOVA was also used to test multi-interactions between weight, 
pellet consumption and functional behavior at baseline and at different timepoints within 
and between the groups. All other data were assessed by one-way ANOVA, t-tests, or the 
Mann-Whitney U test. The Kolmogorov-Smirnov and Shapiro-Wilk normality tests were 
used to investigate outliers and spread. Outliers were also identified using the Grubbs’ 
method, also known as ESD (extreme studentized deviate; www.graphpad.com). Only 
two animals were excluded from the study after using these exclusion methods in our 
behavioral data. To analyze neurometabolic alterations, multivariate data analysis 
(MVDA) -partial least squares projections to latent structures discriminant analysis (PLS-
DA) - was performed using MetaboAnalyst software. Spearman’s rank correlation tests 
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were used to explore associations between the top metabolic ratios contributing to model 
variability and the behavioral phenotypes. Data are presented as mean  SEM. Statistical 
differences were considered significant at p < 0.05. 
 
Results 
The rationale behind the chosen ω-3 PUFAs dose, pretreatment schedule, and 
end-point measures was based upon (1) studies that indicate that animals that are fed diets 
enriched with 6% fish oil, such as the one used in this study, can take up to 8 weeks to 
significantly alter the lipid profile of the rat brain,[34] (2) studies that demonstrate that 
fatty acid incorporation occurs in a manner that is highly correlated with the amount 
consumed and with brain needs,[35, 36] (3) studies revealing that the beneficial effects of 
ω-3 PUFAs in the central nervous system (CNS) could be readily observed with dietary 
interventions lasting 6-8 weeks and at doses ranging from 10 mg/day to 400 
mg/kg/day,[19, 37-39] and (4) evidence that supports that damage/repair processes take 
place following chronic SCI.[40-43] The study design is summarized in Fig. 1A.  
 Animals were housed in individual cages and the baseline food consumption was 
monitored daily. Food intake resulted in an average intake of 15 pellets per day (Fig. 1B). 
This amount resulted in approximately 500 mg docosahexaenoic acid (DHA) and 250 mg 
eicosapentaenoic acid (EPA) per kilogram of animal body weight (BW). It is known that 
rats and humans have similar dietary requirements for PUFAs (% of total energy). 
However, the relationship between body size and the rate of metabolic processes (and 
thus time) needs to be taken into account when dosing. For instance, the relationship 
between basal metabolic rate (BMR) and body weight in different size mammals is 
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described by the function Y = aX0.75, where Y is basal metabolic rate (kJ/d), X is body 
weight (kg) and a is basal metabolic rate per kg0.75 per day, which is 300 kJ/(kg0.75 ・ d).     
 Thus, the BMR in different size species is proportional to the body weight raised 
to the 0.75 power, also known as the metabolic weight. Assuming that the BMR 
comprises 75% of the total metabolic rate, then the total metabolic rate can be described 
by the function Y = 400 X0.75. From this relationship, the total metabolic rate of a 70-kg 
human is 400 × 700.75 = 9680 kJ or 138 kJ per kg body weight. Similarly, the total 
metabolic rate of a 200 g rat is 400 × 0.2000.75 = 120 or 600 kJ per kg body weight. Thus, 
the absolute energy expenditure expressed in kJ per kg body weight is greater in rats than 
in humans. Therefore, although the DHA dose used in this study (500 mg/kg) would be 
equivalent to approximately 35 mg of DHA/day in a 70-kg human, this amount would be 
far less when corrected for metabolic weight. Also, when using this correction, the 8-
week feeding period used herein is analogous to approximately one year in humans.[44]   
 Two-way ANOVA analyses identified time as the only significant source of 
variation in food intake between groups [F(8,1082) = 29.33; p < 0.0001, n = 8 control 
groups, n = 18 experimental groups]. Post hoc analysis revealed a significant reduction in 
the amount of pellets ingested at one week post-operation (wpo) when compared to 
baseline consumption (30 % reduction; p < 0.05). Normal feeding behavior was re-
established by week 2 after surgery when compared to baseline values (p > 0.05).   
Two-way ANOVA revealed that diet/surgical intervention [F(3,7044) = 62.97] 
and time [F(8,3439) = 11.53] had significant effects on animal weights (p ≤ 0.0001 for 
both) (Fig. 1B). Post hoc analysis showed no significant differences in animal BW at 
baseline (p > 0.05). Although in both groups the injury resulted in a 8-10% reduction in 
 87 
body weight, post hoc analysis demonstrated no significant differences in BW when 
comparing 1 wpi to baseline values in animals fed with the ω-3 PUFA-enriched diet (p > 
0.05). In contrast, significant BW loss was found in the control-diet fed animals at 1 week 
post-injury (wpi) (p < 0.01). In both diet groups, baseline BW was re-established at 3 
wpi. It is noteworthy that although sham animals showed similar pellet consumption 
when compared to injured rats, no differences in weight were observed in the first few 
weeks after operations. In contrast, injured rats showed a marked metabolic disconnect, 
as evidenced by weight loss despite similar caloric intake to sham counterparts.   
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Figure 1. Dietary and weight monitoring. (A) Timeline outlining experimental 
design. (B) Baseline food resulted in an average intake of 15 pellets per day (500 mg 
docosahexaenoic acid and 250 mg eicosapentaenoic acid per kg of animal body weight per 
day). Surgery resulted in a significant reduction in food intake that returned to baseline 
levels at 2 weeks post-operation (wpo). No significant differences were found between 
groups (p>0.05, n=8–18 animals per group). (C) Dietary ω-3 polyunsaturated fatty acids 
(PUFAs) pre-treatment prevented significant weight losses when compared with injured 
rats receiving control diets at 1 week post-injury (wpi). Although dietary intake was 
similar, sham animals gained more weight than injured counterparts.  
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Dietary ω-3 PUFA Prophylaxis Accelerates Bladder Recovery, Improves Locomotor 
Function, and Ameliorates Sensory Dysfunction 
SCI results in a period of marked bladder dysfunction.[45] Because animals need 
assistance with bladder voiding during the first few days after SCI, we collected and 
quantified the residual urine volume to assess whether a dietary ω-3 PUFA intervention 
show efficacy in accelerating autonomic bladder recovery. Of special significance, 
ANOVA identified type of diet as a significant source of variance between groups in the 
course of 11 days post-injury (dpi) [F(1,69.42) = 5.88; p = 0.0208, n = 18 per group] (Fig. 
2A). Further, full autonomic recovery of bladder control (two or more days with a 
residual volume equal or less than 0.5 mL) occurred significantly earlier in animals 
receiving ω-3 PUFA-enriched diets (6.1  0.6 dpi) when compared with controls (9.5  
0.4 dpi) (Unpaired t-test t = 4.97 df = 34; p < 0.0001) (Fig. 2B).  
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Figure 2. Beneficial effects of dietary ω-3 PUFAs prophylaxis on autonomic function after 
contusion injury. (A) Residual urine volumes (mL) differed significantly between control 
and ω-3 polyunsaturated fatty acids (PUFAs) pre-treated groups (analysis of 
variance, p=0.0208, n=18). Dashed line represents cutoff volume used to determine 
complete autonomic recovery. (B) For each animal, the number of days needed to attain 
full autonomic recovery was defined as residual volume of 0.5 mL for 2 or more 
consecutive days. Dietary ω-3 PUFAs prophylaxis resulted in fewer days to attain full 
bladder recovery (Mann-Whitney U test, p<0.0001, n=18  
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To characterize the effects of dietary ω-3 PUFA prophylaxis in motor recovery 
after SCI, we used the Basso Beattie, Bresnahan (BBB) locomotor behavior scale 
followed by score transformations.[28] Two-way ANOVA followed by Bonferroni’s post 
hoc testing demonstrated significant differences in BBB locomotor scores between 
animals receiving ω-3 PUFA-enriched diets and control diets [Untransformed data: 
F(3,8636) = 460.1; Transformed data: F(3,1542) = 117.7; for both p < 0.0001) (Fig. 3A 
and B). A striking finding of this study is that locomotor recovery was significantly 
accelerated in the group of animals receiving ω-3 PUFA-enriched diets when compared 
to controls. This was evidenced by their ability to produce extensive joint movements and 
occasional weight supported steps at 1 wpi (transformed BBB scores, mean  SEM: 
control diet = 1.53  0.38, n = 17 vs. ω-3 PUFA-enriched diet = 5.47  0.62, n = 17; p < 
0.0001) (Fig. 3B). Interestingly, post hoc analysis showed that these differences in 
locomotor behavior persisted at least until 8 wpi (p < 0.05). End-point outcome measures 
showed that animals receiving control diets were able to step occasionally or frequently 
but with no signs of locomotive coordination at 8 wpi (transformed score: 8.2  0.86). In 
contrast, rats receiving ω-3 PUFA-enriched diets displayed consistent weight-supported 
plantar steps (or frequent plantar stepping and occasional dorsal stepping), consistent 
coordination, and paw rotation during locomotion at 8 wpi (transformed score: 11.88  
0.08). 
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Figure 3.  Dietary ω-3 polyunsaturated fatty acids (PUFAs) prophylaxis improves 
somatic function after contusion injury. (A) Dietary ω-3 PUFAs prophylaxis results in 
significant early and long-lasting functional milestones after SCI. (B) These results 
remained significant after pooling unusual observations and improving the metric 
properties using the Basso-Beattie-Bresnahan (BBB) score transformations. Interestingly, 
control animals reached a recovery plateau at 4 weeks (occasional weight supported plantar 
steps with no coordination: BBB score=10; transformed BBB score=8), whereas dietary 
prophylaxis resulted in prolonged recovery when compared with controls (displayed 
consistent weight-supported plantar steps and coordination at 8 weeks post-injury: BBB 
score=14; transformed BBB score: 12). Data are presented as mean±standard error of the 
mean (SEM); asterisks indicate significance level: Two-way analysis sof variance followed 
by Bonferroni post hoc*p<0.05, **p<0.01, ***p<= 0.001, n=8–18.   
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 To examine the effect of dietary ω-3 PUFA on sensory function after SCI, the rats 
were subjected to electronic von Frey testing using a nonpunctate blunt probe. A 
remarkable finding of this study is that the ω-3 PUFA diet prevented major sensory 
deficits (mechanical hypoalgesia or loss of sensitivity) associated with chronic SCI in 
adult rats [43] [F(1,14919) = 8.592; p = 0.0039] (Fig. 4A). Post hoc analyses showed 
significant differences in normalized hindpaw withdrawal thresholds between animals fed 
with control diets (≈ 66 % change from baseline) and ω-3 PUFA-fed groups (≈ 9 % 
change from baseline) at 8 wpi (p < 0.01) (Fig. 4A).  
 To determine whether a diet enriched in ω-3 PUFA reduces the likelihood of 
developing sensory dysfunction, we used the K-means clustering method to assign all rats 
to three groups according to their mechanical sensory thresholds changes at 8 wpi. 
Clustering resulted in a group of animals with statistically significant increases in 
hindpaw withdrawal thresholds at 8 wpi when compared to their respective baseline 
values (hypoalgesia cluster). The second cluster of animals did not show significant 
threshold changes between baseline and 8 wpo (normal cluster). The third cluster 
(hypoalgesia ++) also revealed hypoalgesic behaviors when compared to baseline (this 
cluster contained three animals fed with control diets). It is noteworthy that the average 
baseline value from this third cluster was also significantly lower when compared to the 
other two groups. Clustering validation results are summarized in Fig. 4B [hypoalgesic 
behavior (cluster): F(2,634.2) = 4.03,  p = 0.022; time: F(1,2543) = 32.33, p < 0.0001]. 
Remarkably, we found that only 23% of the animals receiving ω-3 PUFA diets were 
clustered in the group of animals with significant sensory dysfunction (hypoalgesic 
clusters combined; Fig. 4C). In marked contrast, more than 75% of the control animals 
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showed significant sensory deficits. Fisher’s exact test revealed that this difference was 
significant (p = 0.02; strength of association analysis demonstrated an odds ratio of 0.09 
[95% CI = 0.01 to 0.60], with a sensitivity of 0.23 [95% CI = 0.05 to 0.54] and a 
specificity of 0.23 [95% CI = 0.05 to 0.54]).   
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Figure 4. Dietary ω-3 polyunsasturated fatty acids (PUFA)s prevents sensory dysfunction 
after chronic spinal cord injury (SCI). (A) Electronic von Frey test shows that SCI results 
in increased withdrawal threshold (hypoalgesia). Remarkably, ω-3 PUFAs prophylaxis 
prevented alterations in paw sensitivity when compared with baseline (BL) (p>0.01). Post 
hoc revealed significant effects were observed between dietary groups at 8 wpi (p<0.05). 
Data are expressed as %Δ paw withdrawal threshold from BL (and normalized to %Δ in 
sham animals; mean±standard error of the mean [SEM], n=13). (B) K-means clustering 
divided mechanical sensory thresholds (g of force required to elicit hind paw withdrawal) 
into three groups: (1) normal (no differences between baseline and 8 weeks post-operation 
(wpo); two-way analysis of variance followed by Bonferroni's post-hoc test, p>0.05), (2) 
hypoalgesia (significant difference between baseline and 8 wpo; p<0.05), and (3) 
hypoalgesia++ (extremely significant difference between baseline and 8 wpo; p<0.05). 
Data are presented as mean±SEM. (C) Dietary ω-3 PUFAs prophylaxis significantly 
reduced the number of animals in which sensory dysfunction developed. K-means 
clustering was followed by the Fisher exact test to determine whether diet altered the 
predisposition of animals for development of sensory deficits. Analyses revealed that 
dietary ω-3 PUFAs reduced the probability of development of major sensory dysfunction 
(hypoalgesia) by 54% when compared with controls (Fisher exact testp=0.02, n=26).  
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Distinctive Neurolipidomic Signatures are Associated with Injury Operations and 
Dietary Interventions 
To investigate the neurolipidome, we interrogated the levels of lipid metabolic 
features across 36 spinal cord epicenters using both LC/MS and GC/MS. Unsupervised 
hierarchical clustering was used to arrange the lipid metabolites on the basis of their 
relative levels across tissue samples and generate heat maps of the spinal cord 
neurolipidome (Fig. 5). Remarkably, we found distinctive metabolic lipid signatures in 
each studied group.  
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Figure 5. Heat map representation of unsupervised hierarchical clustering. Data are 
arranged in metabolites (rows) by sample type (columns). Metabolite family description: 
A, carnitine metabolism; B, eicosanoids; C, essential fatty acids and free fatty acids; D, 
glycerolipids; E, inositol metabolism; F, ketone bodies; G, long chain fatty acids; H, 
lysolipids; I, medium chain fatty acids; J, monoacylglycerols; K, sphingolipids; L, sterols 
and steroids. Green and red colors represent metabolite decreases and increases, 
respectively, relative to the median metabolite levels. See color scale. 
PUFA=polyunsaturated fatty acids; SCI=spinal cord injury. 
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 Partial least squares projections to latent structures – discriminant analysis (PLS-
DA) was performed to determine if the lipid features were capable of distinguishing 
group separations using a supervised projection technique (Fig. 6B). Of significance, our 
analyses revealed a projection in which the groups were significantly separated (p < 0.01 
by permutation test). PLS-DA score plot was obtained using the variation scores of the 
first two principal components, PC1 (34.3%) and PC2 (18.1%) (Fig. 6A). Each plot mark 
corresponds to an animal subject and the variability in relative lipid metabolite levels 
detected for that animal. The first component, PC1, separated the sham animal spectra 
from injured animals. The second component, PC2, separated the spectra from control 
diets and animals receiving ω-3 PUFA-enriched diets. Hotelling’s T2 confidence ellipse, 
at a significance level of 0.05, revealed no outliers. Since score plots and loading plots 
are complementary, superimposing them depicts the impact of metabolites in the score 
plot model and show how the metabolites are correlated (most influential variables are 
further from zero on each loading; correlated variables are grouped together). As 
expected, the PLS-DA loading plot showed that the levels of ω-3 and ω-6 PUFAs had the 
strongest influence on the separation observed in our score plot model (Fig. 6B). Variable 
influence on projection (VIP) analyses, which reflects the impact of metabolites in the 
PLS-DA model, confirmed these findings by showing that PUFAs had a robust impact in 
both components of our PLS-DA model (VIP values higher than 1). Interestingly, DHA 
levels had only a slight effect in the projection model (low VIP values or low influence), 
which supports its fast metabolism and avid incorporation in neural membrane 
phospholipids. Figure 7 summarizes the main effects of chronic SCI and diet on the 
biosynthetic pathway of ω-3 and ω-6 PUFAs. We found that the ω-3 PUFA-enriched diet 
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significantly skewed the PUFA metabolism towards increased ω-3 at the expense of 
reduced ω-6 PUFA levels in both sham and injured animals.  
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Figure 6. Multivariate data analyses. (A) PLS-DA score plot containing two first 
components. Each plot mark corresponds to an observation (individual rat spinal cord 
sample). The confidence ellipses are based on the Hotelling T2 and illustrate the 95% 
confidence regions. Principal component 1 (PC1; x-axis) describes differences in the 
spectra between sham and injury operations. Principal component 2 (PC2; y-axis) shows a 
marked separation between control and ω-3 diets. Score plot analyses revealed statistically 
significant separations between groups (p<0.01 by permutation test). (B) Loading plot 
between PC1 and PC2. Loading 1 explains differences between sham and injured animals, 
whereas features in loading 2 explain differences between dietary interventions. Groups 
with stronger impact are further away from the plot origin (represented by dashed lines). 
Data demonstrate that ω-3 polyunsaturated fatty acids (PUFAs) contributed significantly 
to lipidomic differences between injured animals (location in loading 2 is far from zero). 
In contrast, analyses revealed that ω-6 PUFAs present a major contribution to both model 
loadings (loading 1: surgery effects and loading 2: diet effects), validating their role in 
chronic spinal cord injury and modulation by dietary ω-3 PUFAs. Correlated metabolites 
were grouped together to facilitate data presentation. 
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Figure 7. Chronic spinal cord injury (SCI) results in marked deregulation of ω-3 (A) and 
ω-6 (B) Polyunsaturted fatty acid (PUFA) metabolic pathways corrected by ω-3 PUFA-
enriched diet. Green (decrease) and red (increase) arrows represent statistically significant 
alterations when compared with controls (two-way analysis of variance followed by post-
hoc testing was performed. Differences were significance at p<0.05). (C) Box and 
whiskers legend depict metabolite relative levels relative to the median metabolite levels 
in each group. For each ω-3 and ω-6 PUFA metabolite, variable influence on projection 
(VIP) values were included for projections to latent structures discriminant analysis 
principal component (PC) 1 and 2. For each component, VIP scores higher than 1 are 
considered significant contributors to the group separations. (D)Summary of PUFA 
biosynthetic pathways. AA, arachidonic acid; DGLA, dihomo-γ-linolenic acid; GLA, γ-
linolenic acid; DPA, docosapentaenoic acid; SDA, stearidonic acid; PG, prostaglandins; 
LT, leukotrienes; TX, thromboxanes; HEPE, hydroxyeicosapentaenoic acid; HETE, 
hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid. 
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Chronic Spinal Cord Injury Dysfunction is Linked to DHA Deficiency and Corrected 
by a Preventive ω-3 PUFA Dietary Intervention 
 A number of studies have shown that feeding animals increased amounts of fish 
oil ω-3 PUFAs has a profound effect on PUFA biosynthetic pathways, particularly 
increasing tissue levels of DHA (22:6, ω-3), DPA (22:5, ω-3) and EPA (20:5, ω-3) at the 
expense of AA (20:4, ω-6).[46] Our results validate these findings and demonstrate that 
chronic SCI results in dramatic alterations in PUFA metabolism that can be corrected and 
prevented by dietary prophylaxis with ω-3 PUFAs. Previous evidence supports that 
dietary supplementation with ω-3 PUFAs results in improved CNS function.[47] On the 
other hand, deficiencies in ω-3 PUFAs have been associated with numerous neurological 
impairments.[48-52] DHA deficiency is accompanied by concomitant increases in 
docosapentaenoic acid (DPA; 22:5, ω-6) levels, thus the ratio of ω-6 DPA to DHA has 
been suggested as a biochemical marker of low ω-3 PUFA status.[53, 54] Using liquid 
and gas chromatography coupled with mass spectrometry (LC/MS and GC/MS), we 
measured the relative levels of ω-6 DPA and DHA in the spinal cord lesion/laminectomy 
epicenter area. We used the ω-6 DPA to DHA ratio to determine: (1) whether chronic 
SCI results in a DHA deficiency, (2) whether our dietary intervention altered this ratio, 
and (3) whether this deficiency has functional consequences in SCI. One-way ANOVA 
showed very significant differences in ω-6 DPA to DHA ratios between groups 
[F(3,10.66) = 67.53, p < 0.0001]. Post hoc analyses demonstrated that SCI resulted in a 
significant ω-6 DPA to DHA ratio increase (DHA deficiency) when compared to sham 
animals at 8 wpo (p < 0.0001 and p < 0.01, respectively) (Fig. 8A), showing that DHA 
nutritional requirements may be enhanced after SCI. Remarkably, the dietary ω-3 PUFA 
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diet significantly reduced this DHA deficiency when compared to the animals fed with 
control chow during chronic SCI (p < 0.0001; n = 10). Although DHA levels were 
increased in the animals receiving diets enriched with ω-3 PUFAs, no significant 
differences were observed when comparing the ω-6 DPA to DHA ratio in sham animals 
from both dietary groups (p > 0.05, n = 8 rats per sham group). This supports the 
proposed idea that PUFAs are tightly regulated under physiological conditions and shows 
that the control diet itself did not generate the DHA deficiency. It is also noteworthy that 
the observed effects are not likely due to a deficiency in ω-6 fatty acids in the animals fed 
with ω-3 PUFA. This is supported by the finding that diet type had no significant effect 
on the levels of mead acid (20:3, ω-9), a biomarker of linoleic acid (18:2, ω-6) deficiency 
(data not shown).  
To investigate the potential pathophysiological consequences of DHA deficiency 
in recovery after SCI, we performed Spearman’s correlation analyses to determine the 
relationship between the ω-6 DPA to DHA ratio and functional behavior. Because it has 
been proposed that molecular determinants of early autonomic recovery may also 
influence locomotor function (and vice versa),[55] we also investigated the correlation 
between chronic DHA deficiency and bladder recovery. Notably, increases in the ω-6 
DPA to DHA ratio were positively associated with the number of days needed to full 
bladder recovery in animals receiving control diets (r value = 0.80, p < 0.001; n = 17 
pairs) (Fig. 8B). The ω-6 DPA to DHA ratio showed a robust negative correlation with 
BBB locomotor scores (r = -0.82, p < 0.0001) (Fig. 8C). Further, this ratio was positively 
correlated with mechanical hypoalgesia (r = 0.74, p < 0.01) (Fig. 8D). Together, these 
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findings show for the first time that DHA deficiency after SCI may increase susceptibility 
for dysfunction and/or hinder functional recovery.  
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Figure 8. Chronic spinal cord injury results in significant dicosahexaenoic acid (DHA) 
deficiency that is corrected by a ω-3 polyunsaturated fatty acid (PUFA)-enriched 
diet. (A) Deficiency of the dietary-essential DHA (22:6, ω-3) was measured by assessing 
the levels of docosapentaenoic acid (DPA) (22:5, ω-6). After injury, both dietary groups 
presented significant increases in the ω-6 DPA to DHA ratio. Notably, injured animals 
consuming ω-3 PUFAs showed a significant reduction in the ω-6 DPA to DHA ratio when 
compared with injured animals receiving control diets at 8 weeks post-injury (wpi). This 
reduction was comparable to the baseline levels observed in the sham-operated animals 
receiving the control diet. The ω-6 DPA to DHA ratio was similar in both sham groups. 
Spearman rank correlation showed that the ω-6 DPA to DHA ratio is strongly associated 
with bladder (B), locomotor (C), and sensory function (D). Data were generated by 
correlating the levels of the ω-6 DPA to DHA with the number of days needed for full 
bladder recovery (1–11), the Basso-Beattie-Bresnahan (BBB) locomotor scores (0–21), 
and mechanical threshold changes from baseline at 8 wpi (% change from baseline). This 
was repeated for each animal receiving control diets (n=15–17 pairs for each behavioral 
test). R and p values are included for each graph. Line depicts the regression line. Black 
arrows in Y-axes represent direction of increased dysfunction in each behavioral test. Grey 
arrows in X-axes represent direction of increased DHA deficiency. 
  
 106 
Dietary ω-3 PUFAs Increase Protein Kinase B/Akt and CREB mRNA Levels, Even in 
Sham-operated Animals 
 Protein kinase B/Akt (Akt) and the cyclic AMP-response-element-binding protein 
(CREB) have been implicated in regulating neural plasticity[56-58] and pro-survival and 
regenerative responses in SCI.[22, 59-61] Prior studies from our lab and others have 
shown that DHA-mediated beneficial effects may be mediated, at least partially, through 
activation of Akt and/or CREB signaling pathways.[22, 62] To determine whether a diet 
rich in ω-3 PUFAs results in modulation of these neuroreparative molecules after chronic 
SCI, we examined Akt and CREB mRNA levels at 8 wpi. ANOVA followed by 
Bonferroni’s multiple comparison test revealed no significant changes in Akt mRNA 
levels when comparing both injury groups [F(3,0.26) = 0.91, t = 0.40, CI(-0.76 to 0.56), p 
> 0.05] (Fig. 9A). In contrast, our analyses revealed a 1.9-fold increase in CREB mRNA 
levels in animals that were fed with ω-3 PUFAs when compared to controls at 8 wpi 
[F(3,3.73) = 9.03, t = 3.44, CI(-1.72 to -0.09), p < 0.05, n ≥ 4) (Fig. 9A). Western blot 
analyses demonstrated that n ω-3 PUFA-enriched diet resulted in a 2.6-fold increase in 
Akt protein levels when compared to controls at 8 wpi (Mann Whitney U (4.0), two-
tailed, sum (25,53), p = 0.026, n = 6) (Fig. 9B). Further, when compared to controls, 
dietary ω-3 PUFAs induced a significant 4.3-fold increase in the protein levels of CREB 
at 8 wpi  (Mann Whitney U (2.0), two-tailed, sum (17,49), p = 0.017, n = 6) (Fig. 9B).  
 
  
 107 
 
 
 
 
Figure 9. Dietary ω-3 polyunsaturated fatty acids (PUFAs) prophylaxis results in increased 
expression of pro-restorative signaling molecules. (A)Quantitative analyses of real-time 
polymerase chain reaction crossing thresholds showed a significant increase in cyclic AMP 
responsive element binding (CREB) protein mRNA levels in the ω-3 PUFA-pre-treated 
group when compared with control animals at 8 weeks post-injury (analysis of variance 
followed by Bonferroni post hoc, p<0.05, n≥4–5). (B) Immunoblot of spinal cord samples 
showing Akt (60 kDa) and CREB (approximately 47 kDa) protein upregulation after 
dietary pre-treatment with ω-3 PUFAs. Analyses show that dietary ω-3 PUFA prophylaxis 
resulted in increased Akt and CREB protein levels when normalized to actin levels (Mann-
Whitney U test, p<0.05, n=6). Error bars represent standard error of the mean.   
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Discussion 
The present study shows that a diet enriched in ω-3 polyunsaturated fatty acids  
(PUFAs) prophylaxis is sufficient to ameliorate autonomic, motor, and sensory function 
after experimental contusion SCI in rats. These improvements showed a significant 
association with the cord lipidome, particularly an ω-3 PUFAs accumulation at the 
expense of ω-6 PUFAs. Chronic SCI resulted in distinct lipidomic signatures, including a 
marked DHA deficiency, which was accompanied by dysfunction and a limited capacity 
to support functional recovery.  Notably, a diet enriched with ω-3 PUFAs was effective in 
reducing this deficiency and resulted in the up-regulation of the pro-survival and repair 
proteins, Akt and CREB. A proposed mechanism for ω-3 PUFA-mediated prophylaxis 
against SCI is presented in Fig. 10.  
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Figure 10. Putative mechanisms underlying the beneficial effects of dietary ω-3 
polyunsaturated fatty acids (PUFAs) prophylaxis in spinal cord injury (SCI). A preventive 
nutritional therapy with ω-3 PUFAs results in accumulation of ω-3 PUFAs in the spinal 
cord neural membranes, which may provide extended neuroprotection and repair substrates 
after SCI. Lipid metabolism alterations under this dietary regime leads to reduced ω-3 
deficiencies, particularly dicosahexaenoic acid (DHA), and preferentially activates ω-3 
PUFA metabolism. This response may result in regaining PUFA homeostasis and enhanced 
pro-restorative signaling, such as protein kinase B/Akt and cyclic AMP responsive element 
binding (CREB) protein and/or additional uncharacterized mechanisms. Omega-3 PUFAs 
may provide important substrates implicated in stress resistance, such as induction of 
antioxidant gene expression, cell growth, and membrane homeostasis and remodeling. 
Together, this response should result in improved tissue sparing, plasticity, and repair. 
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Pretreatment with a ω-3 PUFA-enriched Diet Improves Somatic and Autonomic 
Recovery after Contusion SCI 
The spinal cord is at high risk of injury during surgeries, high-impact sports, 
military conflicts, and in several congenital and degenerative CNS disorders.[63-65] Of 
significance, for patients undergoing SCI, the recovery of autonomic bladder function is a 
high priority for improving their quality of life.[66] Following incomplete SCI, there is 
initial disruption of bladder control followed by partial recovery, which correlates 
negatively with injury severity and damage.[67] Full autonomic bladder function 
recovery is a consequence of adaptive plasticity, particularly sprouting and reconnection 
of spinospinal pathways.[68] Here, we found that a ω-3 PUFA-enriched diet not only 
results in amelioration of autonomic bladder function but also accelerates its complete 
recovery, suggesting reduced damage and/or activation of repair responses. 
Recent published reports have shown that supplementation with ω-3 PUFAs or 
with interventions that increase DHA levels promote locomotor recovery when 
administered after SCI.[12, 17-24] These findings led us to examine the efficacy of a 
preventive diet enriched with ω-3 PUFAs to reduce dysfunction after injury. Our results 
validate the role of fatty acids in functional recovery and show for the first time that 
dietary enrichment with ω-3 PUFA alone, without additional DHA supplementation or 
AA blockade, is sufficient to significantly improve hindlimb function in a clinically 
relevant contusion SCI. This was evidenced by weight-supported steps during the first 
week after injury in the group of animals receiving ω-3 PUFA prophylaxis, which 
represents an important finding because voluntary locomotion with full weight support 
requires supraspinal control.[69, 70] More importantly, our results show that these 
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beneficial effects are long lasting because BBB scores continued to improve in relation to 
controls for at least 8 weeks. These rapid and prolonged beneficial effects suggest that 
dietary ω-3 PUFA prophylaxis may be attributable to a combination of early (i.e., 
neuroprotection, plasticity, and remyelination) and late (i.e., sprouting and regeneration) 
protective/repair mechanisms. Although previous findings demonstrate that a combined 
intravenous and dietary DHA regime has the ability to sustain functional recovery, the 
efficacy of dietary DHA had limited positive effects when administered alone after 
injury.[18] Our findings suggest that the lack of dietary DHA efficacy reported by these 
investigators may have resulted as consequence of reduced food intake and altered lipid 
metabolism during the first week post injury, which may lead to suboptimal DHA levels. 
Likewise, administration of fenretinide (a retinoic acid analog shown to reduce AA and 
increase DHA), after 24 hours post-injury failed to sustain locomotor recovery in 
mice,[71] suggesting the relevance of the PUFA balance in the acute stages of SCI and 
supporting a role for endogenous ω-3 PUFAs in prophylaxis against neurotrauma. The 
novel experimental paradigm used in this study, which fed the animals with an ω-3 
PUFA-enriched diet before SCI, underscores the value of the pretreatment. Further, these 
data clearly demonstrate a potential therapeutic window for ω-3 PUFAs, which may be 
dependent on the ω-3 source and dosage, and warrants further investigation. 
Sensory deficits and pain are common clinical problems after chronic SCI.[72] 
We show that a diet enriched with ω-3 PUFA prevents the development of major sensory 
dysfunction (hypoalgesia), as evidenced by no significant changes in the force required to 
elicit hindlimb withdrawal when compared to controls. Although the pathophysiological 
mechanism responsible for the loss or presence of sensory function after injury are only 
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partly understood, evidence demonstrates a paradoxical combination of sensory loss 
within the area where chronic pain is felt suggesting that both neurodegenerative and pro-
inflammatory responses may play a role [73-74] Because we used the spinal cords for 
lipidomic profiling and RNA/protein extractions, we could not morphologically 
determine the extent of injury in this study. However, sensory function has been 
correlated with the amount of white matter spared.[75] Further, assessment of recovery 
using the BBB locomotor scale and bladder function provide an indirect measure of 
injury magnitude and spared tissue.[27, 67] Along with the results of others, we have 
shown that this ω-3 PUFA-mediated positive functional outcomes could be explained, at 
least in part, by the ability of DHA and EPA to dampen various secondary damage 
events, activate neuroprotective mechanisms, increase white matter sparing, and reduce 
axonal pathology in SCI.[12, 17-22] 
 
ω-3 PUFA-enriched Diet Reduces DHA Deficiency and Results in Distinctive Lipid 
Signatures Associated with Functional Recovery After SCI 
The precise mechanisms underlying the beneficial effects of dietary ω-3 PUFAs 
prophylaxis in the CNS are only partly understood, and our findings showing the 
important nutritional contributions and implications in functional behavior after trauma 
reveal various novel features. First, although the CNS is highly resistant to dietary 
PUFAs deficiencies,[76, 77] our data show that SCI itself leads to DHA nutritional 
deficiencies, which were associated with functional impairments. This data is supported 
by rodent studies showing that SCI results in an acute reduction in DHA plasma 
levels[71] and accelerates DHA metabolism.[78] Second, both chronic SCI and dietary 
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supplementation with ω-3 PUFAs had a profound impact on the spinal cord 
neurolipidome.  
Notably, dietary enrichment with ω-3 PUFAs prevented a chronic DHA 
deficiency and led to across-the-board increases in short and long chain ω-3 PUFAs, 
which were accompanied by similar decreases in ω-6 species. Retroconversion of DHA 
to shorter chain PUFAs is known to occur and could account, in part, for the increased 
levels of other ω-3 PUFAs.[79, 80] On the other hand, the corresponding decrease in ω-6 
PUFAs supports an ω-3 PUFA role in modulating genes and enzymes involved in the 
transport, synthesis, esterification, storage, and degradation of fatty acids.[81] Moreover, 
the PUFA balance can impair the interconversion of EPA and DHA by modulating the 
activity of Δ6-desaturase in vivo.[82] Although little is known about the particular 
mechanisms involved in the regulation of lipid metabolism after SCI, it is now clear that 
an ω-3 PUFA-enriched diet causes a global shift towards ω-3 lipids, which may have an 
important impact on resiliency to damage.  
 Despite its therapeutic and prognostic potential, the literature is scarce with regard 
to reports discussing endogenous determinants of vulnerability to neurological 
dysfunction in experimental models of injury. A very likely post-traumatic endogenous 
site is the cell membrane, which undergoes marked structural and functional alterations. 
After SCI, membrane phospholipids are converted into potent signaling molecules 
through the action of multiple phospholipases, including the calcium-dependent 
phospholipase A2 that preferentially hydrolyzes AA from the sn-2 position of 
phospholipids [83]. Therefore, altering the membrane phospholipid acyl-chain 
composition by administration of ω-3 PUFAs has the potential to change phospholipid-
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mediated cell signaling by three important processes: (1) altering the availability of AA, 
(2) changing the suitability of the phospholipids to serve as substrates for an array of 
phospholipases, and (3) mediating broad scale changes to membrane lipid composition 
which, in turn, may affect fluidity, signaling, and function. Although the involvement of 
membrane remodeling in the response to SCI has not been studied extensively, abnormal 
remodeling following injury has been implicated in membrane protein and channel 
dysfunction.[84, 85]  
 A third and final notable feature of this study is that dietary supplementation with 
ω-3 PUFAs results in increased levels of protein kinase B/Akt and CREB. Interestingly, 
several studies, including ours, have shown that Akt and CREB may play a role in DHA-
mediated neural resiliency, neuroprotection, and plasticity.[22, 52, 62, 86] Our finding 
supports the idea that ω-3 PUFAs may modulate cellular switches involved in controlling 
vulnerability to damage after SCI. Future studies incorporating inhibitors of Akt/CREB 
could provide further insight on whether this mechanism is essential for the prophylactic 
efficacy of dietary ω-3 PUFAs in SCI.  
 In summary, we show that SCI leads to chronic DHA deficiency associated with 
dysfunction. We present the first evidence that demonstrates that dietary ω-3 PUFA 
prophylaxis results in distinctive neurolipidomic alterations that may reduce cellular 
vulnerability and facilitate functional recovery after SCI. Our findings have significant 
implications for the current Western diet. For instance, recovery after neurotrauma may 
be hindered by our modern diet. Thus, based on clinical and epidemiological evidence for 
the beneficial effects of ω-3 PUFAs,[87] together with evidence of safety and 
tolerability,[88, 89] dietary ω-3 PUFAs prophylaxis against neurotrauma deserve 
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consideration.  
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Abstract 
Chronic neuropathic pain is a frequent comorbidity following spinal cord injury 
(SCI) and often fails to respond to conventional pain management strategies. Preventive 
administration of docosahexaenoic acid (DHA) or consumption of a diet rich in omega-3 
polyunsaturated fatty acids (O3PUFAs) confers potent prophylaxis against SCI and 
improves functional recovery. The present study examines whether this novel dietary 
strategy provides significant antinociceptive benefits in rats experiencing SCI-induced 
pain. Rats were fed control chow or chow enriched with O3PUFAs for 8 weeks before 
being subjected to sham or cord contusion surgeries, continuing the same diets after 
surgery for another 8 more weeks. The paw sensitivity to noxious heat was quantified for 
at least 8 weeks post-SCI using the Hargreaves test. We found that SCI rats consuming 
the preventive O3PUFA-enriched diet exhibited a significant reduction in thermal 
hyperalgesia compared to those consuming the normal diet. Functional 
neurometabolomic profiling revealed a distinctive deregulation in the metabolism of 
endocannabinoids (eCB) and related N-acyl ethanolamines (NAEs) at 8 weeks post-SCI.   
We found that O3PUFAs consumption led to a robust accumulation of novel NAE 
precursors, including the glycerophospho-containing docosahexaenoyl ethanolamine 
(DHEA), docosapentaenoyl ethanolamine (DPEA), and eicosapentaenoyl ethanolamine 
(EPEA). The tissue levels of these metabolites were significantly correlated with the 
antihyperalgesic phenotype. In addition, rats consuming the O3PUFA-rich diet showed 
reduced sprouting of nociceptive fibers containing CGRP and dorsal horn neuron p38 
MAPK expression, well-established biomarkers of pain. The spinal cord levels of 
inositols were positively correlated with thermal hyperalgesia, supporting their role as 
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biomarkers of chronic neuropathic pain. Notably, the O3PUFA-rich dietary intervention 
reduced the levels of these metabolites. Collectively, these results demonstrate the 
prophylactic value of dietary O3PUFA against SCI-mediated chronic pain. 
Key words: DHA; EPA; dietary fatty acids; endocannabinoid metabolome; spinal cord 
injury; chronic pain 
Abbreviations: Spinal cord injury (SCI); docosahexaenoic acid (DHA); omega-3 
polyunsaturated fatty acids (O3PUFAs); endocannabinoids (eCBs); N-acyl ethanolamines 
(NAEs); docosahexaenoyl ethanolamine/synaptamide (DHEA); docosapentaenoyl 
ethanolamine (DPEA); eicosapentaenoyl ethanolamine (EPEA); thermal hyperalgesia 
(TH); hindpaw withdrawal latency (HWL); ultrahigh performance liquid 
chromatography/tandem mass spectrometry (UHPLC/MS/MS2); gas 
chromatography/mass spectrometry (GC/MS); growth-associated protein 43 (GAP43); 
calcitonin gene-related peptide (CGRP); partial least square-discriminant analysis (PLS-
DA); glycerophospho-containing N-acyl ethanolamines (GP-NAEs); Basso, Beattie and 
Bresnahan (BBB); linoleyl ethanolamine (LEA); arachidonoyl ethanolamine (AEA); 
eicosenoyl glycerol (EG); 2-arachidonoyl glycerol (2-AG); 2-palmitoyl glycerol (2-PG); 
1-oleoyl glycerol (1-OG); palmitoyl ethanolamine (PEA); phospholipase D (PLD); 
phospholipase A/B or α-β-hydrolase 4 (Abh4); glycerophosphodiesterase (GDE1); N-
acyl phosphatidyl ethanolamine (NAPE); glycerol-3-phosphate (G3P); lyso-phosphatidic 
acid (LPA); phosphatidic acid (PA).  
 126 
Introduction 
 
Chronic neuropathic pain is one of the most important determinants in the 
perceived quality of life of spinal cord injury (SCI) patients [1]. Unfortunately, current 
therapeutics to treat this condition lack necessary efficacy and are limited in scope by 
unwanted side effects and poor tolerance. These shortcomings could be partly overcome 
with the use of preventive approaches that can provide resilience to damage prior to 
irreversible biochemical alterations have occurred in the perturbed cord. Trauma to the 
spinal cord triggers a robust secondary pathophysiological response, leading to cell death, 
inflammation, and dysfunction [2, 3]. Neuroinflammation is regarded as a hallmark 
mechanism underlying injury progression and pain processing [4, 5], and thus represents 
an attractive target for therapeutic strategies [6, 7].  
Dietary-essential omega-3 polyunsaturated fatty acids (O3PUFAs), such as 
docosahexaenoic acid (DHA), are integral components of neural membrane 
phospholipids and play crucial roles in anti-inflammatory responses [8]. Longstanding 
studies have demonstrated that dietary PUFAs are mediating factors in pain processing, 
as evidenced by increased threshold for thermal pain and neuropathic pain in rats fed with 
high omega-3 to omega-6 PUFA ratios [9]. Recent studies have shown that O3PUFAs 
and their derivatives can exert strong antinociceptive effects against thermal and 
chemical stimulation in various animal models [10-12]. Given this evidence, it would 
seem reasonable to consider that dietary O3PUFAs may also play important roles in SCI-
induced pain. 
In a recent report, we showed that SCI causes a robust PUFA deregulation and 
leads to a marked DHA deficiency, which was associated with impaired recovery and 
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dysfunction [13]. Notably, administration of O3PUFAs maintained the cord PUFA 
homeostasis, conferred neuroprotection, prevented dysfunction and facilitated recovery 
after acute and chronic SCI, even when administered in a prophylactic manner [13, 14]. 
These findings led us to hypothesize that a preventive diet enriched in O3PUFAs 
modulates behavioral responses implicated in pathological nociception in rats. This idea 
is supported by studies showing that the diet type at the time of injury can affect pain 
behaviors associated with nerve lesions [15-19]. Despite this evidence, diet remains a 
largely unexplored therapeutic avenue to ameliorate pain in SCI.  
This study is an initial attempt to assess the effects of dietary O3PUFAs on 
thermal pain stimuli in SCI rats. Because N-Acylated ethanolamines (NAE) and related 
endocannabinoids (eCBs) are bioactive lipids implicated in pain processing [20-22], we 
focused on identifying the involvement of dietary O3PUFAs in their local modulation 
following SCI. Here, the eCB metabolome has been expanded to include the 
ethanolamines, glycerides, and metabolic precursors, intermediates, and derivatives. 
These metabolites have been implicated in regulating anti-inflammatory responses and 
can exert cannabimimetic actions as endogenous agonist of cannabinoid receptors [23-
26], but whether dietary PUFAs impact the levels of these bioactive lipids in SCI has not 
been comprehensively evaluated. To address this issue, we employed both LC/MS and 
GC/MS-based metabolomics on cord samples collected from sham and contusion SCI 
operated Sprague-Dawley rats that received either control or O3PUFA-enriched diets. 
Deciphering the neurometabolomic profile that distinguishes pain-like behaviors may 
have important clinical implications for pain management and allow for improved 
prognosis in SCI.  
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Materials and Methods 
Animals 
 All animal studies were performed in compliance with the Loma Linda University 
School of Medicine regulations and institutional guidelines consistent with the NIH 
Guide for the Care and Use of Laboratory Animals. Female Sprague-Dawley rats were 
received from Charles River Laboratories (Portage, MI) and housed in individual cages 
on alternating 12 h light/ dark cycles. It is worth noting that in this study we used two 
independent cohorts of animals. Although both cohorts received the same dietary and 
surgical interventions, and behavioral testing, there were differences in the time allowed 
for survival (cohort 1: at least 4 animals per diet group, allowed to survive until 12 weeks 
post-injury; cohort 2: at least 13 animals per diet group, allowed to survive until 8 weeks 
post-injury). Animals in cohort 2 were also used to determine the effect of dietary 
O3PUFAs in sensorimotor and autonomic dysfunction after SCI [13].  
 
Diet Composition 
 Custom AIN-93-based diets were prepared with modifications to the fat 
composition as described previously [13]. Briefly, dietary fats were approximately 6% of 
the pellets dry weight and were supplied as either soybean oil (control chow) or 
menhaden fish oil (O3PUFA-enriched chow: DHA = 12.82-gm and EPA = 6.91-gm per 
100 gm of diet). Diets were matched for cholesterol content.  
 
Surgical and Post-Operative Procedures 
 Eight weeks after the dietary pretreatment, animals were deeply anesthetized with a 
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mixture of ketamine/xylazine (80 mg/kg and 10 mg/kg, respectively). The spinal cord 
injuries were generated using the well-characterized New York University (NYU) 
Impactor [27]. Notably, trauma caused using this device induces below-level pain that is 
well developed and longstanding, suggesting that the model is suitable for chronic pain 
research [28]. To produce the contusion, the skin and the muscles overlying the spinal 
column were cut. A laminectomy was performed at the T9-T10 level and the T8 and T12 
spinal processes were clamped to the Impactor, and the exposed dorsal surface of the 
cord was subjected to weight drop impact using a 10-g rod released from a height of 
12.5-mm. Sham animals received only a laminectomy. The animals body temperature 
was maintained at 37°C during the procedure. After operation, muscle layers were 
sutured and skin layers closed. The bladders of injured rats were expressed using the 
Crede’s maneuver three times a day until voiding reflexes were restored. Cefazolin 
(Bristol Myers Squibb, New York, NY; 25 mg/kg, s.q.) and Buprenex® (buprenorphine; 
Reckett and Colman Pharmaceuticals, Inc. Richmond, VA; 0.05 mg/kg, s.c.) were given 
to all rats for 5 and 3 consecutive days, respectively. Animals were allowed to survive for 
8 or 12 weeks post-operation and the spinal cord tissue dissected for metabolomics and 
immunohistochemical analyses, respectively. 
 
Nociceptive Testing 
 Thermal hyperalgesia (TH) was assessed using the well-established Hargreaves 
withdrawal test to thermal noxious stimulus [29]. This behavior has been found to be a 
sensitive and reproducible behavioral test to investigate chronic neuropathic pain and is 
exhibited approximately 28 days following contusion injury [30-33]. In the week prior to 
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the baseline recordings, the animals were habituated to the behavioral testing apparatus 
by undergoing 5 different daily testing sessions. Once plantar paw placement was re-
established, rats were evaluated weekly until animals were euthanized. Briefly, the 
animals were placed in a Plexiglas enclosure that rested on an elevated glass floor 
(Plantar Test, UGO BASILE, Biological Research Apparatus, Comerio, Italy). After 
allowing the animals to acclimate to the chamber for 30 min, a movable focused infrared 
emitter was placed under the animal’s paw. A photocell automatically turned the emitter 
off when the animal moved its paw and the latency time for the animal to withdraw its 
paw was recorded. Strength of stimulation was adjusted to produce hindpaw baseline 
latencies close to 12 seconds (approximately 50–60 C). A safety cutoff of 20 sec was 
used to prevent prolonged exposure to the noxious heat. Five different trials were 
performed per paw with at least 5 min allowed between each trial. The instrument 
operators were blinded to the treatment assignations. Minimum and maximum latency 
values were excluded from each paw analysis at each time point.  
It is well-recognized that the testing season, the climate (humidity and 
temperature), the time of day, the cage density, the animal weight, the locomotor 
behavior, the number of instrument operators, and order of testing have a significant 
impact on the results of pain studies in rodents [34-37]. Furthermore, the repetitive nature 
of the Hargreaves test makes it very susceptible to learning phenomena [38]. Dietary 
lipids, including DHA, are known modulators of learning and sensitization processes, 
which could introduce unwanted confounding effects and affect the outcome of sensory 
results [39-43]. On the basis of this evidence and to facilitate data interpretation, the 
thermal latencies are represented as percent change from baseline and were normalized to 
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changes observed in sham animals as previously reported [13]. Briefly, the nociceptive 
phenotype was determined by the following equation:  
 
EQ.1 HWL% = [(HWLib-HWLix) / HWLib] - [(HWLsb-HWLsx) / HWLsb] (x100) 
 
HWL% = hindpaw withdrawal latency percent change from baseline normalized to 
week-to-week changes in sham animals; ib = latency from injured animal in diet A at 
baseline; ix = latency from injured animal in diet A at time x; sb = averaged latency from 
all sham animals in diet A at baseline; sx = averaged latency from all sham animals in 
diet A at time x. 
 
Metabolomic Profiling 
Unbiased metabolic profiling was performed as previously described [13]. 
Animals were deeply anesthetized and transcardially perfused with ice-cold PBS to limit 
blood contamination. Spinal cord samples (75-100 mg) were flash frozen in liquid 
nitrogen and immediately stored at -80oC. Samples were homogenized in water at the 
time of analyses. The protein was precipitated with methanol containing four standards to 
report on extraction efficiency. The resulting supernatant was split into equal aliquots for 
analysis on the three platforms. Aliquots were dried under nitrogen and vacuum-
desiccated. The metabolomics profiling platform employed for this analysis was based on 
a combination of three independent platforms: ultrahigh performance liquid 
chromatography/tandem mass spectrometry (UHPLC/MS/MS2) optimized for basic 
species, UHPLC/MS/MS2 optimized for acidic species, and gas chromatography/mass 
spectrometry (GC/MS). Controls were analyzed concomitantly with the experimental 
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samples. For instance, aliquots of a well-characterized human plasma pool served as 
technical replicates throughout the data set, extracted water samples served as process 
blanks, and a cocktail of standards spiked into every analyzed sample allowed instrument 
performance monitoring. Experimental samples and controls were randomized across 
platform run days. The metabolites were identified by automated comparison of the ion 
features in the experimental samples and compared to a reference library of chemical 
standard entries that included retention time, molecular weight (m/z), preferred adducts, 
and in-source fragments as well as associated MS spectra. The neurometabolomics 
features were curated by visual inspection for quality control using software developed at 
Metabolon [44]. Archived mass spectrometry data from our previously reported study, 
which was curated for only identified ‘named’ compounds in Metabolon’s chemical 
reference library [13], was re-curated to further investigate the unidentified compounds 
that were detected in the study. 
Of particular importance, inositols features have been implicated as osmolytes 
and clinical metabolic markers of inflammation [45, 46], SCI-mediated chronic pain [47], 
and recently as a marker of SCI progression [48]. Since SCI-induced edema and water 
disturbances may introduce bias in the quantification of osmolytes, the relative levels of 
Ins were quantified relative to creatine levels (Ins/Cr ratio). 
 
Metabolomics Analyses 
An estimate of the false discovery rate (FDR), which is given by the q-value, was 
calculated to take into account the multiple comparisons that normally occur in 
metabolomic-based studies as previously reported [49, 50]. For example, when analyzing 
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200 compounds, it is expected to see about 10 compounds meeting the p ≤ 0.05 cut-off by 
random chance. Thus, the q-value describes the false discovery rate; a low q-value (q < 
0.10) is an indication of high confidence in a result.  
The partial least square-discriminant analysis (PLS-DA) is a supervised method 
that uses multivariate regression techniques to extract via linear combination of original 
variables (X) the information that can predict the class membership (Y). This regression 
was performed using the plsr function provided by R pls package. The classification and 
cross-validation were performed using the corresponding wrapper function offered by the 
caret package. To assess the significance of class discrimination, prediction accuracy 
during training and the separation distance permutation test were performed. In each 
permutation, a PLS-DA model was built between the data (X) and the permuted class 
labels (Y) using the optimal number of components determined by cross validation for 
the model based on the original class assignment. The variable importance in projection 
(VIP), which is a weighted sum of squares of the PLS loadings and takes into account the 
amount of explained Y-variation in each dimension was used to measure the impact of 
each metabolite in the model. Generally, features with high impact have VIP values 
higher than 1. 
 
Immunodetection 
Immunofluorescence methods has been described previously [14]. Briefly, spinal 
cord sections were dried at room temperature for 10-15 min, washed with PBS, and post-
fixed with 4% PFA for 10 min. The sections were blocked and incubated at 4°C ON in 
20% normal donkey serum with 0.1% Tween-20 with rabbit anti-phosphorylated-p38, p-
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p38 (1:200; R&D Systems, Minneapolis, MN) and mouse anti-NeuN monoclonal 
antibody (1:250; Millipore, Billerca, MA). Additional experiments used mouse anti-
CD11b (OX42, 1:100; AbD Serotec, Raleigh, NC) to examine reactive microglial cells. 
Alternatively, sections were incubated with rabbit anti-GAP43 (1:500; Abcam, 
Cambridge, MA) and sheep polyclonal calcitonin gene-related peptide (CGRP; 1:500; 
Abcam). The sections were then washed with PBS and incubated in secondary antibodies 
[Alexa Fluor® 594-conjugated donkey anti–rabbit or donkey anti-sheep (1:500; 
Invitrogen, Carlsbad, CA) and Alexa Fluor® 488-conjugated donkey anti–mouse or 
donkey anti-rabbit (1:500; Invitrogen)]. Primary antibody omission and normal serum 
controls were used to confirm the specificity of the immunoreaction. Slides were 
examined with an Olympus Optical Fluoview FV1000 confocal microscope. Unbiased 
stereological methods were followed as previously reported [14]. Two blinded observers 
quantified the immunoreactivity in lamina I to III, which were identified by 
superimposing photomicrographs with spinal cord diagrams from the Watson, Paxinos, 
and Kayalioglu spinal cord atlas. For each animal, the p-p38-positive neurons were 
counted manually in at least 4 randomly selected areas of the superficial dorsal horns. 
The mean number of p-p38-expressing neurons was then tabulated for each animal and 
group. For fiber sprouting analyses, the CGRP-GAP43 double labeling immunoreactivity 
was quantitated by inverting merged images into black (marker-positive) and white in the 
NIH Image J program for measurement of positive pixels/area in the dorsal horns laminae 
I to III. Results were obtained by averaging measurements made by blinded investigators. 
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Statistical Analysis 
 Statistical analyses were performed using SPSS version 20.0 (IBM: SPSS, Armonk, 
New York), Prism 5 software v5d (GraphPad Software Inc., San Diego, CA), the “R” 
program (http://cran.r-project.org/), and metaboanalyst [51, 52]. Two-Way Analysis of 
Variance (ANOVA) followed by Bonferroni post-hoc comparisons was used to determine 
the effect of the diet type, injury, and time on hindpaw thermal withdrawal latencies and 
differences within and between groups. To determine the antinociceptive effects of 
dietary O3PUFAs in time we calculated the area under the nociception versus time curve 
(AUC) and subjected AUCs to t-tests as previously described [53-55]. ANOVA contrasts 
were used to identify features that differed significantly between tested groups. All other 
data were assessed by Mann-Whitney U test. The Kolmogorov-Smirnov and Shapiro-
Wilk normality tests together with the Grubbs’ method, also known as ESD (extreme 
studentized deviate; www.graphpad.com), were used to investigate outliers and spread. 
Spearman’s rank correlation tests were used to explore associations between detected 
metabolites and the sensory phenotype. Data are presented as mean  SEM. Statistical 
differences were considered significant at p < 0.05 unless otherwise specified. 
 
Results 
General Conditions and Summary of Previously Published Findings 
Related to this Study 
Previously, we reported that experimental spinal cord injury (SCI) leads to a 
marked docosahexaenoic acid (DHA) deficiency and motor and autonomic deficits, 
which were corrected by dietary omega-3 polyunsaturated fatty acids (O3PUFAs) 
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prophylaxis [13]. Here, we hypothesized that this dietary prophylactic intervention would 
reduce thermal hypersensitivity in SCI. We characterized the antihyperalgesic effects of 
this dietary strategy and investigated the extent to which dietary O3PUFAs impact the 
levels of bioactive metabolites and cellular targets associated with nociception and 
inflammation in the injured cord. 
To examine the effect of dietary O3PUFAs on the onset and maintenance of 
neuropathic pain after SCI, we used the paw thermal sensitivity to noxious heat 
(Hargreaves testing). We found no differences in the average baseline hindpaw 
withdrawal latencies between groups (10.61 ± 0.59 s for control-fed animals and 11.34 ± 
0.44 s for animals receiving O3PUFA diets; mean ± SEM, p > 0.05). Because of 
differences in survival times and missing data points between animal cohorts, we used 
two-way ANOVA to identify the effect of the diet type and operation in the thermal 
latencies differences. We found that both diet type and the surgical intervention were 
significant sources of variation in our data set [for the diet effect F(3,49253) = 40.22, p = 
0.0001, n = 8-18 rats per group]. Post hoc analysis revealed significant differences in 
thermal thresholds between sham and injured animals receiving control diets from week 8 
to week 12 post-operation (p < 0.05). A novel finding of this study is that the animals 
consuming diets rich in O3PUFAs showed no significant alterations in their hindpaw 
withdrawal latencies when compared to their sham counterparts (p > 0.05). Post hoc 
comparisons between injured groups revealed that the most significant differences in 
nociception occurred between after 7 wpi and hence the focus period of this current 
investigation (p < 0.05; Fig. 1A). Sham-operated rats receiving O3PUFA-rich diets did 
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not show significant changes in their thermal thresholds when compared to animals being 
fed with control diets (p > 0.05). 
Calculation of the area under the thermal withdrawal latency change versus time 
curve (AUC) showed a potent antihyperalgesic effect of dietary O3PUFAs in SCI rats 
(Fig. 1B; Mann Whitney U rank test p = 0.0008; n = 18).  
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Figure 1. Responsiveness to thermal stimulation in animals receiving control and 
O3PUFA-enriched diets. (A) Thoracic contusion to the spinal cord leads to below-level 
thermal hyperalgesia in animals receiving control diets. Hindpaw withdrawal latencies 
(averaged percent change from baseline) are plotted versus time (weeks post-injury, wpi). 
For each timepoint, the individual latencies were adjusted to the percent change from 
baseline observed in sham animals receiving the same diet using equation 1 (see Materials 
and Methods section). No significant latency alterations were observed between sham 
animals. Notably, dietary O3PUFAs prevented the development of thermal hyperalgesia (p 
> 0.05 when compared to sham animals). TW-ANOVA identified the diet type and surgery 
as significant sources of variation [for diet/surgery F(3,49253) = 40.22, p = 0.0001, n = 8-
18]. Bonferroni’s post hoc analyses showed significant thermal withdrawal latency 
changes when comparing injured animals receiving the different diet types (p < 0.05). (B) 
To investigate the overall effect of O3PUFA in thermal hindpaw sensitivities, the 
hyperalgesic index was generated using the area under the curve (AUC). Analyses of the 
AUC revealed that the O3PUFA diet had a significant antihyperalgesic effect (Mann 
Whitney U rank test; p < 0.001). Each bar represents mean ± SEM; n = 18. 
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Metabolomic Profiling Reveals Distinctive Endocannabinoid Signatures Associated 
with Chronic SCI and Dietary O3PUFAs 
We used an untargeted metabolomics approach [13] to investigate the 
neurochemical consequences of O3PUFAs consumption on the endocannabinoid (eCB) 
metabolome. Figure 2A summarizes the four groups analyzed in this study and the 
metabolomic interactions between them. A total of 275 named metabolites and 76 
unnamed biochemical were detected and analyzed. The diet rich in O3PUFA significantly 
changed more than 20% of the detected metabolic features (74 total altered features: 40 
upregulated, 34 downregulated when compared to animals receiving control diets). Of 
significance, more than 40% of these altered metabolites were associated with the 
endocannabinoid metabolome and are the focus of the present study. In this study, data 
was protected against false positives using the false discovery rate q value. We first 
sorted the metabolomic data by the p-value and chose the cutoff for significance at p < 
0.05. We found that the false discovery rate of various diet-derived metabolites with 
significant p values were extremely low (q < 0.1%) when comparing injured animals, 
validating the significance of our results (see below). 
 The partial least square-discriminant analysis (PLS-DA) score plot was obtained 
using the variation scores of the first two principal components, component 1 (22.7%) 
and component 2 (44.5%). These analyses revealed distinctive endocannabinoid-related 
profiles between groups (Fig. 2B). Each plot mark corresponds to an animal subject and 
the variability in relative metabolite levels detected for that animal. Hotelling’s T2 
confidence ellipse, at a significance level of 0.05, showed no outliers. Permutation 
analyses validated the class discrimination and neurometabolomic separation (observed 
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test statistic p < 0.01). Consequently, more than 67% (component 1 + component 2) of 
the metabolomics differences can be explained with certainty by the generated PLS 
model. For simplicity, only the prediction accuracy during training result is shown (Fig. 
3A). We found that both chronic SCI and the preventive diet enriched in O3PUFAs had a 
significant impact in the levels of acyl glycerol class endocannabinoids and in the 
metabolism of N-acyl ethanolamines (Figure 3B). Also, the cord of injured animals 
receiving the O3PUFAs showed higher levels of eicosenoyl, palmitoyl, arachidonoyl, and 
oleoyl glycerols when compared to control fed injured animals. In general, the diet rich in 
O3PUFAs skewed the metabolomic profile towards increased levels of long-chain N-acyl 
ethanolamines. In particular, we identified a selective group of glycerophospho-
containing N-acyl ethanolamines (GP-NAEs). These molecules showed the strongest 
influence (highest variable importance in projection, VIP, values) to the observed 
metabolomics differences between groups. 
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Figure 2. SCI and dietary O3PUFAs modulate the endocannabinoid-related 
neurometabolome. (A) Venn diagram depicting the numerical interactions among data sets. 
ANOVA contrasts analyses were used to evaluate the regulation pattern differences 
between groups. The total number of features detected across 36 spinal cord tissue samples 
was 351 metabolites. Diagram illustrates the number of total metabolites significantly 
altered between groups (e.g., O3PUFA diet SCI/Control diet SCI contrast resulted in 60 
significantly altered metabolites; 38 upregulated and 22 downregulated; p < 0.05). (B) 
Partial least square discriminant analysis (PLS-DA) distinguished subgroups based on 
dietary intake at 8 weeks post-injury (wpi). Model was constructed using scaled intensity 
peaks of the detected features associated with the endocannabinoids (eCBs) system: classic 
eCBs, eCBs glycerols, and related N-acyl ethanolamines (NAEs) and metabolites. 
Projections provided statistically significant separations between subgroups. 
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Figure 3. PLS-DA model validation and metabolite impact. (A) Prediction accuracy 
training permutation test validate the PLS-DA model by showing a significant observed 
statistic (p < 0.01). (B) The variable influence on projection (VIP) analyses, which reflect 
the importance of metabolites showed the significant contribution of selective NAEs, 
endocannabinoids, endocannabinoid glycerols, and O3PUFA-derived glycerophospho 
ethanolamines (GP-NAEs) in our PLS model. The colored boxes on the right indicate the 
relative concentrations of the corresponding metabolite in each group under study. 
Abbreviations: GP, glycerophospho; EPEA, eicosapentaenoyl ethanolamine; DPEA, 
docosapentaenoyl ethanolamine; AEA, arachidonoyl ethanolamine; EG, eicosenoyl 
glycerol; LEA, linoleoyl ethanolamine; 2-AG, 2-arachidonoyl glycerol; 2-PG, 2-palmitoyl 
glycerol; 1-OG, 1-oleoyl glycerol; PEA, palmitoyl ethanolamine.  
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Dietary O3PUFA Leads to a Marked Accumulation of Diet-derived N-acyl 
Ethanolamine (NAEs) Precursors 
The beneficial neurological effects of O3PUFAs are partly related to their anti-
inflammatory properties, however the exact mechanisms behind these actions are 
unknown. A putative mechanism could be via their conversion to related N-acyl 
ethanolamines (NAEs). Here, we present new evidence demonstrating the significant 
impact of diet in the regulation of these bioactive lipids after chronic SCI. In agreement 
with previous studies[56], we found that dietary O3PUFAs lead to a robust accumulation 
N-acyl ethanolamines glycerophospholipids containing DHA, DPA, and EPA fatty acids 
(Fig. 4A). Interestingly, metabolomic analysis revealed very low abundance of these 
lipids in the cord of animals receiving control diets. 
Figure 4B illustrates the current knowledge on the NAEs biosynthetic pathways 
[57, 58]. Briefly, it has been proposed that NAEs are biosynthesized from their 
corresponding N-acyl phosphatidyl ethanolamines (NAPEs) occur through a single 
NAPE-PLD-dependent pathway (NAPE-PLD). Alternatively, NAPE-PLD-independent 
multi-step processes have been recently reported and involve alpha/beta-hydrolase 4 
(ABDH4 or Abh4) and the glycerophosphodiesterase, GDE1. The results presented 
herein suggest a marked activation of NAPE-PLD-independent pathways following 
chronic SCI.  
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Figure 4. Chronic O3PUFAs consumption leads to a robust accumulation of diet-derived 
glycerophospho ethanolamines in the spinal cord. (A) Box and whiskers graphs illustrate a 
marked increase in the levels of O3PUFA-dervied GP-NAEs (relative to the median 
metabolite levels in each group). (B) Potential metabolic pathways for the biosynthesis of 
NAEs. This illustration is adapted and modified from previous reports [57, 58]. Reaction 
1 is mediated by an NAPE-selective phospholipase D (PLD). Pathways 2-3-4 and 2-5 are 
NAPE-PLD independent. Recent studies suggest the involvement of a novel phospholipase 
A/B, named Abh4, α-β-hydrolase 4 in the NAPE conversion to GP-NAE (reaction 2 and 
3). The secretory PLA2 can also release fatty acid from sn-2 position of NAPE (reaction 
2). Reaction 4 is catalyzed by a new glycerophosphodiesterase, GDE1. Lyso-PLD 
catalyzes reaction 5. Abbreviations: DHEA, docosahexaenoyl ethanolamine; DPEA, 
docosapentaenoyl ethanolamine; EPEA, eicosapentaenoyl ethanolamine; GP, 
glycerophospho, NAE, N-acyl ethanolamine; NAPE, N-acyl phosphatidyl ethanolamine; 
G3P, glycerol-3-phosphate; LPA, lyso-phosphatidic acid; PA, phosphatidic acid.  
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Table 1. The endocannabinoid (eCB) metabolome is altered following chronic SCI and 
influenced by dietary O3PUFAs. ANOVA contrasts were performed to determine 
statistical differences in metabolite relative amounts (differences were considered 
significant when p < 0.05; n = 8 rats per sham group and 10 rats per injury group). 
Comparisons were made between the four studied groups: (1) sham control diet, (2) SCI 
control diet, (3) sham O3PUFA-rich diet, and (4) SCI O3PUFA-rich diet. Notably, in spinal 
cord injured animals, the O3PUFA diet decreased the levels of the glycerophospho 2-LEA 
and 2-AEA and dramatically increased the levels of O3PUFA-derived GP-NAEs. Numbers 
represent fold of change. Heat map color legend: red, significant increase; green, 
significant decrease; light red and green represent marginal statistical significance. 
Abbreviations: LEA, linoleyl ethanolamine; AEA, arachidonoyl ethanolamine; GP-NAEs, 
glycerophospho n-acyl ethanolamines.  
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The effects of the diet and chronic SCI on the detected metabolites associated 
with the endocannabinoid and related NAEs are summarized in Table 1. ANOVA 
contrasts were performed to determine statistical differences in metabolite relative 
amounts between groups (differences were considered significant when p < 0.05; n = at 
least 8 rats per group). The false discovery rate showed very low q-values for features 
associated with the diet-derived O3PUFAs (EPEA = 8 X 10-15; DPEA = 2.40 X 10-9; 
DHEA = 0.012), supporting the significance of the observations.   
Spearman’s correlation analyses were used to explore the linear trends between 
cord metabolite levels and changes in thermal thresholds. The relative levels of NAEs 
containing 22 carbons N-acyl chains and the glycerophospho NAEs of O3PUFAs were 
positively correlated with reduced thermal withdrawal latency changes (Fig. 5A-D; 
Spearman r values > 0.50; p < 0.05). We also found a significant positive correlation 
between the relative levels of palmitoyl ethanolamine (PEA) and non-hyperalgesic 
responses, supporting its anti-inflammatory roles in SCI [59, 60]. Together, our findings 
suggest that these diet-derived metabolites may play significant roles in antinociception.  
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Figure 5. Metabolic features correlated with pain-like phenotypes. Scatter plot shows the 
significant relationship between the levels of (A) ethanolamines containing 22-carbon N-
acyl chains, (B) GP-DHEA, (C) GP-DPEA, (D) PEA and the hindpaw thermal withdrawal 
latency change from baseline. For every correlation, the Spearman r was higher than 0.50, 
with a p < 0.05, XY = 20 pairs. 
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Functional Metabolomics Implicate the NAEs Biosynthetic Pathways in SCI-induced 
Neuropathic Pain 
The biochemical basis and etiology underlying chronic neuropathic pain remains 
poorly understood and has limited the development of effective interventions. To 
characterize the unique lipidomic changes underlying neuropathic pain-like behaviors 
after contusive SCI, we first used the K-means clustering method to assign the animals to 
three groups according to their thermal threshold changes (Fig. 6A). This partitioning 
method identified a group of animals that showed no significant alterations in their 
thermal threshold (normal behavior, non-hyperalgesic; p > 0.05). Another cluster was 
shown to exhibit significantly reduced latencies when compared to their baseline values 
(hyperalgesic behavior; p < 0.05). The algorithm also identified animals with increased 
thermal latencies at 8 wpi when compared to baseline values (hypoalgesic behavior; p < 
0.05). The mean baseline values did not differ significantly between clustered groups (p > 
0.05), demonstrating that the different phenotypes developed after SCI.  
Notably, the glycerophospho N-acyl ethanolamines (GP-NAEs) derived from the 
O3PUFA-rich diet were the most relevant metabolites for explaining the differences 
between non-hyperalgesic and hyperalgesic animals (Fig. 6B). The metabolomics 
analyses revealed decreased levels of the O3PUFA-derived GP-NAEs in the hyperalgesic 
animals, suggesting a potential role for these in neuropathic pain.  
Although additional factors contribute to the development of pain following SCI, 
it is well established that the extent of cord damage is a major determinant [61, 62]. To 
determine the relative contribution of tissue spared to the observed metabolomics 
differences, we assessed the cord damage between the animals exhibiting thermal 
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hyperalgesia and those showing no significant differences in paw withdrawal thresholds 
when compared to baseline values (p > 0.05). Because the spinal cords were used for 
metabolomics studies, we could not determine the extent of injury using stereological 
techniques. However, the Basso, Beattie and Bresnahan (BBB) locomotor score provides 
a reliable indirect measure of the injury magnitude [63]. We found that the BBB 
locomotor scores were not significantly different between clustered groups, indicating 
that the extent of injury (and repair) was similar (p > 0.05; Fig. 6C). This observation 
validates that additional processes such as chronic neuroinflammation and 
hyperexcitability play major roles in pathological nociception after SCI.  
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Figure 6. (A) K-means clustering divided animal based on their nociceptive behavior (Δ latency = 
latencyendpoint - latencybaseline). A group of animals exhibited no significant Δ latency changes at 
endpoint (“normal” or non-hyperalgesic cluster). The clustering algorithm identified two additional 
groups: hyperalgesic rats (significant Δ latency decrease at endpoint) and hypoalgesic (increased Δ 
latency at endpoint). Data is presented as mean ± SEM. Data was analyzed by TW-ANOVA 
followed by Bonferroni’s post hoc: ns, not significant; (*) = p < 0.05; (****) = p <0.0001. (B) 
Metabolomic analyses using the normal and hyperalgesic clusters confirmed the potential role of 
the NAE metabolism in pain processing after SCI. In particular, the O3PUFA-derived NAEs were 
shown to have a significant impact in the metabolic differences observed between thermal pain 
behaviors. Notably, the animals showing hyperalgesic phenotypes exhibited reduced levels of these 
metabolites. Abbreviations: X-11204, unnamed compound which has been tentatively identified as 
an unsaturated hydroxyl fatty acid with an empirical formula of C13H24O3; GP, glycerophospho; 
OEA, oleoyl ethanolamine; DHEA, docosahexanoyl ethanolamine; DPEA, docosapentaenoyl 
ethanolamine; EPEA, eicosapentaenoyl ethanolamine. (C) Basso, Beattie and Bresnahan locomotor 
scores measured in hyperalgesic (n = 6) and non-hyperalgesic (n = 13) rats. Repeated measures 
ANOVA did not identify pain classification (non-hyperalgesia vs. hyperalgesia) as a significant 
contributor of the total variance (p > 0.05). Pain classification accounted for 1.54% of the total 
variance (after adjusting for matching) with a p value of 0.2669. F statistics (1,66.88) = 1.318, 
indicating that the extent of the injury was similar in both groups. To determine whether the mean 
differences were more apparent, the data was analyzed using the Mann-Whitney U t-test at the time 
points showing greatest difference. The analysis revealed a p value of 0.2005 at 4 weeks post-
injury, which can be interpreted as no reason to reject the null hypothesis. In other words, the 
locomotor score distributions of both dietary groups are identical at 4 wpi. This observation 
proposes underlying neurochemical mechanisms that may be independent of the injury severity and 
to the amount of spared tissue. Data represents mean ± SEM.   
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Animals Fed with a Diet Rich in O3PUFAs Exhibit Reduced Levels of p38 MAPK 
Expression in Dorsal Horn Neurons Following SCI 
 To examine the anti-inflammatory effects of the O3PUFA-enriched diet, we 
determined the mRNA levels of key cytokines, chemokines, and receptors that have been 
associated with inflammatory pain (e.g., IL-1β, IL-6, TNF-α, CCL2, CCR2, CX3CL1, 
and CX3CR1). We found that the O3PUFA diet did not reduce the mRNA levels of these 
pro-inflammatory factors in below-level cord segments when compared to control-fed 
animals at 8 wpi (p > 0.05; data not shown). Histological analyses showed no significant 
differences in the dorsal horn immunoreactivity (IR) to OX42 between treatment groups 
(Fig. 7A-C). These results do not contradict the well-established roles of dietary 
O3PUFAs but rather suggest that these anti-inflammatory effects may occur during the 
initial inflammatory trigger in a time- and context-dependent manner. This observation 
also points to the involvement of additional mechanisms. For instance, although we did 
not observe significant differences in the expression of these biomarkers, qualitative 
differences were noticeable in cell morphology. In particular, we found microglia with 
morphological features typically implicated in activated states in the spinal cords of 
animals receiving control chow (e.g., hypertrophied cell bodies and thick processes) (Fig. 
7D). Interestingly, a few animals receiving the preventive dietary intervention rich in 
O3PUFAs exhibited microglial cells with small soma containing thin and radially 
projecting processes (Fig. 7E), confirming previous observations on the DHA-elicited 
immunomodulatory effects in microglia [64].  
 Because LC/MS and GC/MS-based metabolomics provide a more sensitive 
method to assess inflammatory biomarkers, we measured the levels of inositol (Ins; see 
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Experimental Procedures). Interestingly, the averaged relative levels of the major omega-
3 PUFA-derived GP-NAEs were negatively associated with Ins relative levels (Spearman 
r = -0.68, p < 0.0001; Fig. 7A). Further, dietary O3PUFAs significantly reduced the cord 
Ins levels (Fig. 7B; p < 0.0001, n = 10). Altogether, these data support an anti-
inflammatory and antinociceptive role for O3PUFAs in chronic SCI.  
A number of pharmacological studies implicate the spinal p38 mitogen-activated 
protein kinase, p38 MAPK, as one important underlying mechanism of nociception and 
neuronal hyperexcitability in SCI [65, 66]. Here, we used immunohistochemistry to 
examine the expression of this established pain biomarker in rats treated with dietary 
O3PUFAs relative to animals receiving control diets. We found that the cords of animals 
receiving O3PUFAs had decreased phosphorylated p38-positive neurons in the 
superficial dorsal horns relative to controls at 12 wpi (Fig. 8A-G; p < 0.05; n = at least 4 
animals). Not surprisingly, we found a significant positive correlation between the 
expression levels of neuronal p-p38 MAPK and the hyperalgesic behaviors (data not 
shown). 
The growth-associated protein 43 (GAP43) and calcitonin gene-related peptide 
(CGRP) have been widely used as biomarkers of nociceptive fiber sprouting and 
neuropathic pain [67-69]. Thus, we tested whether the preventive O3PUFA-enriched diet 
reduces the sprouting of CGRP-containing primary afferents following chronic SCI. 
Laser confocal microscopy showed CGRP and GAP43 colocalization in spinal cord 
sections obtained from regions 3-5 mm caudal to the injury site (Fig. 9A). CGRP (Fig. 
9B,F) and GAP43 (Fig. 9C,G) labeled photomicrographs from animals receiving control 
chow (Fig. 9B-E) or O3PUFA-rich (Fig. 9F-I) diets were merged (Fig. 9D,H) and 
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subsequently converted to binary format to facilitate automated analyses (Fig. 9E,I). 
Quantitative double labeling immunofluerescence revealed decreased sprouting of 
CGRP-positive primary afferents at 12 wpi (Mann Whitney U test p < 0.05, n = at least 4 
animals) (Fig. 9J). 
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Figure 7. Dietary O3PUFA did not reduce microglial cell immunoreactivity in superficial 
dorsal horns following chronic SCI. Representative images from OX42 immunoreacted 
spinal cord injured caudal sections from animals receiving control (A) or O3PUFA (B) 
diets. Quantitative analyses showed no significant changes in inflammatory markers 
immunoreactivity between treatment groups in the dorsal horn laminae I-III at 12 weeks 
post-injury (C). Closer examination revealed that following chronic SCI, spinal microglia 
displayed hypertrophied cell bodies and thick processes, which are characteristic of their 
activated state (D). Interestingly, some animals treated with dietary O3PUFA showed 
microglial cells with small soma containing thin and radial projecting processes (resting 
state of microglia, E). Scale bar = A-B, 200 μm; D-E, 20 μm. The arrows indicate OX42-
positive cell somata. Dietary O3PUFA-derived GP-NAEs levels are potentially implicated 
in anti-inflammatory responses. (F) A scatter plot shows the relationship between the levels 
of the O3PUFA-derived GP-NAEs (O3DGP-NAEs) and the total inositol-to-creatine levels 
(Ins/Cr). The Spearman r = -0.68, CI(-0.83 to -0.44), p = 0.0001, XY = 18 pairs includes 
sham and injury-operated animals fed with control diet. (G) Preventive administration of 
dietary O3PUFAs resulted in a significant reduction in the Ins levels (Mann-Whitney U 
test, **** p < 0.0001, n = 10). Data represents mean ± SEM. 
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Figure 8. Preventive dietary O3PUFAs reduce the expression of phosphorylated p38 in 
below-level dorsal horn neurons. At 12 weeks post-injury, laser confocal microscopic 
evaluation revealed dorsal NeuN-positive neurons (A) containing the phosphorylated p38 
MAPK (B). Merged photomicrographs (C) and inset (D) show distinctive neuronal 
subpopulations expressing this inflammatory marker after chronic SCI. Dorsal horn 
photomicrographs show noticeable differences in the number of p-p38-containing neurons 
when comparing dietary groups (control = E vs. O3PUFA = F). (G) Manual cell counts 
confirmed that the dietary O3PUFA intervention significantly reduced the percent of 
NeuN-positive cells expressing p-p38 MAPK in below-level dorsal horn superficial 
laminae (p < 0.05; n = at least 4 animals). Scale bars = A-C and E-F, 100 μm; D, 20 μm. 
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Figure 9. Dietary O3PUFA-pretreatment reduces nociceptive fiber sprouting following 
chronic SCI. (A) Double labeled spinal cord section showing calcitonin gene-related 
peptide (CGRP) and growth-associated protein 43 (GAP43) immunoreactivity (IR) in 
spinal cord. Confocal photomicrographs showing CGRP (B) and GAP43 (C) 
immunoreactivity in control chow-fed rat. Images were merged to quantify the 
immunoreactivity of CGRP-containing sprouting afferent fibers (D). Optical density was 
most intense in laminae I to III of the dorsal horns. Sections were morphometrically 
analyzed using stereological methods after thresholding binary images using ImageJ 
software (E). Representative image from CGRP (F) and GAP43 (G) immunoreactivity in 
an animal fed O3PUFA-enriched diets. Merged (H) and binary (I) images depict CGRP-
containing GAP43+ fibers in the dorsal horn (H). Boxes represent areas showing 
colocalization. Scale bar = 100 μm. (I) Results from quantification of binary particle counts 
of dorsal horn superficial laminae. Analysis showed that O3PUFA-enriched diet 
significantly reduced the colocalization of GAP43 and CGRP, suggesting a reduction in 
nociceptive fiber sprouting. Bars represent means ± standard error of the mean; Mann 
Whitney U test *p < 0.05, n = at least 4 rats. 
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Discussion 
This study shows that a preventive diet rich in omega-3 polyunsaturated fatty 
acids (O3PUFAs) reduces thermal hyperalgesia in rats experiencing chronic spinal cord 
injury (SCI). This antihyperalgesic effect was directly correlated with the levels of a 
series of novel glycerophospho ethanolamines containing O3PUFA acyl chains. The anti-
inflammatory effects of this O3PUFA-enriched diet were evident by a significant 
reduction in levels of inflammatory biomarkers, including cord inositols and the 
phosphorylated p38 MAPK in dorsal horn neurons. 
 Chronic neuropathic pain is a debilitating co-morbidity associated with SCI and 
persists even at the later stages of recovery and rehabilitation. This condition often 
manifest as evoked pain, including hyperalgesia (amplified pain response to noxious 
stimuli) and/or allodynia (painful response to innocuous stimuli). The intensity and 
frequency of neuropathic pain is particularly influenced by trauma-induced 
neurochemical and neuroanatomical changes in synaptic circuitry and dorsal horn neuron 
hyperexcitability [65, 66, 70]. Current approaches to treat neuropathic pain include 
behavioral, pharmacological, and surgical modalities, however, none of these 
interventions are regarded as highly effective. This could be partly due to patients being 
treated after considerable and perhaps irreversible changes have developed. There is thus 
a need to develop preventive approaches to build resilience to damage. Complementary 
with current strategies, this type of approach may be particularly important in individuals 
at high risk of traumatic injuries like those actively participating in contact sports, 
selected surgeries, first responders, and our men and women in the military service. The 
promise of using preventive approaches to treat chronic neuropathic pain is supported by 
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studies showing that central pain can be prevented by pre-administration of opiates [71], 
anti-inflammatory molecules [72], or by prophylactic cell transplantation strategies [73, 
74]. Although it may seem unreasonable to use these approaches in individuals 
undergoing SCI due to potential and unwanted side effects, prophylactic treatment with 
dietary O3PUFAs offers an excellent profile of clinical safety and may be beneficial in 
preventing pain and dysesthesias in individuals at risk [75, 76].  
 O3PUFAs, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA), are ubiquitous lipid messengers that regulate crucial neural processes in health 
and disease. We recently reported that dietary O3PUFAs exert a stringent control over 
phospholipid production and are principal determinants of the cord lipid composition 
following chronic SCI [13]. Further, when the spinal cord is enriched with O3PUFAs 
before SCI, these lipids mediate robust neuroprotection, recovery, and activate pro-
restorative responses [13, 14, 77]. Several recent studies have shown the importance of 
PUFAs in nociception, supporting the hypothesis that dietary lipids are key elements of 
the nociceptive pathways [9-12, 78]. Consistent with this idea, the present study shows 
that consumption of a diet rich in O3PUFAs produces significant thermal anti-
hyperalgesia when compared to animals receiving control diets after contusion SCI. In 
contrast, thoracic contusion to the cord resulted in a significant reduction in below-level 
thermal withdrawal latencies in animals receiving control chow. Importantly, we reported 
that control-fed injured rats exhibited significant sensory deficits to mechanical 
stimulation on their hindpaws after SCI [13]. Together, these findings discard the idea 
that thermal hyperalgesia was due to a hyperreflexic responses, a common occurrence in 
contusive SCI (Christensen and Hulsebosch, 1997a). This observation further suggests 
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that both neurodegenerative and pro-inflammatory responses may play important roles in 
the development of neuropathic pain after SCI [79-80].  
Several lines of evidence demonstrate that the level of spinal cord damage play 
significant roles in the development and maintenance of pain-like behaviors [61, 62, 81], 
suggesting that pain may be amenable to neuroprotective approaches. In agreement with 
others, evidence from our lab has shown that O3PUFAs confer potent neuroprotection 
against SCI [13, 14]. Together, these data suggest that neuroprotection may be an 
underlying mechanism involved in the anti-nociceptive responses mediated by the dietary 
O3PUFAs. However, neuroprotective approaches do not always result in anti-nociceptive 
responses (Mills et al., 2002). We found comparable open-field locomotor scores when 
animals were grouped based on their thermal withdrawal phenotypes. While 
neurodegenerative differences between clusters may be subtle or undetectable as 
measured by the BBB locomotor scores, we interpret this finding as evidence supporting 
additional underlying causes of neuropathic pain.  
 The neurometabolomic etiology of neuropathic pain remains poorly understood and 
this gap in the literature has limited the development of effective therapeutics. N-
Acylated ethanolamines (NAE) and related endocannabinoids (eCBs) are a large class of 
naturally occurring lipids that exhibit diverse bioactivities, including neuroprotective [82] 
and antinociceptive [20-22] responses. Notably, it has been shown that SCI rats exhibit 
profound alterations in the metabolic pathways associated with these lipids [83]. These 
lipids are produced on demand from membrane phospholipids and glycerophospho-
linked precursors by a series of intracellular enzymatic reactions, followed by immediate 
signaling and metabolism [56, 84-88]. The findings reported in the present study support 
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and expand on these observations by showing that chronic SCI results in a marked 
deregulation in the metabolic pathways of NAEs and related eCBs. In particular, we 
found reduced levels of palmitoyl ethanolamine (PEA) in the chronically injured cord, 
which were correlated with hyperalgesic behaviors in SCI rats. PEA has been implicated 
in anti-inflammatory responses and functional recovery after SCI [59, 60, 89] and reduces 
pain-like behaviors in experimental models of neuropathic pain [53, 90]. Notably, dietary 
prophylaxis with O3PUFAs sustained the levels of PEA after SCI. Further, the O3PUFA-
derived NAEs identified in this study are precursors of docosahexaenoyl ethanolamine 
(DHEA; synaptamide) and eicosapentaenoyl ethanolamine (EPEA), which bind to 
cannabinoid receptors in rats [91] and may contribute to the beneficial effects mediated 
by dietary O3PFAs [92-94]. Although the metabolic pathways involved in NAE 
biosynthesis remain unclear, our results strongly suggest that NAPE-PLD-independent 
(N-acyl phosphatidyl ethanolamine phospholipase D) pathways are activated in chronic 
SCI and represent a promising therapeutic target [95]. Because NAEs can modify the 
response to nociceptive stimuli and are tightly regulated by diet, O3PUFAs could have 
important implications for chronic pain management.  
There is now strong evidence linking the neuroinflammatory milieu after SCI to 
changes in sensory electrical activity and pain-related behaviors [96]. For instance, 
accumulating evidence implicates the activation of the spinal p38 mitogen-activated 
protein kinase, p38 MAPK, as a molecular mechanism underlying neuronal 
hyperexcitability and pain after SCI [65, 66, 97]. Remarkably, animals consuming dietary 
O3PUFAs exhibited reduced numbers of dorsal neurons expressing p-p38, indicating a 
potential molecular link between dietary lipids and pain. This finding is supported by 
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studies demonstrating that both DHA and EPA alone attenuate the activation of p38 in 
endothelial cells stimulated by TNF-α [98]. More recent studies showed that DHA also 
impairs p38 MAPK signaling in microglial cultures [99]. In agreement with these 
findings on the potential anti-inflammatory and antinociceptive roles of dietary 
O3PUFAs, this study shows a marked reduction in the levels of inositols and CGRP-
positive sprouting fibers in the chronically injured cord. Importantly, the p38 MAPK has 
been linked to the regulation of inositol levels in human peripheral blood monocytes and 
macrophages [100] and to the expression of calcitonin gene-related peptide in rats [101]. 
This study supports the dynamic interplay among these biomarkers of the nociceptive 
system. Further studies are necessary to evaluate these molecular interactions and to 
investigate their potential as useful biomarkers to discriminate pain severity in SCI-
related neuropathic pain.  
Although experimental contusion SCI is a well-established and validated animal 
model for evaluating the development of pain and analgesic strategies [28, 30-33], there 
are limitations in extrapolating findings from experimental animal models and to humans. 
It has been suggested that the mechanisms underlying evoked responses in SCI animals 
may differ from those of underlying spontaneous neuropathic pain in patients [102]. The 
proper interpretation of animal pain-like behaviors thus remains a challenge and warrants 
further research. Given the significant contribution of supraspinal structures in pain 
processing [103-105], futures studies should employ integrated pain-associated behaviors 
to facilitate data interpretation and to gain better understanding of the antinociceptive 
targets of dietary O3PUFAs. In summary, this study shows for the first time that dietary 
O3PUFAs prophylaxis attenuates the development of thermal hyperalgesia following 
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SCI, possibly by providing a better bioavailability for anti-inflammatory lipid mediators. 
Even though recent advances in pain research suggest that combinatorial strategies to 
both prevent and combat chronic neuropathic pain are a feasible goal [106], identifying 
targets with the intention of preventing pain is an enormous conceptual challenge that has 
so far stymied drug discovery. The study presented herein supports the use of preventive 
alternative approaches in individuals at risk of developing neuropathic pain and identifies 
diet as a potential risk factor for poor outcome. Although further research is needed, our 
findings have remarkable public health implications to reduce the burden of pain, 
particularly in populations at risk. Because dietary O3PUFAs are safe, well tolerated, and 
confer robust protection against experimental SCI they should be favored for early pain 
management in human SCI.   
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Abstract 
The pathology associated with Spinal Cord Injury (SCI) generates debilitating 
autonomic dysfunctions, paralysis and significant sensorimotor impairments. These 
outcomes may be influenced an increased levels of free radical part of the oxidative stress 
observed after the trauma. The present study investigates the impact of an eight weeks 
dietary enrichment with vitamin E (alpha-tocopherol) on key functional outcomes 
prevalent during the acute phase of SCI. Female adult Sprague-Dawley rats were fed 
either with a normal diet or a regiment supplemented with Vitamin E for eight weeks. 
Following the treatment animals were exposed either to a contusion SCI or Sham and 
evaluated using standard functional behavior analysis. We report that dietary vitamin E 
promoted locomotor recovery and a reduction in conduction deficits.  Rats consuming the 
Vitamin E enriched diet showed a significant improvement in the BBB locomotor scores 
and a significant accelerated bladder recovery. The dietary intervention did not seem to 
preserve neurons in the ventral horn of injured rats,  but it significantly increased the 
numbers of oligodendrocytes. Further analysis showed, that dietary Vitamin E inhibited 
H-reflex depression and increased the levels of supraspinal serotonin immunoreactivity. 
Our findings support the complementary use of vitamin E to ameliorate sensory and 
autonomic dysfunctions observed following SCI such as bladder dysfunction. 
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Introduction 
Primary mechanical injury to the spinal cord sets in motion a complex cascade of 
secondary harmful events that result in serious neurological dysfunction and paralysis. 
Following the initial lesion, events associated with a secondary injury can last several 
days and weeks after injury. Disorders associated with the secondary injury include 
dramatic metabolic alterations [1- 9], a general increase in oxidative stress and 
inflammation [10-20], demyelination [20-25], and apoptosis [26-29]. During the first 
week after injury there is an extensive loss of neurons and oligodendrocyte [23,28-33], 
lipid peroxidation [10,34], and axon degeneration [14]. The production of free radicals 
during this period is believed to contribute to these detrimental outcomes by disrupting 
cell membranes, causing organelle dysfunction, and disturbing calcium homeostasis [34]. 
The free radical production peaks at 12 h after the initial injury and it remains elevated 
for at least 1 week after injury. Examples of elevated free radicals after injury are 
hydrogen peroxide, hydroxyl radical, and peroxynitrite radical [14,35]. Previous studies 
have shown a reduced antioxidant defense after SCI [36] and antioxidant agents such as 
tempol have shown to be neuroprotective in the context of SCI [37]. 
Previous reports from our laboratory showed that dietary prophylaxis with omega-
3 lipids is protective during SCI. For instance, dietary omega-3 polyunsaturated fatty 
acids (O3PUFAs) modulated multiple pathways that contribute to secondary acute and 
chronic damages following SCI [38-39]. Administration of O3PUFAs restored the spinal 
cord lipid homeostasis, confers neuroprotection, prevents sensorimotor dysfunction and 
neuropathic pain, and facilitates locomotor recovery following acute and chronic SCI 
when administered before and during SCI [38,39,40]. Another nutrient with demonstrated 
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antioxidant capability that could be important in stimulating recovery following SCI 
injury is vitamin E. Previous studies using dietary vitamin E supplementation for 5 days 
prior to the SCI in cats found a reduction of arachidonate and prostanoids [41] associated 
with less ischemia [42] and enhanced locomotion recovery [43]. Further, dietary vitamin 
E for 8 weeks before SCI decreased reactive oxygen species (ROS) while improved 
locomotion, blood flow and spinal cord evoked potentials, and decreased ROS in rats 
[44]. While these studies did not use the standardized scale to measure locomotion after 
SCI, the Basso, Beattie, and Bresnahan (BBB) scale, their findings provided support for a 
promising neuroprotective role of vitamin E. Further, dietary vitamin E supplementation 
for 14 days after injury was shown to improve BBB scores [45-46] potentially involving 
the inhibition of lipid peroxidation products such as thiobarbituric acid reactive 
substances and malondialdehyde [44,47-48].  
Thus, prior studies suggest a neuroprotective role of vitamin E during SCI, but 
little is known about potential targets, primary cellular processes involved and whether it 
can affect other primary functions affected by SCI. For instance, it is unknown whether 
dietary prophylaxis with vitamin E can specifically address specific impairments 
associated with SCI such as bladder dysfunction and spasticity. These processes can be 
especially sensitive to oxidative stress, serotonin levels or adequate number of 
oligodendrocyte. The present study evaluates the effects of two months dietary exposure 
to vitamin E supplementation on selected physiological outcomes and examined potential 
mechanisms. The underlying hypothesis of the current study is that a balanced 
antioxidant dietary regimen containing adequate levels of vitamin E may enhance the 
ability of the spinal cord to response to traumatic injury. The data suggest that dietary 
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vitamin E supplementation significantly improved BBB locomotor scores following SCI. 
Further, we also report for the first time that prophylactic vitamin E administration 
stimulates bladder recovery, inhibited H-reflex depression, supraspinal serotonin levels 
and preserved oligodendrocytes survival. 
 
Materials and Methods 
Experimental procedures were compliant with the Loma Linda University School 
of Medicine regulations and institutional guidelines consistent with the National Institutes 
of Health Guide for the Care and Use of Laboratory Rats. 
 
Animals 
Experimental procedures were compliant with the Loma Linda University School 
of Medicine regulations and institutional guidelines consistent with the National Institutes 
of Health Guide for the Care and Use of Laboratory Rats. All animal work reported in 
this manuscript was performed under the approval the Loma Linda University Health 
Institutional Animal Care and Use Committee approval number 8170021. A total of 60 
female Sprague-Dawley rats weighing 182–212 g were acquired from Charles River 
Laboratories (Portage, MI, USA). The female rats were housed in individual cages with 
food and water ad libitum with alternated exposure of light and dark periods of 12 h. 
 
Study Design 
The female rats were acclimatized for 1 week after arrival at the animal care 
facility and were randomly divided into two main groups: (Group 1) rats on the control 
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diet (n = 30) and (Group 2) rats on the vitamin E-enriched diet (n = 30) (Figure 1). After 
8 weeks, the rats were further categorized based on their dietary and surgical 
interventions: Group 1a was the control diet/sham operated group (n = 15); Group 1b was 
the control diet/spinal cord injured group (n = 15); Group 2a was the vitamin E-enriched 
diet/sham operated group (n = 15); and Group 2b was the vitamin E-enriched diet/spinal 
cord injured group (n = 15). Dietary interventions were continued after surgery for 1 
week post-operation (wpo). During the first week after operation functional recovery and 
behavioral analysis was performed in a blinded manner. Spinal cord tissue was collected 
for analyses at 1 wpo. We opted for not including a group with a vitamin-E enriched diet 
after injury only because it has been shown the number of pellets eaten the week 
following spinal cord injury, the acute phase, substantially decreases [39,40]. In a setting 
where the sub-acute and/or chronic effects of a vitamin-E enriched diet post injury were 
being studied, such group would definitely contribute to the study, but not in our acute 
phase, study. 
 
Diets 
AIN-93G-based custom isocaloric diet formulations were prepared with modified 
fat compositions (Bio-Serv, Frenchtown, NJ). The amount of dietary fat was supplied as 
either soybean oil (control diet) or vitamin E-enriched diet and it was approximately 6% 
of dry weight. They were both stored in a refrigerated area. Gas chromatography and 
mass spectrometry analysis showed principal nutrients in the diet as follow: (i) the 
amount of Vitamin E in the control diet was .0816 IU/gram and the Vitamin E-enriched 
diet had 51 IU/gram; (ii) total saturated fat was 1.13 g/100gram and 1.00 g/100gram, total 
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monosaturated fat was 1.61 g/100gram and 1.49 g/100gram, total polysaturated fat was 
4.09 g/gram and 4.34 g/gram for control diet and Vitamin-E enriched diet, respectively; 
(iii) the percentage for kcal carbohydrates was 64.7 and 60.5, the percentage for kcal 
protein was 18.8 and 21.1, and  the percentage for kcal fat was 16.5 and 18.4 for control 
diet and Vitamin-E enriched diet, respectively. The selection of soybean oil as the control 
fat in our diets was based on our previous studies [1-3] 
 
Surgical and Post-Operative Procedures 
The female rats were on dietary pretreatment for eight weeks. After that they  
were anesthetized with a combination of ketamine/xylazine (80 mg/kg and 10 mg/kg, 
respectively). The New York University (NYU) Impactor was used to generate the spinal 
cord lesions [4].  This device causes the necessary trauma to induce bladder dysfunction, 
which suggests this model is appropriate for evaluating the therapeutic potential of our 
intervention ([5, 6]). In order to expose the spinal cord to generate the contusion, the skin 
and the muscles overlying the spinal column were removed. Laminectomy was 
performed at the T9-T10 level and the T8 and T12 spinal processes were clamped to the 
Impactor exposing the dorsal surface of the spinal cord. The dorsal surface was then 
subjected to weight drop impact with a 10-g rod released from a height of 12.5-mm. 
Sham rats were not subjected to weight drop impact and only received a laminectomy. 
The female rats body temperature was maintained at 37°C during the whole procedure. 
After  laminectomy or weight drop impact, muscle layers were carefully sutured and skin 
layers closed. Crede’s maneuver was performed three times per day to express the 
bladders of the injured rats until voiding reflexes were restored. All rats were inyected 
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twice per day with Cefazolin (from Bristol Myers Squibb, New York, NY; 25 mg/kg, 
s.q.) for 5 consecutive days and Buprenex® (also known as buprenorphine; from Reckett 
and Colman Pharmaceuticals, Inc. Richmond, VA; 0.05 mg/kg, s.c.) for 3 consecutive 
days. Rats were sacrificed 1 week post-operation and the spinal cord tissue was dissected 
and collected for immunohistochemical analysis. 
 
Behavioral Evaluation of Spontaneous Locomotion 
The Basso-Beattie-Bresnahan (BBB) scale is a 22-point (0–21) measurement 
scale that evaluate the rat’s spontaneous open-field locomotion [55]. First, the rats were 
acclimatized in an empty-plastic black pool simulating an open field environment for five 
daily sessions 1 week before SCI. After SCI, rats were videotaped weekly in the open 
field locomotion test. In a blind manner, two observers independently assessed: (1) 
locomotive function, (2) joint movement, (3) paw placement and rotation, (4) paw 
coordination, (5) tail position, and (6) trunk position and stability. The average score 
from both blind observers for each hind paw was used for analyses. According to this 
measurement scale, a score of 0 is given to a completely paralyzed rat, scores between 1 
and 8 are given to rats with increasing joint movements without weight support (recovery 
stage 1), scores between 9 and 13 are given to rats with abnormal locomotion that are 
able to produce weight supported steps (recovery stage 2), scores between 14 and 20 are 
given to rats that have reached graded coordination patterns, paw position, and trunk 
stability (recovery stage 3), and a score of 21 is given to normal (and sham) rats with no 
dysfunction in locomotion. 
 
 179 
H-reflex Recording 
The rats were placed on a heated (approximately 37 °C) metal platform. The 
Hoffmann’s reflex (H-reflex) was recorded from the plantar muscles of the hind paw, 
with the active needle electrode (30-gauge) inserted between the fourth and fifth 
metatarsals, and the reference electrode inserted in the skin of the fifth digit. To elicit the 
H-reflex and study its rate sensitivity, the tibial nerve at the ankle was stimulated for 0.1 
ms at 0.1, 0.3, 1, 2, 3 and 5 Hz using the TECA Sapphire 4ME EMG unit. The cathode 
needle was inserted subcutaneously at the ankle, just above the heel, and the anode needle 
was inserted subcutaneously at the plantar surface of the heel. The intensity of the 
stimulus was adjusted to elicit the maximal consistent H-wave amplitude. The recorded 
signal was passed to a differential amplifier and bandpass filtered at 0.1 Hz and 10 kHz. 
The analog signal was then sent to an A/D converter and the digital waveform (recorded 
at 30 kHz) and stored. Sixteen consecutive waveforms were collected at each frequency. 
The differences in amplitudes of M- and H-waves as determined by the peak-to-peak 
values of each waveform were used to calculate the H-reflex depression. The investigator 
was blinded to the experimental groups during data recording and analyses. 
 
Autonomic Bladder Control Recovery 
Crede’s maneuver was used to express the bladders of the injured rats. We used 
this technique to express the bladder three times a day until bladder function was 
restored. Each morning we counted how many rats in each diet regained bladder control 
before 7 dpi and after 7 dpi. Bladder function is restored when the maximum amount of 
collected volume is 500 μL or less for at least two consecutive days. 
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Immunohistochemistry Studies and Microscopy 
Spinal cord coronal sections were dried at room temperature for 10–15 min, 
washed with Phosphate Buffer Saline (PBS) for 5 min, and post-fixed with 4% PFA for 
10 min. The sections were blocked with 20% Bovine Serum Albumin (BSA) for 2 h at 
room temperature, and incubated at 4 °C in antibody solutions containing either mouse 
anti-Neuronal Nuclei (NeuN) monoclonal antibody (clone A60, 1:100; from Millipore, 
Billerica, MA, USA), mouse anti-adenomatous polyposis coli (APC)-7 monoclonal 
antibody (clone CC-1, 1:200; from Calbiochem, San Diego, CA, USA), and rabbit 
polyclonal anti-5HT antibody (1:500; from Abcam, Cambridge, MA, USA) to examine 
the immunoreactivity (IR) and cell numbers of neurons, mature oligodendrocytes, and IR 
of serotonin. On the next day, the sections were incubated with Alexa Fluor®488 or 594-
conjugated donkey anti-mouse (1:500; from Invitrogen, Carlsbad, CA, USA). Control 
slides were incubated without primary antibodies to further confirm the specificity of the 
IR. The slides were examined with a BIOREVO BZ-9000 fluorescent microscope 
(Keyence, Itasca, IL, USA) 
 
Statistical Analyses 
Data are presented as mean +/– SEM. One-way analysis of variance (ANOVA), 
followed by Bonferroni post-hoc comparisons, was used to determine the effect of spinal 
cord injury and vitamin E supplementation on open-field locomotion scores, H-reflex 
depression, NeuN+ cell counts, APC+ cell counts, and 5HT IR. Unpaired t-test was used 
to analyze the difference of APC+ cell counts between uninjured and injured vitamin E 
groups. Fisher’s Exact Test was used to determine the effect of vitamin E in bladder 
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recovery during the first week post-SCI. Statistical analyses were performed using Prism 
6 Software (GraphPad Software Inc., San Diego, CA, USA). Outliers were identified 
using the Grubbs’ method, also known as ESD (extreme studentized deviate). Only one 
rat was excluded from the study after using these exclusion methods. Statistical 
differences were considered significant at p <0.05. 
 
Results 
Dietary Vitamin E Improves Locomotor Recovery after SCI 
One week after behavioral habituation period, female Sprague-Dawley rats were 
provided ad libitum access to one of two diets: control diet or vitamin E-enriched diet 
(See Table 1 for detailed diet composition). The rats remained on their assigned diets for 
a total of 8 weeks before injury and 1-week post-SCI. Functional recovery was assessed 
during the first week after injury. At the end of the study, the spinal cords were harvested 
and tissues were used for immunohistochemical studies (Figure 1 summarizes the study 
timeline). The BBB locomotor grading scale was used to evaluate the effects of vitamin E 
pre-administration on the functional recovery of injured rats. A video recording of each 
subject’s performance in the open field was obtained at 1 and 7 days post-injury (dpi). 
We found significant improvements in locomotor behavior in rats from dietary vitamin E 
prophylaxis group (n = 12) compared to rats fed with control diet at 7 dpi (n = 14) 
(Figure 2A) (F (3, 4190) = 367.2, CTL INJ, n = 14 versus VIT E INJ, n = 12 *** p < 
0.001). Still images from representative rats fed control diets shows limited movement, 
dragging of hindlegs, and slight movement of hindlimb joints (Figure 2B) at 7 dpi. 
Interestingly, rats fed with the vitamin E enriched diet exhibited signs of intermediate 
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locomotor recovery, as indicated by their ability to generate extensive movements of all 
three joints with dorsal-stepping patterns (Figure 2).  
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Table 1. Detailed diet composition for 
Control and Vitamin E – Enriched Diet 
 
 
Figure 1. Timeline showing the vitamin E diet supplementation schedule and the time 
points of behavioral assays, surgical procedures, and tissue sample collection. 
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Figure 2. Beneficial effects of dietary vitamin E prophylaxis on the hindlimb neurological 
function of rats after a moderate injury, as assessed by the Basso-Beattie-Bresnahan (BBB) 
locomotor rating scale. (A) Effect of dietary vitamin E prophylaxis on locomotor function. 
Time (in days) following pretreatment and spinal cord compression (injury) is shown on 
the horizontal axis, BBB locomotor rating scores are shown on the vertical axis. Injured 
rats in the dietary vitamin E prophylaxis group had higher BBB scores of at least 7 when 
compared to controls. Open-field locomotion still images from control diets- (B) and 
dietary vitamin E prophylaxis rats (C) at 7 days post-injury (dpi). Mean dietary vitamin E 
prophylaxis scores revealed that most rats exhibited extensive movements of three joints 
with dorsal-stepping patterns at 7dpi. Bonferroni test analysis was carried out to determine 
the statistically significant differences between diet treatments. Error bars represent 
means±standard error of the mean (CTL INJ versus VIT E INJ ***p<0.001; CTL 
INJ, n=14; VIT E INJ , n=12). 
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Dietary Vitamin E Prophylaxis Restores H-reflex Depression at 7dpi at 5Hz 
Hyperreflexia and spasticity are common complications in SCI with limited 
availability for safe and effective treatment. A central mechanism in spasticity is 
hyperexcitability of the spinal stretch reflex. This reflex presents symptomatically as a 
velocity-dependent increase in tonic stretch reflexes and exaggerated tendon jerks, 
resulting in functional deficits, pain, and musculoskeletal deformities. Given that the 
Hoffmann’s reflex (H-reflex) can be evoked in rats, we chose to study the efficacy of our 
dietary intervention to restore this reflex. As expected, we found reduced H-reflex 
depression as the stimulation frequency was increased in SCI rats. Notably, the rats that 
consumed the vitamin E-supplemented diet showed improved H-reflex depression, 
suggesting less SCI-induced hyperreflexia. Sham-operated rats exhibited normal H-reflex 
depression in both dietary groups (control diet and vitamin E prophylaxis) (Figure 3A). 
Vertical bars in Figure 3B represent the size of the difference between the M-
wave and the H-wave at 5 Hz compared to low frequency stimulation (0.1 Hz). A lower 
vertical bar on the y-axis indicates a bigger difference between the M-wave and H-wave 
(the latter being smaller), thus showing more H-reflex depression. A higher vertical bar 
on the y-axis value indicates a smaller difference between the M-wave and the H-wave at 
5 Hz compared to 0.1 Hz thus less H-reflex depression. 
In uninjured control rats and uninjured rats that received and vitamin E diet, the 
H-wave steadily decreased with increasing stimulus frequency with the maximum 
frequency being 5 Hz. However, in injured rats that received a control diet before SCI, 
the H-wave depression was inhibited showing how the H-reflex was less sensitive to 
increased stimulus frequency at 5 Hz. As shown in Figure 3, injured rats that received a 
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vitamin E diet before SCI showed a decrease in H-wave depression similarly to uninjured 
control rats and uninjured vitamin E rats. This finding is indicated by a lower H-wave 
amplitude at 5 Hz compared to injured rats from a control diet (Figure 3) (F (3, 20,287) = 
8.231, (** p < 0.01 CTL SHAM vs. CTL INJ and ** p < 0.01 CTL INJ vs. VIT E INJ 
and * p < 0.05 VIT E SHAM vs. CTL INJ; CTL SHAM n = 6, CTL INJ n = 6, VIT E 
SHAM n = 6, VIT E INJ n = 7). In summary, H-reflex depression became abnormal after 
SCI only in injured rats that received a control diet before SCI but not in injured rats that 
received a vitamin E diet before SCI. 
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Figure 3. Dietary vitamin E prophylaxis restores H-reflex depression at 7dpi at 5Hz. 
Increased amplitudes on the y axis at 5Hz indicate less H-reflex rate depression, whereas 
decreased amplitudes indicate more rate depression. The H-reflex depression after 
increased frequency (i.e. 5 Hz) was abnormal in rats on a control diet after SCI but it was 
restored in rats on dietary vitamin E prophylaxis after SCI at 7dpi (A). Higher percent 
changes from .1Hz at 5 Hz indicate  abnormal H-reflex rate depression after SCI in rats on 
a control diet  but not in rats on dietary vitamin E prophylaxis at 7dpi where there was a 
lower percent change from .1Hz (B). (**P < 0.01 CTL SHAM vs CTL INJ and **P < 0.01 
CTL INJ vs Vit E INJ and *P < 0.05 VIT E SHAM vs CTL INJ; CTL SHAM n=6, CTL 
INJ n=6, VIT E SHAM n=6, VIT E INJ n=7) 
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Beneficial Effects of Dietary Vitamin E Prophylaxis on Autonomic Function After SCI 
SCI results in a period of distinctive bladder dysfunction[7-14]. Manual collection 
and quantification of the residual urine volume was done to assess whether dietary 
vitamin E prophylaxis show efficacy in accelerating autonomic bladder recovery (Fig. 4). 
For each rat, the number of days needed to attain full autonomic recovery was defined as 
residual volume of 0.5 mL for 2 or more consecutive days. A key finding is that Fisher’s 
Test analysis of contingency tables found a significant decrease on the number of days 
(<7) required for bladder control recovery in the rats on the vitamin E prophylactic group. 
(*P < 0.05 CTL INJ vs VIT E INJ; CTL INJ n=19, VIT E INJ n=13).  
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Figure 4. Beneficial effects of dietary vitamin E prophylaxis on autonomic 
function after contusion injury. (A) Residual urine volumes (mL) differed 
significantly between control and dietary vitamin E prophylaxis pre-treated 
groups at 7dpi. For each rat, the number of days needed to attain full autonomic 
recovery was defined as residual volume of 0.5 mL for 2 or more consecutive 
days. Dietary vitamin E prophylaxis resulted in fewer days (<7) to attain full 
bladder recovery (*P < 0.05 CTL INJ vs VIT E INJ; CTL INJ n=19, VIT E INJ 
n=13). 
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Dietary Vitamin E Does Not Preserve Neurons at 1 Week After SCI  
To determine the number of motor neurons in the ventral gray matter of the spinal 
cord, immunohistochemical analyses were performed during the first week following 
SCI. This represents a critical period in apoptotic cell death in SCI models [15-19]. 
Consistent with previous findings, we found a significant decrease in the number of 
neuronal nuclei positive (NeuN+) cells in the ventral gray matter of injured rats when 
compared to uninjured sham rats at 1-week post-SCI. Representative images from 
sections labeled anti-NeuN (Fig 5A) did not show significant differences in motor neuron 
cell counts when comparing vitamin E-fed rats with controls at 7 dpi (p > 0.05) [F (3, 13, 
256) = 13.19, **P < 0.01, CTL SHAM, n=6 vs  CTL INJ, n=6; ***P < 0.001 CTL 
SHAM, n=6 vs  VIT E INJ, n=7; P > 0.05, CTL INJ, n=6 vs VIT E INJ, n=7) ] 
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Figure 5. Vitamin E prophylaxis doesn’t preserve neurons at 1 week after spinal cord 
injury (SCI). (A) Expression of neuronal markers was quantified in the ventral gray matter 
(VGM). (B) Manual quantification of cell numbers and normalization to controls shams 
revealed decreased numbers of NeuN+ cells in the VGM in injured control rats and injured 
vitamin E fed rats. The number of NeuN+ cells in the ventral gray matter of the spinal cord 
from injured control rats was not significantly different from injured vitamin E fed rats. 
Bonferroni test analysis was carried out to determine the statistically significant differences 
between diet treatments. Error bars represent means±standard error of the mean (**P < 
0.01, CTL SHAM, n=6 vs  CTL INJ, n=6; ***P < 0.001 CTL SHAM, n=6 vs  VIT E INJ, 
n=7; P > 0.05, CTL INJ, n=6 vs VIT E INJ, n=7).  
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Dietary Vitamin E Preserves Oligodendrocytes Following SCI 
We performed immunohistological analyses to determine the quantity of 
oligodendrocytes in the white matter at 7 dpi. Oligodendrocytes were immunodetected 
using the anti-adenomatosis polyposis coli (APC) antibody. Our results confirmed 
previous studies showing a significant decrease in the number of oligodendrocytes at one-
week post-SCI. Representative images from injured sections labeled with the APC 
antibody show increased number of APC positive cells in the spinal cord of rats fed the 
vitamin E diet when compared to controls. Additionally, there was an increased number 
of APC positive cells in the spinal cord of injured rats that were fed the Vitamin E diet 
compared to control injured rats. There was no significant difference between APC 
positive cells between uninjured rats in the control diet and Vitamin E diet. (p < 0.05) 
(Fig. 6) [F ( 3, 26.619 ) = 18.05, ***P < 0.001, CTL SHAM, n=6 vs  CTL INJ, n=6); 
**P<0.01, VIT E INJ, n=7 vs CTL INJ, n=6); P>0.05, CTL SHAM, n=6 vs VIT E 
SHAM, n=6 ]. There was a significant difference in APC positive cells between 
uninjured rats in the Vitamin E diet and injured Vitamin E diet when they were analyzed 
using an unpaired t-test (P=0.0059). 
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Figure 6. Vitamin E prophylaxis preserves oligodendrocytes at 1 week after spinal cord 
injury. (A)Expression of oligodendrocyte markers was quantified in the white matter of the 
spinal cord. (B) Manual quantification of cell numbers and normalization to control shams 
revealed decreased numbers of APC+ in the white matter of injured control rats, but not in 
injured vitamin E fed rats. There was a statistically significant increase of APC+ cells in 
vitamin E fed rats compared to injured control rats.  Bonferroni test analysis was carried 
out to determine the statistically significant differences between diets. There was a 
significant difference in APC positive cells between uninjured rats in the Vitamin E diet 
and injured Vitamin E diet when they were analyzed using an unpaired t-test *(P=0.0059). 
Error bars represent means±standard error of the mean ( ****P < 0.0001, CTL SHAM, 
n=6 vs  CTL INJ, n=6; P > 0.05 CTL SHAM, n=6 vs  VIT E INJ, n=7; ***P<0.001, VIT 
E INJ, n=7 vs CTL INJ, n=6). 
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Dietary Vitamin E Upregulates Serotonin Immunoreactivity Following SCI 
Previous studies have shown decreased serotonin levels after moderate-contusive 
SCI[20]. Serotonin inhibits afferent transmission and spinal reflexes and plays crucial 
roles in motor control and recovery[21-27]. Serotonergic signaling is a key mechanism 
underlying neuronal hyperexcitability after SCI, which has been demonstrated to underlie 
the pathogenesis of spasticity after SCI [28-32]. Here, we investigated the effects of this 
dietary intervention on serotonin levels in the spinal cord. We found a significant increase 
in the levels of serotonin in rats fed the vitamin E- prophylactic diet compared to the 
control diet in uninjured (*P < 0.05 , CTL SHAM, n=5 vs VIT E SHAM, n=5)  and 
injured rats (*P < 0.05 , CTL INJ, n=5 vs VIT E INJ, n=5) (Fig. 7b). Interestingly, we 
found no significant difference between sham and injured rats (P > 0.05, p = at least 5 
rats).  
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Figure 7. Vitamin E prophylaxis upregulate subspinal serotonin immunoreactivity in the 
white matter at 7dpi. Subspinal serotonin IR was quantified in the white matter at 7dpi in 
all four groups (Fig. 7a). There was a diet-dependent upregulation of 5-HT-IR in uninjured 
rats (*P < 0.05 , CTL SHAM, n=5 vs VIT E SHAM, n=5)  and injured rats (*P < 0.05 , 
CTL INJ, n=5 vs VIT E INJ, n=5) (Fig. 7b). There was no difference between uninjured 
and injured rats in the control diet (P > 0.05, CTL SHAM, n=5 vs CTL INJ, n=5) and 
between uninjured and injured rats in the vitamin E diet (P > 0.05, VIT E SHAM, n=5 vs 
VIT E INJ, n=5). 
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Discussion 
The present study reports novel findings showing that a two-month chronic 
dietary supplementation with vitamin E (alpha-tocopherol) improves recovery during the 
acute phase of SCI and identify potential targets. The significant prophylactic effects of 
vitamin E supplementation included improved functional locomotor outcomes, 
accelerated bladder recovery measured in urinary retention time, and reduced 
hyperreflexia after SCI. Further, the dietary intervention increased numbers of 
oligodendrocytes and increased supraspinal serotonin IR, indicating potential targets 
underlying the restorative potential of vitamin E in SCI. 
Spinal cord injury has a devastating effect on affected individuals. Patients 
experience serious secondary complications such as urinary retention, a sign of 
autonomic bladder dysfunction, that has serious practical physiological and psychological 
consequences [77,78]. Thus, the search of alternative complementary interventions with 
the potential to lessen the effect of this condition is needed. Although there have been 
several studies considering the effects of vitamin E during spinal cord injury, little 
progress has been made in developing appropriate evidence-based complementary 
therapies. Questions needed to be address for further assessment include appropriate 
dosage, timing of administration and proper use of dietary prophylaxis. Also, while 
several studies have shown the effects of vitamin E on improvement locomotion and 
other parameters, these effects on locomotion has not been quantified using the BBB 
scores and it is unknown whether this complementary treatment is beneficial in 
addressing urinary retention time, or the H-reflex. To properly evaluate a potential 
vitamin E effect on these parameters it is important to ensure that the animal is exposed 
 197 
to the proper levels of vitamin E. The current study uses dietary prophylaxis with vitamin 
E by exposing the animals to a chronic dietary intervention for two months before the 
animal were subject to the traumatic contusion injury on the cord. A chronic dietary 
intervention was deemed to be a better approach to avoid potential hurdles associated 
with vitamin E stability. This approach allowed us to assess with confidence key 
functional outcomes and determine whether vitamin E had a significant impact. We also 
proceeded to assess selective functional parameters and quantifying vitamin E effects on 
locomotion using for the first time the BBB scores. 
The well documented antioxidant actions of vitamin E would be beneficial in 
physiological process that, while affected by the injury, still have functional connections. 
In this context, we evaluate whether bladder dysfunction was a good target for this 
treatment. Current interventions used to reduce bladder dysfunction after SCI include 
cholinergic muscarinic receptor antagonists [79,80,81,82,83,84,85], chemical blockade of 
C-fiber afferent neurotransmission with capsaicin or resiniferatoxin 
[86,87,88,89,90,91,92] and alpha1- acetylcholine receptor (AR) receptor antagonists 
[93,94,95,96,97,98,99]. Additional interventions include suppression of motorneuron or 
interneuron excitation in the spinal cord by glycine, GABA agonists, and baclofan is 
being used to treat dysfunctional contraction of the external urethral sphincter 
[100,101,102,103,104,105,106]. Botulin toxin, a presynaptic neuromuscular blocker, is 
now FDA-approved to treat bladder hyperreflexia by inducing reversible muscle 
weakness [107,108,109,110,111,112].  
Various studies support the use of antioxidant therapy to address bladder function 
following SCI. For instance, treatment with quercetin was shown to improve bladder 
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contractility, while decreasing reactive oxygen species, plasma cytokines, and caspase 3, 
and prevented depletion of free radical scavengers after SCI in rats [113]. Additional 
treatment with antioxidant cranberry extract supplements for at least 6 months showed a 
decrease in urinary tract infections [114]. These approaches to address bladder recovery 
following SCI suggest that complementary therapies that can improve nerve conduction 
may be useful as part of comprehensive treatment. In this context, vitamin E could 
specifically decrease urinary retention through the improvement of nerve conduction. For 
instance, spinal cord evoked potentials after injury showed greater recovery of both 
amplitude and latency in a vitamin E supplemented group compared to control [44,48]). 
Also, in the present study we found that vitamin E supplementation significantly inhibits 
the H-reflex depression.  
These findings are consistent with a role of vitamin E in enhancing nerve 
conductivity in the injured cord which is may also explain the significant increase in the 
BBB locomotion scores seen in these animals fed with the enriched vitamin E diet 
reported here. These data expand previous work showing vitamin E improving 
locomotion when administered in a prophylactic manner [43,44,48] or after injury 
[45,46]. When compared to vitamin C supplementation after injury, vitamin E was shown 
to be more effective for locomotion recovery [46]. Proven actions of vitamin E in 
reducing lipid peroxidation products such as thiobarbituric acid reactive substances 
[44,48] and malondialdehyde [47] may be responsible at least in part for these effects 
[36]. Further, vitamin E improves recovery by decreasing ischemia [42] and 
downregulating arachidonate and prostanoids [41]. 
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The improved outcomes exhibited by the rats that consumed the vitamin E-
enriched diet were associated with an increased preservation of oligodendrocytes of the 
injured cord. Interestingly, this increase of oligodendrocytes survival was not accompany 
with an increased survival of neurons. This finding is consistent with reports showing the 
high vulnerability of oligodendrocytes to oxidative stress. For instance, oligodendrocytes 
and pre-oligodendrocytes have been shown to be highly sensitive to abnormal high levels 
of intracellular free radicals that follow cysteine deprivation and treatment with vitamin E 
and other ROS scavengers (ascorbate, idebenone, and N-tert-butyl-alpha-phenylnitrone) 
promote their survival [115,116]. Vitamin E also protects murine oligodendrocytes in 
culture from ROS generation and apoptosis caused by cytotoxic oxysterols 
[117,118,119], and from lipid peroxidation in combination with ascorbate acid [120]. 
Although this was not directly addressed in the present study, a significant increase in 
oligodendrocytes in the rats that consumed the vitamin E diet may be implicated in the 
improvement seen on H-reflex depression, bladder reflex recovery, and locomotion in 
these rats because of myelin and axonal preservation [25,121,122,123,124,125,126].  
Therefore, vitamin E may be able to exert its beneficial effects in the event of 
spinal cord injury even in the absence of neuronal preservation due to increased survival 
of oligodendrocytes. Future clinical study may be necessary to assess the value of a 
similar strategy to treat bladder dysfunction and improve nerve conductivity following 
SCI. 
Our results showing a significant upregulation in serotonin levels in rats fed a 
vitamin E prophylactic diet further strengthens vitamin E as a potential therapeutic agent 
for SCI complications. This is supported by several studies showing an improved voiding 
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efficiency after SCI following increased catecholaminergic and serotonergic axonal 
growth [127,128,129,130]. This is consistent with findings showing a direct correlation 
between low serotonin and abnormal H-reflex depression [64]. Serotonin depletion has 
also been found to positively correlate with the degree of paralysis and disease severity in 
rat model for multiple sclerosis [131,132]. In models of SCI regeneration of spinal 
serotonergic neurons is associated with functional recovery [133,134]. 
In summary, we propose increased survival of oligodendrocytes and upregulation 
of serotonin levels as potential mechanisms through which dietary vitamin E prophylaxis 
improves locomotion, H- reflex depression, and bladder recovery in the context of SCI. 
The findings reported herein are consistent with previous studies from our lab 
showing that administration of antioxidants such as omega-3 fatty acids stimulate 
recovery following contusion injury to the spinal cord [38,39,40]. To date, several studies 
have shown the beneficial effects of antioxidants to restore function after trauma. 
However, studies investigating the effects of dietary vitamin E in neural repair are 
limited. Our findings suggest the potential of this nutritional-based intervention to 
ameliorate functional impairments and cell survival following SCI. Furthermore, our 
study supports the importance of nutrition to ameliorate the augmented state of cellular 
oxidative stress observed during SCI. 
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CHAPTER SIX 
SPATIOTEMPORAL EXPRESSION OF FAT/CD36 AFTER CENTRAL 
NERVOUS SYSTEM TRAUMA AND ITS POTENTIAL IMPLICATIONS FOR 
ALTERED LIPID TRANSPORT IN SPINAL CORD INJURY 
Abstract 
Traumatic injury to the central nervous system (CNS) is a devastating life event 
for which no current effective treatments are available. A growing body of evidence 
shows that complementary approaches including administration of Vitamin E and omega-
3 polyunsaturated fatty acids (ω3PUFAs) are capable of attenuating CNS damage, while 
promoting functional recovery after spinal cord injury (SCI). However, the precise 
molecular mechanisms coupling ω3PUFAs and Vitamin E to pro-restorative targets, is 
not well understood. Due to the hydrophobicity of ω3PUFAs and Vitamin E, membrane 
transport may be required to facilitate their mobilization and meet the increased 
metabolic demand at the injury site. The fatty acid translocase/membrane cluster of 
differentiation 36 (FAT/CD36) is a B class scavenger receptor, which has been 
implicated in the uptake and signaling of hydrophobic molecules, including ω3PUFAs 
and Vitamin E. This study investigated the 1) FAT/CD36 mRNA/protein expression 2) 
cellular profile of FAT/CD36 3) potential modulation of FAT/CD36 by ω3PUFAs and 
Vitamin E in neurons and oligodendrocytes following thoracic contusion SCI (T10) in 
adult rats. We found that FAT/CD36 mRNA levels are increased at 7 days post-injury 
while its protein levels remained constant despite marked neuronal and oligodendrocyte 
loss. Immunofluorescence microscopy showed low FAT/CD36 immunoreactivity (IR) in 
pro-inflammatory astrocytes expressing the glial fibrillary acidic protein (GFAP) and in 
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CD11b-positive microglia. We did not observe FAT/CD36 in NG2+ oligodendrocytes 
precursor cells. Surprisingly, we observed the highest IR in motor neurons and 
interneurons of the ventral gray matter and mature oligodendrocytes expressing the 
adenomatous polyposis coli protein (APC). We found increased neuronal FAT/CD36 
expression in the rats that consumed Vitamin E after SCI. Altogether, our data shows a 
differential expression pattern for FAT/CD36 in SCI, which seems to amenable to dietary 
Vitamin E. Our results suggests that FAT/CD36 may be an important player in the 
promotion of cellular uptake, transport, and/or metabolism of fatty acids in neurons 
following SCI. Given the beneficial roles of ω3PUFAs and Vitamin E in ameliorating 
functional recovery, FAT/CD36 may be a contributor to basic protection mechanisms in 
the injured spinal cord. Future pharmacological studies will confirm the role of 
FAT/CD36 in cell survival after SCI. 
 
Introduction 
Spinal cord injury (SCI) is a major cause of disability in the US, devastating the 
lives of more than 12,000 young adults annually. Although SCI may prove difficult to 
prevent in most instances, there is a need to further investigate factors affecting 
susceptibility to functional dysfunction in the event of injury. In ongoing studies, we have 
shown that the metabolism of fatty acids is markedly deregulated during the first few 
days after SCI. In agreement with others, our studies show that these alterations may 
determine the extent of functional recovery after such insult. We demonstrated that 
omega-3 polyunsaturated fatty acids (O3PUFAs) and vitamin E are major modulators of 
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repair mechanisms following SCI in rodents. However, the molecular mediators coupling 
these beneficial fatty acids to functional recovery after SCI remain largely understudied.  
The fatty acid translocase membrane cluster of differentiation 36 (FAT/CD36) is 
a B class scavenger receptor highly expressed in models of neurological and 
cardiovascular injury and implicated in the uptake and signaling of fatty acids and 
vitamin E [1-4]. FAT/CD36 have been shown to be both beneficial and detrimental after 
injury [5-10]. The objectives of this study are to investigate 1) the spatiotemporal 
FAT/CD36 expression and 2) whether FAT/CD36 can be targeted by ω3PUFAs and 
Vitamin E following thoracic contusion SCI (T10) in adult rats. We hypothesize that 
FAT/CD36 is acutely upregulated following SCI and it is modulated by ω3PUFAs and 
Vitamin E. This hypothesis is based on: 1) FAT/CD36 ability of transporting 
hydrophobic molecules such as O3PUFAs and Vitamin E and 2) our studies showing that 
O3PUFAs are neuroprotective after SCI. Our rationale is that, knowledge of how 
O3PUFAs and vitamin E modulate neuroprotection after SCI will provide the foundation 
for the development of interventions aimed at restoring function. Here, we characterized 
the expression and putative targets and roles of FAT/CD36 in experimental SCI. We 
anticipate that this study will provide new evidence for the molecular mechanisms 
involved in the beneficial effects of nutritional fatty acids in neurological injury, which is 
expected to lead to new therapeutic targets for SCI.  
Understanding how dietary omega-3 polyunsaturated fatty acids and vitamin E 
mediate neuroprotection and nervous system repair will require examining specific 
molecular targets regulated by these lipids. These interactions include, but are not limited 
to transport, internalization, and metabolism. The fatty acid translocase/cluster 
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differentiation receptor FAT/CD36 facilitates DHA metabolism and functions as a ROS 
scavenger receptor [4, 11], making this protein an ideal coupling molecule between diet 
and function. This study focused on the spatiotemporal expression and roles of 
FAT/CD36 and its potential role in nutrient-mediated repair following SCI in rats. 
The most innovative feature of this study is the identification of lipid transport 
proteins as potential therapeutic targets for traumatic neurological injury (Figure 1). This 
idea is in agreement with findings showing that genetic deletion of a major membrane 
lipid transport protein, FAT/CD36, exacerbates traumatic brain injury (TBI) in neonatal 
mice [10]. In marked contrast, FAT/CD36 appears to mediate detrimental effects after 
CNS injury in the adult. This is evidenced by findings showing that FAT/CD36 deletion 
or blockade ameliorates recovery after TBI, SCI, and cardiac ischemia [6, 8, 9, 12, 13].  
Together, this evidence suggests that the roles of this lipid transporter are context 
dependent. It is also reasonable to assume differences in fatty acid levels between the 
neonatal and adult brain may play a role in determining the role of this lipid transporter 
[14-18].  
Our Preliminary studies have shown that SCI triggers a robust lipid deregulation, 
characterized by docosahexaenoic acid (DHA) deficiency. This DHA deficiency was 
correlated with neurological dysfunction such as poor locomotion, chronic neuropathic 
pain, and delayed bladder reflex recovery. We found that consumption of a diet rich in 
O3PUFA corrects this DHA deficiency and ameliorates neurological dysfunction in SCI 
rats [19]. Studies have shown that Vitamin E also improves recovery after SCI in rodents 
[20-23]. However, the mechanisms implicated in these beneficial responses remain 
unknown. Vitamin E decreases DHA peroxidation, suggesting a potential mechanism 
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controlling to repair and protection[24, 25]. Further, both vitamin E and DHA bind to the 
FAT/CD36 receptor protein[1, 2, 4, 11, 26]. The experimental data obtained is expected 
to help lay foundation for future interventions that target lipid transport in order to 
prevent secondary damage and neurodegeneration. 
 
 
Figure 1. Suggested FAT/CD36 role in SCI in the context of O3PUFAs 
and Vitamin E transport. 
 
 
Materials and Methods 
Animal Subjects, Diet Intervention, and Spinal Cord Injury 
Young adult female-Sprague Dawley rats were allowed to acclimatize for 1 week 
after arriving at the animal facility. Rats were placed on four different groups according 
to their diets: control diet, O3PUFA diet, vitamin E diet, and O3PUFA/Vit E diet. The 
spinal cord was injured at thoracic level 10 (T10) using the well-characterized NYU 
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Impactor. Spinal cord tissue was collected for analyses at 7 days after injury. For more 
detailed information about these procedures see Figueroa et al., 2013 and Cordero et al., 
2016. 
 
Real Time-PCR 
 RNA was extracted from epicenter sections of Sprague- Dawley female rat spinal 
cords subjected to control diet injury and control diet sham treatments. To observe 
changes in mRNA expression of CD36, the extracted RNA from each of the samples was 
subsequently used to make cDNA. Using the Bio-Rad C100 Thermal Cycler, the 
sequence of interest was amplified through Real-Time RT-PCR for forty cycles. The data 
for each of the samples, normalized to GAPDH as the house-keeping gene, was evaluated 
using the Bio-Rad CFX Manager.  
 
Immunoblotting  
Rabbit anti-FAT/CD36 polyclonal antibody was used to detect the protein levels 
of FAT/CD36 from spinal cord tissue homogenates following previously published 
protocols from our laboratory. 
 
Immunofluorescence 
Double immunofluorescent labeling experiments were conducted with antibodies 
for different cellular markers and FAT/CD36 to study the spatial distribution of 
FAT/CD36 in the spinal cord and the effect of SCI in FAT/CD36 expression. The 
sections for both injured animals and SHAM animals were washed, blocked and 
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incubated in rabbit FAT/CD36 and either mouse anti-neuronal nuclei (NeuN), anti-cluster 
differentiation 11b (CD11b), anti-glial fibrillary acidic protein (GFAP), anti-adenomatous 
polyposis poli (APC), anti- NG2 Chondroitin Sulfate Proteoglycan (NG2), to examine 
immunoreactivity (IR) of FAT/CD36 in neurons, microglia, astrocytes, mature 
oligodendrocytes, and immature oligodendrocytes respectively.  
 
Statistical Analyses 
Data are presented as mean +/– SEM. Unpaired t-test was used to analyze the 
difference of FAT/CD36 mRNA expression through RT-PCR, FAT/CD36 overall protein 
expression through immunoblotting, and CD36+ ventral horn neurons and CD36+ mature 
oligodendrocyte counts through immunofluorescence between uninjured and injured 
groups. One-way analysis of variance (ANOVA), followed by Bonferroni post-hoc 
comparisons was used to determine the effect of spinal cord injury and O3PUFA/Vitamin 
E supplementation in CD36+ ventral horn and CD36+ mature oligodendrocyte counts 
through immunofluoresence. Statistical analyses were performed using Prism 5 Software 
(GraphPad Software Inc., San Diego, CA). Outliers were identified using the Grubbs’ 
method, also known as ESD (extreme studentized deviate). Only one rat was excluded 
from the study after using these exclusion methods. Statistical differences were 
considered significant at p < 0.05. 
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Results 
FAT/CD36 mRNA Levels are Upregulated and the Protein Levels Remained 
Constant at 7dpi 
FAT/CD36 mRNA was upregulated at 7 dpi (Fig. 2A). There was a trend for 
increased FAT/CD36 protein levels, but we did not find a significant change in the spinal 
FAT/CD36 protein levels at 7dpi (Fig. 2B). This finding is important because this time 
point is characterized by a wave of neuronal apoptosis and inflammation. It is reasonable 
to propose that maintaining the levels of this protein in a pro-inflammatory and 
degenerative condition may be an important mechanism for neuronal survival. There are 
several possibilities that may explain this phenomenon. First, it has been shown that 
steady-state transcript abundances only partially predict protein abundances, suggesting 
that after experimental errors have been eliminated, other modes of regulation must be 
invoked to explain how the levels of proteins are set within cells. For example, it has 
been implied that ∼40% of the variation in protein concentration can be explained by 
knowing mRNA abundances. Several mechanisms have been proposed to play a role in 
this discrepancy. Regulatory proteins may have to be produced and degraded very rapidly 
to react to a stimulus, whereas structural or housekeeping proteins would be much longer-
lived. This is consistent with a very unstable FAT/CD36 protein prone to degradation 
since it is a regulatory protein that is strongly induced after injury.  
Another mechanism that may explain the partial prediction of protein abundances 
by mRNA transcripts is explained by evidence showing that the abundance of an mRNA 
is often an excellent proxy for the presence of a protein: that is, for whether or not that 
protein is detectable within the cells and not necessarily for protein abundance. This is 
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also consistent with our FAT/CD36 levels at 7dpi, which were not upregulated like the 
mRNA transcript, but were not downregulated either. Lastly it has been found that 
mRNA transcripts exhibiting shorter 3′UTRs with fewer micro-RNA (miRNA)-binding 
sites showed decreased miRNA-mediated translation repression. Thus, longer 3′UTRs 
will produce less protein abundance due to increased miRNA-mediated translation 
repression[27]. Second it is possible that FAT/CD36 is upregulated in the spinal cord 
after 7 dpi but only in specific areas. This phenomenon was seen and explained by Cruz-
Orengo et al., 2007 where they only found upregulation of EphA4 receptor in the white 
matter and not in the gray matter after finding an upregulation of the EphA4 receptor 
mRNA transcript [28]. This may be due to massive cell death in the gray matter after 
SCI, therefore changes in FAT/CD36 protein levels could be missed due to dilution of the 
protein content in our samples. 
 
 
 
Figure 2. CD36 mRNA Levels are Upregulated and the Protein Levels Remain Constant 
at 7dpi. 
 
FAT/CD36 Spatial Expression in the Spinal Cord 
Despite the fact the vast majority of the literature has evaluated the roles of 
FAT/CD36 in immune cells, its expression and functions in neurons remains unknown. 
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Preliminary findings supporting this study show that FAT/CD36 is highly expressed in 
NeuN-positive cells (neurons) of the spinal cord (Fig 3, panel A-C) and mature 
oligodendrocytes (Fig 3, panel M-O). We found evidence demonstrating low FAT/CD36 
expression in microglial cells (Fig 3, panel D-F), and immature oligodendrocytes (Fig 3, 
panel P-R), confirming other studies. FAT/CD36 was not found in GFAP-positive cells 
(astrocytes). (Fig 3, panel G-L).  
 
 
 
 
Figure 3. CD36 Spatial Expression in the Spinal Cord 
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FAT/CD36 Levels are Upregulated at 7dpi in Ventral Horn Neurons 
The overall FAT/CD36 protein levels, measured through immunoblotting, were 
not upregulated at 7 dpi. Despite this, we did find an upregulation of FAT/CD36 protein 
levels, measured through immunofluorescence, in ventral gray matter neurons. This is an 
example of the phenomenon explained above where even though the overall protein 
expression did not change, its upregulation is seen in specific areas only, i.e. in a specific 
cell population such as ventral gray matter neurons. An upregulation of FAT/CD36 in the 
surviving neurons may indicate a potential role for this protein in ventral horn neurons 
after injury. 
 
 
Figure 4. CD36 levels are upregulated at 7dpi in ventral horn neurons. 
 
FAT/CD36 Levels Remained Constant at 7dpi in Oligodendrocytes 
Similar to the total FAT/CD36 protein levels in the spinal cord, 
immunofluorescence revealed FAT/CD36 expression in oligodendrocytes at 7 dpi (Fig. 
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5).  It is of importance to mention we counted the amount of FAT/CD36+ 
oligodendrocytes and not total amount of CD36 expression levels. This indicates most of 
the oligodendrocytes that survived after SCI were expressing FAT/CD36, which 
potentially indicates a role for this protein in oligodendrocytes after injury. 
 
 
 
 
Figure 5. CD36 levels remained constant at 7dpi in oligodendrocytes 
 
 
NeuN/CD36 Ratio was Upregulated in Injured Rats by a Vitamin E-enriched Diet Only  
A Vitamin E-enriched diet increased FAT/CD36 expression in neurons after 7 
days post-spinal cord injury. Interestingly, the ω3PUFAs -enriched diet did not increase 
the FAT/CD36 expression (Fig 6). These results are suggestive of FAT/CD36 playing a 
role in the improved recovery after SCI observed in rats fed a Vitamin E-enriched diet. 
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Figure 6. NeuN/CD36 Ratio was Upregulated by a Vitamin E-enriched Diet Only at 7dpi 
 
 
APC/CD36 Ratio was Upregulated in SHAM Rats by an ω3PUFAs -
enriched Diet Only 
An ω3PUFAs-enriched diet increased FAT/CD36 expression in oligodendrocytes 
in SHAM operated rats but not in SCI at 7dpi. Interestingly, the Vitamin E-enriched diet 
did not increase the FAT/CD36 expression in either group (Fig 7). These results are 
suggestive of increased transport of ω3PUFAs by FAT/CD36 in uninjured 
oligodendrocytes but not in surviving oligodendrocytes after SCI. 
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Figure 7. APC/CD36 Ratio was increased by ω3PUFAs Diet Only 
 
 
Discussion 
Our study investigated FAT/CD36 as a potential therapeutic target of Vitamin-E 
and ω3PUFAs. Our results indicate that Vitamin-E and ω3PUFAs modulate FAT/CD36 
in ventral horn neurons and mature oligodendrocytes in the white matter of the spinal 
cord. We found that FAT/CD36 was mainly expressed in these two cell populations in 
the naïve spinal cord. While FAT/CD36 protein levels remained constant, we found that 
mRNA levels were upregulated at 7 dpi. FAT/CD36 was upregulated in ventral horn 
neurons and remained constant in mature oligodendrocytes at 7 dpi. We found that 
consumption of a Vitamin-E enriched diet increases FAT/CD36 expression in ventral 
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horn neurons in SCI rats at 7dpi. Interestingly, we found increased FAT/CD36 in the 
SHAM rats that consumed the ω3PUFAs-enriched diet upregulated at 7 dpo. 
FAT/CD36 has been shown to have a double-edge role in various pathological 
processes including Alzheimer’s disease [29-35], cerebral ischemia, cerebral hemorrhage 
[36-38], and cerebral malaria [39-42]. In re-myelination after nerve crush injury it has 
been shown to have a beneficial effect [43] and in Parkinson’s disease and Prion disease 
the studies show a detrimental effect [44, 45]. These studies suggest FAT/CD36 role in 
the nervous system is complex and possibly depends on many factors. In agreement, this 
study suggests that the lipid microenvironment previous to SCI may contribute to the 
functions of FAT/CD36. 
FAT/CD36 has been shown to have a deleterious effect in SCI contributing to 
inflammation and microvascular dysfunction [46, 47]. In these studies, mice were not fed 
a prophylactic diet, thus it is possible that the lipid microenvironment before and after 
injury was very different to lesion microenvironment in our study. Our findings suggest a 
potential role of FAT/CD36 in the uptake of Vitamin E and ω3PUFAs in ventral horn 
neurons and oligodendrocytes, which can promote improved functional recovery. This is 
consistent with the increased overall mRNA expression and constant overall protein 
expression of FAT/CD36 in the spinal cord at 7dpi. Furthermore at the cellular level there 
was constant expression of FAT/CD36 in oligodendrocytes and upregulated expression in 
ventral horn neurons at in the spinal cord at 7 dpi without any diet intervention or injury 
(naïve spinal cord). Additionally in rats with prophylactic diets, FAT/CD36 was 
upregulated in ventral horn neurons by Vitamin E diet only after injury and upregulated 
in oligodendrocytes in ω3PUFAs diet in SHAM rats only. Based on these results we 
 220 
postulate that the regulation of FAT/CD36 expression in the spinal cord is dependent on 
whether the lipid microenvironment is enriched with Vitamin E or with ω3PUFAs.  
 In conclusion, FAT/CD36 is highly expressed in ventral horn neurons and 
oligodendrocytes in the context of Vitamin E and ω3PUFAs enriched lipid 
microenvironment suggesting a role in the functional recovery conferred by these 
prophylactic diets in SCI.  
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CHAPTER SEVEN 
CONCLUSION 
The Effects of DHA Injections in SCI at 7 Dpi in SCI 
One of the main accomplishments from our studies was providing evidence for 
prophylaxis interventions that can strengthen the spinal cord in order to ameliorate 
functional dysfunction after SCI. DHA injections before injury limited apoptosis of key 
cells in the nervous system and downregulated molecules involved in apoptotic pathways. 
In the acute setting, DHA was proven to be neuroprotective (Table 1).  
 
 
Table 1. Effects of DHA Injections in SCI at 7 dpi 
 
Level Test Result 
 
   Behavioral 
 
 
      BBB and tcMMEP 
 
Improved locomotor recovery, decreased 
conduction latencies 
 
Histological 
 
 
Immunostaining 
 
Immunohistochemistry 
↑Luxol,↑WMS,↑CV 
 
↑NeuN,↑APC,↑NG2,↓NG2/FRAGEL 
 
 
Molecular 
 
 
RT-PCR/IMH 
 
 
↑AKT,↑CREB 
 
 
 
Effects of an O3PUFAs-enriched Diet at 8 and 12 wpi  
A prophylactic diet enriched with O3PUFAs vs regular diets showed chronic 
DHA deficiency correlated with decreased neurological recovery (Table 2). We were first 
to provide evidence prophylaxis with O3PUFAs-enriched diets alter the neurolipidome in 
the spinal cord resulting in decreased cellular vulnerability potentially explaining the 
improvement in neurological recovery after SCI. Specifically we found an O3PUFAs-
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enriched diet resulted in an altered neurometabolome that correlated with decreased 
nociceptive behaviors (Table 3). 
 
 
Table 2. Effects of an O3PUFAs-enriched diet at 8 wpi. 
 
 
 
It is important to mention the implications of our prophylactic studies. Our 
western diets if low in O3PUFAs will result in chronic DHA deficiency, which means 
our current diet has the potential of hindering neurological recovery after neurotrauma. 
On the other hand, individuals may have the ability of decrease functional dysfunction in 
the event of neurotrauma with a safe and tolerable approach that is easily available to the 
general population. In addition to functional recovery our prophylactic diet with 
O3PUFAs attenuated chronic pain after SCI and modulated lipid mediators that have 
been implicated in pain. It is possible our approach can be part of a multifactorial strategy 
to target chronic pain in SCI. 
 
 
 
 
Level Test Result 
 
Behavioral 
 
 
Residual Urine Volume, BBB, 
Hindpaw Withdrawal Treshold 
 
Accelerated bladder recovery, 
improved locomotion, and decreased 
sensory dysfucntion 
 
Molecular 
 
-6 DPA: DHA ratio Increased DHA Content 
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Table 3. Effects of an O3PUFAs-enriched diet at 8 and 12 wpi  
 
 
 
Effects of a Vitamin E-enriched Diet at 7 dpi 
We provided evidence that a two-month chronic dietary supplementation with 
vitamin E (alpha-tocopherol) also aids in the functional recovery of SCI during the acute 
phase and increased survival of motor neurons and oligodendrocytes (Table 4). We found 
that supraspinal serotonin IR is a potential target for the underlying mechanisms of 
vitamin E example on the effects of our diet in the prevention of neurotrauma.and its 
prophylactic effects in this acute phase. Vitamin E prophylaxis is yet another  
 
Table 4. Effects of a Vitamin E-enriched diet at 7 dpi  
 
Level Test Result 
 
Behavioral 
 
Residual Urine Volume, 
BBB, H-reflex 
Improved locomotor recovery, accelerated 
bladder recovery, restored H-reflex 
depression 
 
Histological 
 
Immunohistochemistry 
 
↑NeuN,↑APC,↑5-HT in Neurofilaments 
 
 
 
Level Test Result 
 
Behavioral 
 
Hindpaw Withdrawal 
Latency 
No thermal hyperalgesia developed in animals 
with a O3PUFA-enriched diet 
 
Molecular 
 
Metabolomic analysis 
↑N-acyl ethanolamine precursor correlating with 
decreased thermal hyperalgesia, altered 
endocannabinoid metabolone,  
 
Histological 
 
 
Immunocytochemistry 
 
 
↑p38, decreased sprouting of CGRP-containing 
fibers (pain fibers) 
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FAT/CD36 Expression After SCI and its Modulation by an O3PUFAs and 
Vitamin E-enriched Diet 
Our last step was to study the transport of both O3PUFAs and Vitamin E by 
FAT/CD36, a scavenger receptor and lipid transporter. First we found on the acute setting 
that it was highly expressed in ventral horn neurons and oligodendrocytes  (Table 5).  
 
Table 5. CD36 expression at 7 dpi 
 
 
Total mRNA Total Protein In NeuN+ cells In APC+ cells  
 
CD36 
 
 
 
           ↑  
 
 
Next FAT/CD36 levels were upregulated in oligodendrocytes by O3PUFAs and 
in neurons by Vitamin E. These results suggest O3PUFAs and Vitamin E lipid-rich 
microenvironments may play a role in the functional recovery conferred by these 
prophylactic diets in SCI (Table 6).  
 
Table 6. CD36 modulation by O3PUFAs and Vitamin E-enriched diets at 7 dpi  
 
 NeuN+ APC+ 
O3PUFAs  
 in SHAM rats 
 
Vitamin E  in INJ rats 
 
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In conclusion, while there are many studies that aim to treat the neurological 
dysfunction in SCI there is still room for improvements in the treatments for SCI. Our 
studies provided evidence for the value of studying preventive approaches such as 
O3PUFAs and Vitamin E prophylaxis for the group of people at a higher risk of suffering 
from SCI. 
 
